Abstract

Vertical Tabs

General Information

28AC - Logo Abstracts

SUBMIT YOUR ABSTRACT HERE (Deadline, 01 October 2023, 23h59 CET)

The poster exhibition and the oral poster communication session are the mainstay of the annual European Association of Hospital Pharmacists (EAHP) Congress and only the best are selected!

The EAHP Scientific Committee (SC) encourages all hospital pharmacists, other health care professionals and scientists to submit their work for consideration leading to possible acceptance and display at the annual EAHP Congress. The SC strives to receive submissions of hospital pharmacy related initiatives from applicants in Europe and all over the world. All potential contributors are requested to carefully read and comply with the guidelines presented in this webpage. Abstracts/posters which have already been published at the international level may only be submitted if new data is included, the work is presented from the hospital pharmacy perspective or in a new context giving new inspirations for colleagues. Data, which have been published in international, peer-reviewed journals, should not be submitted.

IMPORTANT: When submitting your abstract, please be sure that your hospital server will accept emails from abstract[at]eahp[dot]eu. Otherwise, you will not receive the emails from our system. Alternatively, you may use a personal email address such as gmail, hotmail, etc... You can submit multiple abstracts. We also recommend that when submitting your Abstract, you use the same name and email address used for registering your participation to the Congress.

DEADLINES	ACTION
Sunday, 01 October 2023	Deadline for abstract submissions. Abstracts submitted after the deadline will not be accepted (Deadline, 23h59 CET)
Monday, 06 November 2023	Authors will be advised of their abstract status after the first review. Please check your spam if you did not receive the email.
Friday, 17 November 2023	Deadline for modifications due from abstract authors who were requested to make changes (Deadline, 23h59 CET)
Friday, 01 December 2023	Authors will be advised of their abstract status after review of modifications
Monday, 04 December 2023	Deadline for Accepted Abstract to notify EAHP they do NOT want be included in the published ELHP (European Journal of Hospital Pharmacy) (Deadline, 23h59 CET)
Wednesday, 24 January 2024	Accepted Abstracts will receive an email with: Abstract Title and Text edit, new Abstract/Poster Number and QR Code
Thursday, 01 February 2024	Accepted Abstract Authors to be registered and have confirmed attendance to the EAHP Congress 2024, in order to be included in the Printed Abstract Book (Deadline, 23h59 CET)
Friday, 01 March 2024	Accepted Abstract Posters to be sent to EAHP in PDF format for inclusion in order to be included on the Online Abstract Poster Wall (Deadline, 23h59 CET)
Friday, 01 March 2024	Accepted Abstract/Poster Authors to be registered and have confirmed attendance to the EAHP Congress 2024, to be guaranteed a Poster Panel at the Congress (Deadline, 23h59 CET)
Wednesday, 20 March 2024	Accepted Abstract/Posters to be delivered and hung in the EAHP Congress 2024 Poster Area (from 10.15 to 17.00)
Friday, 22 March 2024	Accepted Abstract/Posters to be removed from the EAHP Congress 2024 Poster Area (from 13.00 to 14.00)
Tuesday, 21 May 2024	Abstract/Posters present at the EAHP Congress 2024 to request a duplicate of the Poster Certificate (originaly sent on Friday 22 March 2024)

The SC accepts two types of abstracts:

Scientific abstracts and
"Good Practice Initiatives" (GPIs). GPIs comprise hospital pharmacy practice or education initiatives, which may inspire colleagues internationally, but do not necessarily comply with the traditional abstract demands. For further information regarding definition of a GPI, please go here. For authors interested in submitting a GPI, please go here.

If you have any questions concerning the abstract submission process, please send an email to abstract[at]eahp[dot]eu.

Abstract Submissions and guidelines

The SC accepts two types of abstracts: scientific abstracts and "Good Practice Initiatives" (GPIs). GPIs comprise hospital pharmacy practice or education initiatives, which may inspire colleagues internationally, but do not necessarily comply with the traditional abstract demands. For further information regarding definition of a GPI, please go here.

To check if your abstract meets the eligibility criteria for being a GPI or an abstract, answer all the following questions:

Table 1: The eligibility criteria for being a GPI or an abstract.

QUESTION	DEFINITION
1. Is your abstract relevant for hospital pharmacists?	Yes: Your abstract may be a scientific abstract or a GPI
1. Is your abstract relevant for hospital pharmacists?	No: Please do not submit your work to EAHP
2. Does your abstract describe a protocol or plan for a project not yet conducted?	Yes: Please do not submit your work to EAHP
	No: Your abstract may be a scientific abstract or a GPI
3. Is your abstract about the development and implementation of a pharmacy practice or a program in pharmacy education?	Yes: Your abstract may be a GPI
	No: Your abstract may be a scientific abstract
4. Can other colleagues use your experience as the basis to introduce the same type of improvement in their settings by e.g. observing what you did in your setting?	Yes: Your abstract may be a GPI
	No: Your abstract may be a scientific abstract
5. Does your abstract describe a project conducted as a scientific study using e.g. robust methodology?	Yes: Your abstract may be a scientific abstract
	No: Your abstract may be a GPI

For authors interested in submitting a GPI, please go here.

If you want to submit a scientific abstract, please check the instructions below.

ABSTRACT SUBMISSIONS AND GUIDELINES

IMPORTANT: When submitting your abstract, please be sure that your hospital server will accept emails from abstract[at]eahp[dot]eu. Otherwise, you will not receive the emails from our system. Alternatively, you may use a personal email address such as gmail, hotmail, etc... You can submit multiple abstracts. We also recommend that when submitting your Abstract, you use the same name and email address used for registering your participation to the Congress.

The EAHP Scientific Committee (SC) is looking for contributions with:

A high grade of relevance and/or innovation to the European community of Hospital Pharmacists,
A high impact on the future of hospital pharmacy practice, or
A high relevance regarding practice changes due to the investigated intervention.

SCOPE OF ABSTRACTS AND TOPIC GROUPS

We encourage the submission of abstracts from all disciplines of hospital pharmacy or related areas. The major categories and examples of topics are illustrated in the table below. The topics are not meant to represent a complete and exclusive list, but examples only that guide authors to select the most appropriate topic groups during the submission process.

Table 2: Categories for abstract submission with examples.

CATEGORY	EXAMPLES OF TOPICS
Section 1: Introductory Statements and Governance	Management theories, human resources, training requirements, financing, resource optimization, staffing, organisation, working environment, medicines management policies, drug & therapeutics committees, communication technology (telepharmacy, eHealth), national standards of hospital pharmacy services, pharmacoeconomics, health technology assessment
Section 2: Selection, Procurement and Distribution	Procurement processes, logistics, storage conditions, ordering systems, drug distribution technology (e.g., bar code scanning, electronic cabinets, dose dispensing), home delivery, supply chain management, medicines shortages, policy for medicines brought into the hospital by patients, preparation conditions, dispensing conditions, distribution conditions, disposal of medicines, medicines formulary systems, drug use evaluations
Section 3: Production and Compounding	Production technology, use of suitable commercially available pharmaceutical equivalents, risk assessment prior to production, formulation, quality control, best practice quality requirements, procedures for reconstitution or mixing of medicines, stability studies
Section 4: Clinical Pharmacy Services	Multidisciplinary therapeutic decision-making, quality improvement interventions, adherence, seamless care between and within healthcare settings, monitoring medication changes, service evaluation, service implementation, outcome evaluation, medicines reconciliation, medication history, prescription review, medication management review, medication appropriateness, drug-related problems, patient education, career education, health care professional education, patient knowledge, therapeutic drug monitoring, interactions, clinical pharmacokinetics, drug information and pharmacotherapy, nutrition support
Section 5: Patient Safety and Quality Assurance	Medication errors, adverse drug events, pharmacovigilance, medication error reporting, root cause analysis, high-risk medicines, patient safety programmes, risk minimization procedures, computerised decision support, safe transcription steps, accurate recording of allergy etc., quality and safety procedures, safe medicines use (preparation and administration), labelling, quality assurance, traceability, drug efficacy/safety evaluations
Section 6: Education and Research	Development of curricula, participation in European-wide competency frameworks (e.g., for initial post graduate education and training in hospital pharmacy), research methods, publication skills, pharmacy practice research, pharmacoepidemiology, protocols

IMPORTANT ITEMS TO CONSIDER BEFORE WRITING YOUR ABSTRACT

We kindly invite all applicants to carefully consider the following before submitting your abstract:

The prerequisite for a good abstract is a well-conducted study with clear study aims and methodology.
The purpose of the study should be understandable and should allow the reader to follow what has been done at a glance.
The interventions and relevant outcomes should be clearly defined.
The authors are strongly requested, prior to submission, to see what is published in their relevant field and reflect on the added value of their work (e.g. if they present data of national or even local peculiarities).
Before writing the abstract, clarify for yourself what is the new evidence you want to present and consider why colleagues should be interested in your study.

ABSTRACT STRUCTURE

Abstracts must be structured and written in five paragraphs: (1) Background and importance, (2) Aim and objectives, (3) Materials and methods, (4) Results, (5) Conclusion and relevance.

This structure of an EAHP congress abstract has to be strictly adhered to. The online abstract submission will guide you through this process. Abstracts are limited to no more than 350 words (or less if you use graphs or tables) and must be typed in English. The online submission system does not allow you to enter abstracts above this limit.

A blinded approach is used during the abstract review process, so it is recommended that the institution name and/or country name are NOT indicated in the abstract title and text. Contact data will not be displayed during the review process. This process is meant to ensure that the reviews are conducted in the most ethical and professional way possible.

Title: The title of the abstract must be strictly coherent with the data included in the abstract. Do not use abbreviations. If you are submitting a case report, the area of focus and "case report" should appear in the title.
Contact data: The name of every author, preceded by initials, and the name of the presenting author underlined and entered as instructed via the online submission process. Omit degrees, titles or institutional appointments. Then, insert the institution, city, country where the study took place or the case occurred, as well as the email address of the presenting author.
(1) Background and importance: The background sets the frame of your study. To set the scene you must answer the following questions: What is already known about this topic? what are the unmet needs which brought you to conduct this study? To answer those questions, you have to do a literature search to identify whether other observations in this field are already published. You should present the problem you want to focus on and highlight why the answer to the problem is important. For case reports briefly summarize why this case is unique with medical literature references.
(2) Aim and objectives: State the aim of the study. This very clear and concise text should state: What did you investigate and among whom? If you present a case report give patient information regarding the main concerns and symptoms of the patient in this section. Add medical, family, and psychosocial history including genetic information if applicable and needed. Relevant past interventions and their outcomes should also be reported here.
(3) Materials and methods: Describe the method, facilities (e.g. equipment/statistics, models), design, setting and participants and interventions being used. Please describe the intervention and which outcome measures were used, when applicable. If you do a literature review or a meta-analysis you have to give information regarding the data sources and the study selection criteria. For case reports relevant physical examination (PE) and other clinical findings should be reported in this section. Also the timeline of the case with relevant data from this episode of care organized as a timeline could be important. In some cases diagnostics and prognostic characteristics should be given when applicable. Please present therapeutic Interventions in this section.
(4) Results: Present the necessary data in a way that it is easy to understand. There is no discussion of the results in this part. For case reports clinician- and patient-assessed outcomes when appropriate should be given here. Please refer also to important follow-up diagnostic and other test results. Intervention adherence and tolerability (how was this assessed?) besides adverse and unanticipated events should be reported.
(5) Conclusion and relevance: Discuss your results and compare to literature data if available. Are other observations in this field already published and relevant to be mentioned? Based on your results, what are the answers to the problem you focused on? What are the new findings? What are the implications for practice and research? For case reports, please present strengths and limitations in your approach to this case. Please discuss the relevant medical literature and the rationale for your conclusions. You must present the primary "take-away" lessons from this case report.
References and/or acknowledgements: These may be given at the end of the abstract.

Please click here to download the abstract structure template which can give you an idea of an abstract structure before the online submission. Please note that only submitted online abstracts will be reviewed.

We advise authors to use scientifically common principles in abstract writing.

Abbreviations may be used only if they are defined (spelled out in full text at first mention, followed by abbreviation in parentheses). Only general standard abbreviations for e.g. millilitres, seconds, and moles may be used without explanation.
Don't use excessive decimals e.g. a person might weigh 70,237 kg at a given moment, but only 70 kg should be mentioned.
References should be limited to a minimum, unless they are important for understanding methods, background or conclusions drawn. References should be added in a special field during the abstract submission, which is optional for use and not mandatory. Comprehensive bibliography can be displayed on the poster.
The authors are encouraged to submit well-edited abstracts and avoid submission of negligent work.

THE SUBMISSION PROCESS

Please consider the selection of the appropriate topic group before submission and compare with the examples prior to submission (Table 2). The topics are directly related to the EAHP statements.
For every abstract there must be 3-5 keywords selected by the authors. These are used for indexing purposes and have to be strictly in line with the content of the abstract.
You can only add 1 presenting author and up to 10 co-authors.
If you include an image, it must be a JPEG, Max. size of 500pxl. You can upload it in the section required when submitting your text.
You can submit multiple abstracts.

THE REVIEW PROCESS

Each abstract is read, assessed and scored independently by two members of the SC and considered from two perspectives: the scientific content and the practical value of the submission.
In case of divergence between the two reviewers, the full SC discusses the submission in plenum and comes to a view whether to accept the abstract or not.
You will be notified in a timely manner as to the outcomes of the review process. You may be asked to revise your abstract and re-submit it.
All accepted abstracts will be allocated a spot for display at the congress.
The SC selects outstanding abstracts for poster walks and poster prize competition. Only those abstracts that are considered to have a high grade of relevance, innovation and added value in a well-written form are eligible for winning the poster prize.

SPECIFICS REGARDING STUDY TYPES AND METHODOLOGY

Particular attention is given to those abstracts that report scientifically valid results with appropriate study methodology giving the type of study design, interventions and outcomes. Outcomes could comprise either direct patient benefit, economical or clinical outcomes, or a combination of these.
Quantitative studies should include at least 30 patients.
Case Reports of a single or of a few patients will be accepted only if they include original and new data, that is not as yet published in literature. Please find below more information.
Case reports of ADRs will only be accepted if they present some kind of causality or probability assessment (e.g. Naranjo algorithm)
Everyday clinical practice studies are of interest if effectiveness is reported in an adequately chosen size of study population, which is in line with the prevalence of the disease studied.
New drug interactions not already described in the literature are encouraged to be reported but should come with a possible mechanism or explanation.If interventions of improvements processes are reported, please always report baseline values or data regarding the situation prior to the intervention as well. Otherwise comparison is not scientifically valid and therefore of limited value and validity.
Abstracts reporting purely lab sciences or associated sciences to pharmacy (e.g. microbiology, biology, chemistry etc.) are only accepted if the implications of these basic study findings to hospital pharmacy practice are made clear by the authors.
Drug Usage Evaluation (DUE) will only be considered if data of at least 30 patients are reported.
Authors planning to perform and report the results of a DUE are referred to relevant guidelines (e.g. those from American Society of Health-system Pharmacists).

EAHP welcomes well-described reports of cases that include the following:

Unreported or unusual side effects or adverse interactions involving medications.
Unexpected or unusual presentations of a disease.
New associations or variations in disease processes.
Presentations, diagnoses and/or management of new and emerging diseases.
An unexpected association between diseases or symptoms.
An unexpected event in the course of observing or treating a patient.
Findings that shed new light on the possible pathogenesis of a disease or an adverse effect.

Abstracts of case reports submited to the SC of EAHP with the aim to present a poster at the EAHP Congress should make a contribution to medical knowledge and must have educational value or highlight the need for a change in clinical practice or diagnostic/prognostic approaches. EAHP will not consider case reports describing preventive or therapeutic interventions, as these generally require stronger evidence.

Case reports should be writen in the same way like the other abstracts, meaning you have to use the same template.

REASONS FOR REJECTION

Abstracts/posters which have already been published at the international level may only be submitted if new data is included, the work is presented from the hospital pharmacy perspective or in a new context giving new inspirations for colleagues. Data, which have been published in international, peer-reviewed journals, should not be submitted.

This practice is well established in many countries.
This abstract is not relevant to Hospital Pharmacy.
The committee did not understand the abstract either due to English use or other reasons.
Quantitative studies should usually include at least 30 participants.
The abstract does not follow the given structure.
The conclusion does not cover the aim of the study.
Insufficient data was included to support your conclusions.
An inappropriate or weak study methodology was used.
The abstract is not presenting a study with a defined aim, a described method to obtain results, presentation of the obtained results and/or a conclusion based on these findings.
The abstract may be better suited as a GPI. Please resubmit using the appropriate format.
This topic has already been studied and published several times.
If a same author or a same group of authors has submitted the same abstract several times by mistake, they should send an email to the EAHP office to inform them and delete the duplicated abstracts. Otherwise, the judges will reject all abstracts.
If a same abstract has been submitted by its author(s) both as a Good Practice Initiative and as an abstract, the judges will reject both abstracts.
Other

RECOMMENDATIONS

Prior to conducting your study, reflect on the appropriate methodology and the number of patients (e.g. power analysis) that is necessary for this study design. Your study must include at least 30 patients to be accepted.
Ask other colleagues who are not involved in the study if the abstract is understandable and your proposed message is conveyed.
Consider the coherence of the abstract. If not coherent, please strongly consider rewriting your abstract.
The conclusion should be limited to statements that directly arise from the results presented. General statements without reflection of results or not in line with the aim of the study have to be avoided, as this is a common reason for abstract rejection.
The word count has to be adhered to. Be aware, that this is an abstract. The purpose of an abstract is to report clear, concise and relevant scientific results. Additional data, which are not ultimately needed for understanding, can be shown in the final poster.
Please avoid formatting of abstracts, don't use bold type, and ensure that at the final checking stage that any special characters or symbols used are displayed correctly.
Abstracts reporting vague or unclear interventions and/or irrelevant outcomes will be rejected.

DISCLAIMER

While every effort is made by publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned.

Accordingly, the publishers and the European Association of Hospital Pharmacists (EAHP), the editorial committee and their respective employees, officers and agents, accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. While every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, described within this Journal, should only be followed in conjunction with the drug manufacturer's own published literature.

The author is responsible for obtaining the permission and licenses used to complete his/her study. Please note that EAHP cannot be held responsible in case an author disrespects his/her obligation to obtain the permission and licenses.

Please click here to read the author licence from BMJ.

IMPORTANT: The abstracts that were rejected last year CANNOT BE RESUBMITTED again unless major modifications have been made. Should the authors not follow this rule, they will be banned from the submission process for the following EAHP congresses.

Good luck to all!

The EAHP Scientific Committee

Poster guidelines

ABSTRACT POSTER GUIDELINES

The Registration of the Abstract/Poster Submitting Author to the EAHP Congress 2024 must be finalized by 01 March 2024. Passed this deadline, no poster panel will be provided at the Congress.
The PDF Version of the Poster must be sent to abstract[at]eahp[dot]eu by 01 March 2024

SIZE:

841mm wide x 1189 mm high (A0) - portrait format (posters may not be smaller or larger than this size).

ASSISTANCE PROVIDED AT CONGRESS CENTRE

A poster panel on which to hang posters
A number for each poster board: this number indicates your assigned display station and also corresponds to the abstract number
Mounting materials, including double sided adhesive tape. Note that the use of drawing pins will NOT be allowed
Staff to advise during poster mounting

THE FOLLOWING COMPONENTS SHOULD BE INCLUDED AND USED AS HEADING WHERE APPROPRIATE

Title
Contact data
Background and Importance
Aim and Objectives
Materials and Methods
Results
Conclusion and Relevance
References and/or Acknowledgements

IT IS OFTEN USEFUL TO HAVE A SUMMARISED VERSION OF THE POSTER TO HAND TO INTERESTED READERS

You should also provide a notepad so that interested readers can leave their contact addresses, and a drop-box in which they can leave business cards or envelopes.

DESIGNING THE POSTER

Remember that viewers should be able to grasp the meaning of the poster without listening to an explanation or reading a report. To assist in this:

Communicate the message simply
Do not clutter the poster with too much detail
Only use materials that can be mounted on the poster board (plus handouts)
Use title lettering at least 2.5 cm high with text lettering at least 8 mm high and 0.7 mm thick. Test readability from 1 m or more away.
Use pie charts, histograms, graphs, tables, clip art, drawings, symbols and photos to illustrate key points. Use colour effectively in these and make them simple, rather than complex.
Design the poster to be read from left to right and top to bottom
Where possible, use one-line statements or bullet phrases to highlight key points, rather than full sentences (this list is set off by bullet points)
Use bold face type for headings and sub-headings
Proof-read the poster carefully. Ask a person independent of the project to review the text for clarity, organisation and brevity
Bring white correction tape or fluid and black felt tip pen to the meeting to correct errors or scratches

POSTER CERTIFICATES

Poster certificates for the presented posters will be sent to the authors by email within 15 days after the Congress. The duplicates can be provided by the author's request within 60 days after the last Congress. Please note that in case of loss of your poster certificates, the certificate duplicates of the last EAHP congress as well as any other previous EAHP congresses certificates will not be provided after the deadline of 60 days (21 May 2024).

POSTER PDFs FOR WEB SITE

Authors should send a pdf of their poster to abstract[at]eahp[dot]eu for inclusion on the EAHP web site following the congress. Deadline for receipt of your poster pdf is 01 March 2024.

DURING THE CONGRESS

The deadline to deliver and hang your poster at the Congress is Wednesday, 20 March 2024 from 10.15 to 17.00. Please note that there will be no access to the poster area to hang your posters before the indicated time. Please go to the poster area and check-in with the hostesses on duty to find out where and how to hang your poster. Note that all posters will be hung according to the Sections of the European Statements of Hospital Pharmacy and ATC code.

Presenters are expected to be present at their poster during 2 coffee breaks:

Thursday 21 March 2024, from 10.30 to 11.00
Friday 22 March 2024, from 10.30 to 11.30

DISCIPLINARY ACTION

If an author is unable to present his poster during the congress, he absolutely needs to notify the EAHP by sending an email to abstract[at]eahp[dot]eu. If same situation happens 3 years in a row, the EAHP reserves the right to reject any other abstracts submitted by the same author for future congresses. In addition, should the author not insure that their poster is hung during the congress either by the author or a colleague, the abstract will be removed from the online version of the abstract book.

Poster prize winners

ENCOURAGEMENT PRIZE FOR INVESTIGATORS

The best abstracts/posters (up to 12 award nominees) – with regards to aspects like originality, scientific quality and practical applicability – will be awarded with 3 prizes amounting EURO 750, EURO 500 and EURO 250.

Please be aware that the judges reserve the right not to award prizes if there are no clear winners.

Award nominees will be requested to give an oral presentation, taking place in different dates and times throughout the congress.

2024 award nominee oral presentations

TBC

Oral presentations are to consist of 5 minutes for presentation and 2 minutes for questions and answers. Poster prize nominees should disclose whether their work or comparable/similar work was submitted at an earlier International conference or somewhere else. More details will be sent to the authors by email. The winners will be announced at the closing ceremony on 22 March 2024.

Check the posters of past Congress winners below.

The Scientific Committee also choose up to 18 abstracts for the Poster walk. These abstracts will be highlighted in the online poster area in the congress platform and will include a recorded video of their presentation so you can watch their presentation at any time!

2023 Poster prize Winners (click on the title to download the poster)

27AC - Abstract 1st Prize - Shannon Nally

1st Prize

EVALUATING THE POTENTIAL CLINICAL AND ECONOMIC IMPACT OF CHEMOTHERAPY PRESCRIBING BY PHARMACISTS AT A UNIVERSITY TEACHING HOSPITAL

Shannon Nally

2nd Prize

BEDSIDE CHECK OF MEDICATION APPROPRIATENESS (BED-CMA) AS A RISK-BASED TOOL FOR BEDSIDE CLINICAL PHARMACY SERVICES: A PROOF-OF-CONCEPT STUDY AT THE TRAUMA SURGERY WARD

Greet van de Sijpe

3rd Prize

SING A TEXT-MINING APPROACH TO IDENTIFY THE CONTEXT VARIABLES LANGUAGE BARRIER, LIVING ALONE, COGNITIVE FRAILTY AND NON-ADHERENCE FROM ELECTRONIC HEALTH RECORDS (EHRs)

Simone ten Hoope

2022 Poster prize Winners (click on the title to download the poster)

1st Prize

IMPLEMENTATION OF AN INTERPROFESSIONAL PREOPERATIVE MEDICATION MANAGEMENT PROGRAMME IN CARDIAC SURGERY: A PRE–POST QUALITY IMPROVEMENT STUDY

Benedict Morath

2nd Prize

SELECTION OF CLINICAL RULES FOR THE SCREENING OF HIGH-RISK SITUATIONS IN PAEDIATRIC MEDICINE

Christian Skalafouris

3rd Prize

POSITIVE IMPACT OF AN IMPLEMENTED WARD PHARMACIST IN A MULTIPROFESSIONAL CANCER CARE TEAM IN GERMANY

Svenja Dierkes

2021 WINNERS (click on the title of the abstract to download the poster)

1^st Prize - Tessa Jaspers: EFFECT OF A MULTIFACETED CLINICAL DECISION SUPPORT INTERVENTION ON ADHERENCE TO THROMBOPROPHYLAXIS GUIDELINES IN NON-SURGICAL PATIENTS

2^nd Prize - Trine Andersen: A SCREENING MODEL TO IDENTIFY ELDERLY POLYPHARMACY PATIENTS THAT MAY BENEFIT FROM PHARMACIST LED MEDICATION REVIEW DURING HOSPITAL ADMISSION

3^rd Prize - Stefanie Sauer : USING DIFFERENT TECHNIQUES TO PREPARE ORODISPERSIBLE FILMS IN A HOSPITAL PHARMACY

2020 WINNERS (click on the title of the abstract to download the poster)

1^st Prize - Ulrika Gillespie: FACILITATORS AND BARRIERS TO PERFORMING COMPREHENSIVE MEDICATION REVIEWS AND FOLLOW-UP IN OLDER HOSPITALISED PATIENTS BY MULTIPROFESSIONAL WARD TEAMS INCLUDING A CLINICAL PHARMACIST

2^nd Prize - Ana Idoate: COST EFFECTIVENESS ANALYSIS OF MEROPENEM DOSE OPTIMISATION IN CRITICAL PATIENTS

3^rd Prize - Charlotte Quintens: UNDERDOSING WITH HIGH DOSE PIPERACILLIN/TAZOBACTAM ADMINISTERED VIA CONTINUOUS INFUSION IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY: A STABILITY OR VISCOSITY PROBLEM?

2019 WINNERS (click on the title of the abstract to download the poster)

1^st Prize - Meshal Alshakrah: DETERMINING THE NECESSARY COMPONENTS OF A PHARMACEUTICAL CARE COMPLEXITY SCREENING TOOL: AN E-DELPHI STUDY

2^nd Prize - Antonella Tonna: ENCOURAGING THE RESPONSIBLE USE OF ANTIBIOTICS: AWARENESS AND UNDERSTANDING AMONG A UNIVERSITY STUDENT POPULATION OF A COMMUNITY PHARMACY PUBLIC HEALTH CAMPAIGN IN SCOTLAND

3^rd Prize - Rana Al Adawi (the abstract was presented by Antonella Tonna): A SYSTEMATIC REVIEW OF PHARMACIST INPUT IN THE SCREENING, MANAGEMENT AND PREVENTION OF METABOLIC SYNDROME

Online abstract poster walks

Please find below the online abstract Poster Walks of the last EAHP Congresses.

Please select the desired annual Congress to view the posters presented in the different topic categories.

27th Congress of the EAHP

National Poster Prize Winners
PDF document	Poster number	Poster Title
	NP-001	DEVELOPING THE ROLE OF PRIMARY CARE CLINICAL PHARMACIST
	NP-002	“CAPSULE PHARMA”, AN INNOVATIVE DIGITAL TRAINING TOOL TO LEARN ABOUT IMPORTANT STERILE MEDICAL DEVICE (SMD) CONCEPTS
	NP-003	PHARMACEUTICAL INFUSION SCHEDULES AS A TOOL TO IMPROVE FLUID RESTRICTION IN PICU PATIENTS
	NP-004	RETROSPECTIVE STUDY ON INDIVIDUALISED MEDICATION OF DEMENTIA PATIENTS RECEIVING CHRONIC HOSPITAL CARES
	NP-005	SELF-ASSESSMENT ON THE IMPLEMENTATION OF RECOMMENDATIONS OF THE PERIOPERATIVE PROCESS: INFECTIOUS RISK MANAGEMENT IN SURGERY SETTING
	NP-006	IMMUNOTHERAPY IN SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER
	NP-007	RECOMMENDATIONS FOR ADMINISTRATION OF IMMUNOSUPPRESSANTS VIA ENTERAL FEEDING TUBE ACCORDING TO THEIR IN-VITRO ADMINISTRATION
	NP-008	EMERGENCY DEPARTMENT REVISIT SOCORE BASED ON PHARMACOTHERPAY
	NP-009	ASSESSMENT OF MEDICATION DISCREPANCIES BY PHARMACIST-LED MEDICATION RECONCILIATION AT ADMISSION : A PROSPECTIVE STUDY IN TRAUMATOLOGY
	NP-010	DEVELOPMENT OF A 2% LIDOCAINE GEL FOR LOCAL ANAESTHESIA OF THE EYE PRIOR TO INTRAVITREAL INJECTION
	Student Science Award	Around one-third of people with diabetes will develop foot ulcers in their lifetime

Section 1: Introductory Statements and Governance
PDF document	Poster number	Poster Title
	1ISG-001	ECONOMIC IMPACT GENERATED BY NATALIZUMAB OPTIMIZATION
	1ISG-002	MEDICATION WASTE IN AN ORTHOPAEDIC DEPARTMENT: EFFECT OF PATIENT'S OWN MEDICATION USE AND SELF-ADMINISTRATION DURING HOSPITALISATION AND THE VIEWS OF PATIENTS AND HOSPITAL STAFF
	1ISG-003	PROTOCOL FOR THE OPTIMISATION OF PHARMACEUTICAL VALIDATION IN HOSPITALIZED PATIENTS
	1ISG-004	HOME DELIVERY - EFFICIENCY, ECONOMY AND CUSTOMER SATISFACTION OUTCOMES - COMPARISON OF ASSISTANCE MODELS
	1ISG-005	DEPARTMENT COMPUTERISED PHARMACEUTICAL CABINET: RESULTS OF DEMATERIALIZATION AND TRACEABILITY OF DRUGS IN OBSTETRICS AND GYNECOLOGY
	1ISG-006	OPPORTUNITY TO STUDY ADHERENCE AND PERSISTENCE WITH HOME DELIVERY (HD) - REAL WORLD DATA (RWD) AND REAL WORLD EVIDENCE (RWE) ANALYSIS
	1ISG-007	OPPORTUNITIES FOR LOGISTIC REORGANISATION OF THE HOSPITAL PHARMACY WITH NEW CARE MODES: STOCK MANAGEMENT (SM) AND HOME DELIVERY (HD)
	1ISG-008	THE MULTIDISCIPLINARY ASSESSMENT OF RAPID ANTIGEN TESTS FOR THE DETECTION OF THE OMICRON VARIANT: THE ROLE OF THE HOSPITAL PHARMACIST IN A UNIVERSITY HOSPITAL
	1ISG-009	A FRAMEWORK FACILITATING ACCESS TO MEDICINES IN THE EUROPEAN UNION
	1ISG-010	PHARMACY STAFF SATISFACTION AND OPINION OF NEW WEBSITE APPLICATION FOR OUTPATIENT CARE
	1ISG-011	MANAGEMENT OF UNADMINISTERED THERAPIES: IMPACT OF PHARMACIST-DOCTOR COLLABORATION TO OPTIMIZE THE PROCESS OF PREPARING CANCER THERAPIES
	1ISG-012	COST-MINIMISATION ANALYSIS: PROPHYLACTIC TREATMENT OF HAEMOPHILIA TYPE A, WHAT TO CHOOSE BETWEEN FACTOR VIII, RECOMBINANT FACTORS VIII (MOROCTOCOG-ALFA AND OCTOCOG) AND EMICIZUMAB?

Section 2: Selection, Procurement and Distribution
PDF document	Poster number	Poster Title
	2SPD-001	USE AND COST EVOLUTION OF INFLIXIMAB AND ADALIMUMAB OVER 8 YEARS IN A TERTIARY HOSPITAL
	2SPD-002	COST SAVINGS IMPACT OF GENERICS: A LOCAL EXPERIENCE ON LENALIDOMIDE
	2SPD-003	ERRORS DETECTED IN THE TELEPHARMACY PROCEDURE
	2SPD-004	ECONOMIC EVALUATION AND BUDGET IMPACT FOR A REGIONAL HEALTH SERVICE ASSOCIATED WITH THE INCLUSION OF THE FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN A REGIONAL PHARMACOTHERAPEUTIC GUIDELINE
	2SPD-005	NEW CLOSED SYSTEM TRANSFER DEVICE CONTAINS REAL DRUG VAPOURS FOR UP TO 28 DAYS
	2SPD-006	ARE ALL BIOLOGIC AGENTS IN THE TREATMENT OF ANKYLOSING SPONDYLITIS EQUIVALENT ALTERNATIVES?
	2SPD-007	USE OF DRUGS IN SPECIAL SITUATIONS
	2SPD-008	BUDGETARY IMPACT DUE TO THE REPLACEMENT OF ORIGINAL LENALIDOMIDE INTO GENERIC LENALIDOMIDE
	2SPD-009	AVOIDED COSTS FROM THE INCLUSION OF BREAST CANCER PATIENTS IN CLINICAL TRIALS
	2SPD-010	REVIEW OF THE ENVIRONMENTAL CRITERIA INTRODUCED IN THE TENDERING OF DRUGS, MEDICAL DEVICES AND NON-MEDICAL EQUIPMENT IN A HEALTH GROUP PROCUREMENT ORGANIZATION
	2SPD-011	COMPARATIVE EFFICACY OF EPTINEZUMAB, GALCANEZUMAB, FREMANEZUMAB AND ERENUMAB IN THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE
	2SPD-012	COMPARATIVE EFFICACY OF ABROCITINIB, BARICITINIB AND UPADACITINIB IN MONOTHERAPY FOR THE TREATMENT OF ATOPIC DERMATITIS
	2SPD-013	INTERVENTIONAL CARDIOLOGY: ANALYSIS OF STERILE MEDICAL DEVICE’S CONSUMPTION AND ASSESSMENT OF DIFFERING PRACTICES
	2SPD-014	COST STUDY: REUSABLE FLEXIBLE URETEROSCOPES VERSUS SINGLE-USE IN A HEALTHCARE FACILITY
	2SPD-015	INDIRECT COMPARISON OF ANIFROLUMAB VS BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS
	2SPD-016	COMPARATIVE EFFICACY OF BIMEKIZUMAB, IXEKIZUMAB AND BRODALUMAB FOR MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
	2SPD-017	TELEPHARMACY AND HOME DELIVERY PROGRAMME FOR OUTPATIENTS THROUGH THE COMMUNITY PHARMACY
	2SPD-018	BEZLOTOXUMAB: STRATEGIES TO REDUCE ECONOMIC IMPACT
	2SPD-019	EXPLORING ECONOMIC AND QUALITATIVE ASPECTS OF DRUG USE IN A PENITENTIARY INSTITUTE
	2SPD-020	IMPACT OF COVID-19 TREATMENT OPTIONS ON HOSPITAL PHARMACY'S WORKLOAD: LESSONS LEARNED

Section 3: Production and Compounding
PDF document	Poster number	Poster Title
	3PC-001	PREPACKED BOXES FOR OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY (OPAT) - A QUESTIONNAIRE SURVEY ON KNOWLEDGE, OPINION AND WISHES
	3PC-002	HAZARDOUS DRUG AND ANTIBIOTIC RESIDUE SURFACE CONTAMINATION - IS THERE A NEED TO REDUCE EXPOSURE?
	3PC-003	99m-Tc- HMPAO LABELED LEUKOCITES: STUDYING ACUTE INFECTION OUTBREAKS – NUCLEAR PHARMACIST IN NUCLEAR MEDICINE
	3PC-004	ECONOMIC SAVINGS OF ERENUMAB REDOSING IN A THIRD LEVEL HOSPITAL
	3PC-005	CLOSED SYSTEM TRANSFER DEVICE (CSTD) EXTENDS PRACTICAL IN-USE SHELF LIFE TO 28 DAYS AFTER FIRST PUNCTURE OF NON-PRESERVED SINGLE-USE-VIALS IN BOTH CONTROLLED AND UNCONTROLLED ENVIRONMENTS
	3PC-006	CONTAINER CLOSURE INTEGRITY TESTING AND PROCES VALIDATION OF CLOSED SYSTEM TRANSFER DEVICES FOR ASEPTIC RECONSTITUTION OF DRUG VIALS CONNECTED TO FLUID BAGS
	3PC-007	IMPACT OF A SUSTAINABILITY STRATEGY IN THE DEVELOPMENT OF STANDARDIZED NEONATAL PARENTERAL NUTRITION ON DEMAND
	3PC-008	SLOW ANAKINRA DESENSITIZATION PROTOCOL DESIGN FOR DELAYED HYPERSENSIBILITY REACTION
	3PC-009	CYCLOPHOSPHAMIDE SURFACE CONTAMINATION IN A ROBOTIC CHEMOTHERAPY COMPOUNDING PROCESS
	3PC-010	FORMULATION OF TACROLIMUS SOLUTION FOR SUBLINGUAL USE
	3PC-011	A VIRTUAL STERILISATION AREA : AN INTERACTIVE TRAINING TOOL
	3PC-012	IMPACT AND SATISFACTION IN DRUG ADDICTS ATTENTION CENTERS AFTER INCREASING THE STABILITY OF METHADONE ORAL SOLUTION
	3PC-013	FORMULATION AND ELABORATION OF INTRATHECAL TRASTUZUMAB FOR THE TREATMENT OF A MENINGEAL CARCINOMATOSIS
	3PC-014	METAMORPHINE INSTEAD OF POLYSUBSTANCE USE?
	3PC-015	IN-USE STABILITY OF COMIRNATY AND SPIKEVAX CLINICAL SOLUTIONS: PFIZER-BIONTECH AND MODERNA COVID-19 VACCINES. A COMPARATIVE STUDY FROM A HOSPITAL PHARMACY PERSPECTIVE
	3PC-016	DOES A HOSPITAL COMPRESSOR SYSTEM CONTINOUSLY DELIVER MEDICINAL AIR ACCORDING TO THE EUROPEAN PHARMACOPAEIA?
	3PC-017	IMPACT OF AGITATION ON PEMBROLIZUMAB (KEYTRUDA®) SAFETY AND EFFICACY: AGGREGATION AND FUNCTIONALITY.
	3PC-018	TIME TO AVAILABILITY OF INJECTABLE ANTICANCER DRUGS FOR OUTPATIENTS: REASSESSMENT IN A FRENCH COMPREHENSIVE CANCER CENTER
	3PC-019	INDIGO CARMINE SOLUTION AND ADRENALINE IN SUBMUCOSAL CHROMOENDOSCOPY
	3PC-020	CLOBETASOL PETROLATUM OINTMENT 0.015% FOR THE TREATMENT OF CUTANEOUS GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS: A CASE REPORT.
	3PC-021	AMPHOTERICIN AND COLISTIN GELS FOR NECROTIZING WOUNDS: GALENIC AND MICROBIOLOGICAL VALIDATION.
	3PC-022	FORMULATION AND QUALITY CONTROL OF A BISOPROLOL 0.5 MG/ML ORAL SOLUTION FOR PAEDIATRIC USE
	3PC-023	PATCH TESTS WITH ETHAMBUTOL 10%, ISONIAZID 15% AND PYRAZINAMIDE 25%: A CASE REPORT.
	3PC-024	THE PREPARATION PERSONALIZED OF IMMUNOGLOBULIN BAGS TO IMPROVE THE TREATMENT PATH OF NEUROLOGICAL PATIENTS
	3PC-025	OUTPATIENT PARENTERAL ANTIBIOTIC THERAPY (OPAT): AN EXAMPLE DURING THE COVID-19 HEALTH EMERGENCY.
	3PC-026	EFFECTIVENESS AND SAFETY OF INSULIN 1UI/ml EYE DROPS
	3PC-027	STABILITY OF TACROLIMUS ORAL SUSPENSION IN DISPOSABLE POLYPROPYLENE SYRINGE
	3PC-028	FORMULATION OF AN ORAL PLATELET LYSATE GEL TO TREAT CHRONIC GRAFT VERSUS HOST DISEASE ASSOCIATED ORAL MUCOSITIS. EFFECTIVENESS IN A SERIES OF CASES
	3PC-029	MANAGEMENT OF A CHEMOTHERAPY PRODUCTION AFTER A CYBER-ATTACK IN A PUBLIC HOSPITAL
	3PC-030	EVALUATION OF EXCIPIENTS USED IN PAEDIATRIC COMPOUNDED FORMULATIONS PRESCRIBED IN A NEONATAL INTENSIVE CARE UNIT
	3PC-031	A DELPHI METHOD TO STANDARDIZE THE PREPARATION OF AUTOLOGOUS SERUM EYE DROPS ?
	3PC-032	USE OF ORAL KETAMINE FORMULATION IN PATIENTS WITH CHRONIC REFRACTORY PAIN
	3PC-033	ECONOMIC IMPACT OF CENTRALIZING PEDIATRIC INTRAVENOUS ADMIXTURES
	3PC-034	USE OF A MIXTURE OF BLEOMYCIN, LIDOCAINE AND EPINEPHRINE IN THE TREATMENT OF KELOID SCARS.ON THE SUBJECT OF A CASE.
	3PC-035	GALENIC DEVELOPMENT OF A GENERIC SPECIALTY WITH CONVENTIONAL RELEASE BASED ON ACARBOSE
	3PC-036	CENTRALIZED AND PERSONALIZED PREPARATION OF INTRAVENOUS KETAMINE FOR PATIENTS WITH RESISTANT DEPRESSION
	3PC-037	LIQUID CHROMATOGRAPY MASS SPECTROMETRY ANALYSIS OF DOXORUBICIN AND EPIRUBICIN AFTER FREEZING

Section 4: Clinical Pharmacy Services
PDF document	Poster number	Poster Title
	4CPS-001	EMICIZUMAB IN ACQUIRED HAEMOPHILIA TYPE A: A CASE REPORT.
	4CPS-002	SAFETY AND EFFECTIVENESS OF MONOCLONAL ANTIBODIES FOR MIGRAINE PREVENTION AFTER TWO AND A HALF YEARS OF CLINICAL EXPERIENCE
	4CPS-003	EXPERIENCES WITH A BEST POSSIBLE MEDICATION HISTORY (BPMH) CONDUCTED BY PHARMACY STUDENTS IN THE HOSPITAL SETTING: A SCOPING REVIEW
	4CPS-004	TRENDS IN TREATMENTS DURING COVID-19 PANDEMIA IN A UNIVERSITY TERTIARY HOSPITAL
	4CPS-005	SUCCESSFUL TREATMENT OF OSTEOMYELITIS CAUSED BY DIFFICULT-TO-TREAT RESISTANT PSEUDOMONAS AERUGINOSA WITH CEFIDEROCOL AS MONOTHERAPY: A CASE REPORT
	4CPS-006	COMPLETE CLINICAL RESPONSE IN METASTATIC BREAST CANCER AFTER FRONT-LINE TREATMENT WITH RIBOCICLIB/TAMOXIFEN
	4CPS-007	TARGETING PATIENTS WITH PNEUMONIA BY COVID-19 THAT COULD BE BENEFICIATED BY COLCHICINE.
	4CPS-008	DOES COMORBIDITY AFFECT ADHERENCE TO INHALERS IN SEVERE ASTHMA PATIENTS TREATED WITH BIOLOGICS?
	4CPS-009	Δ-9-TETRAHYDROCANNABINOL(SATIVEX) FOR THE TREATMENT OF MULTIPLE SCLEROSIS SPASTICITY : EVALUATION OF EFFECTIVENESS AND SAFETY
	4CPS-010	DUPILUMAB FOR THE TREATMENT OF ATOPIC DERMATITIS: EVALUATION OF EFFECTIVENESS AND SAFETY
	4CPS-011	CLINICAL AND ECONOMIC IMPACT OF PHARMACIST ANTIMICROBIAL INTERVENTIONS IN A SMALL HOSPITAL
	4CPS-012	PLATELET TO LYMPHOCYTE RATIO (PLR) AS BIOLOGICAL MARKER OF INTEREST IN INMUNOTHERAPY
	4CPS-013	TREOSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH SICKLE CELL DISEASE. EFFICACY AND SAFETY.
	4CPS-014	COMPARISON OF TWO PROTOCOLS FOR THE ADMINISTRATION OF LEUCOVORIN RESCUES AFTER HIGH DOSE METHOTREXATE INFUSION OF 24 HOURS
	4CPS-015	ROLE OF CLINICAL PHARMACIST IN THE OPTIMISATION OF NIRMATRELVIR/RITONAVIR PRESCRIPTION IN THE EMERGENCY DEPARTMENT
	4CPS-016	PREDICTIVE PERFORMANCE OF GLOMERULAR FILTRATION RATE EQUATIONS BASED ON CYSTATIN C, CREATININE AND THEIR COMBINATION IN CRITICALLY ILL PATIENTS
	4CPS-017	REAL-WORLD EVIDENCE ON RHEUMATOID ARTHRITIS TREATMENT PERSISTENCE: JANUS KINASE INHIBITORS VERSUS BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS.
	4CPS-018	EVOLUTION OF ANTIMICROBIAL USE IN COVID-19 PATIENTS
	4CPS-019	QUALITY ASSESSMENT OF THE EVIDENCE UNDERPINNING PHARMACIST-LED ANTIMICROBIAL STEWARDSHIPS INTERVENTIONS
	4CPS-020	TREATMENT PERSISTENCE AND DISCONTINUATION REASONS OF JANUS KINASE INHIBITORS IN A REAL-WORLD SETTING OF RHEUMATOID ARTHRITIS PATIENTS.
	4CPS-021	EFFECTIVENESS, PERSISTENCE, AND ADHERENCE OF BARICITINIB IN RHEUMATOID ARTHRITIS: LONG-TERM REAL-WORLD EVIDENCE STUDY
	4CPS-022	ADHERENCE TO EVOLOCUMAB AND ITS IMPACT ON LDL CHOLESTEROL REDUCTION
	4CPS-023	TOPICAL RAPAMYCIN IN RARE TUBEROUS SCLEROSIS DISEASE: LIPOSOMAL FORMULATION STABILITY
	4CPS-024	COMPARISON OF CHANGES IN CLINICAL VALUES OF INTENSIVE CARE PATIENTS AT VETERANS HOSPITAL ACCORDING TO VARIOUS FAT EMULSIONS FOR PARENTERAL NUTRITION
	4CPS-025	FREMANEZUMAB UTILISATION STUDY AND EFFECTIVENESS IN THE ‘REAL WORLD’
	4CPS-026	EFFECTIVENESS OF SODIUM ZIRCONIUM CYCLOSILICATE IN REDUCING POTASSIUM CONCENTRATIONS IN HOSPITALISED PATIENTS
	4CPS-027	COST SAVINGS IMPACT AND EFFECTIVENESS OF OMALIZUMAB OPTIMISATION IN REFRACTORY CHRONIC URTICARIA.
	4CPS-028	DRUG BURDEN INDEX EVALUATION IN INSTITUTIONALIZED GERIATRIC PATIENTS AS A DEPRESCRIPTION STRATEGY
	4CPS-029	ECONOMIC IMPACT OF BIOLOGICAL TREATMENT OPTIMISATIONS IN RHEUMATOLOGICAL AND DERMATOLOGICAL DISEASES
	4CPS-030	IMPACT OF PHARMACEUTICAL PROPOSALS IN MULTIDISCIPLINARY PROGRAMME FOR CLINICAL DECISION-MAKING IN IMMUNE-MEDIATED INFLAMMATORY DISEASES
	4CPS-031	THERAPEUTIC DRUG MONITORING OF CEFTAZIDIME/AVIBACTAM ADMINISTERED BY CONTINUOUS INFUSION: PK/PD TARGET ACHIEVEMENT AND CLINICAL OUTCOMES
	4CPS-032	THE USE OF LEAN METHODOLOGY IN CLINICAL PHARMACOKINETICS - A RETROSPECTIVE ANALYSIS
	4CPS-033	EVALUATION OF THE EFFECTIVENESS OF REINDUCTION OR INTENSIFICATION WITH USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE
	4CPS-034	ANALYSIS OF THE EFFECTIVENESS OF SOTROVIMAB IN PATIENTS DIAGNOSED WITH COVID-19
	4CPS-035	ASSOCIATON OF DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY WITH CAPECITABINE TOLERANCE
	4CPS-036	SUCCESSFUL TREATMENT OF POSTSURGICAL MENINGITIS CAUSED BY BACILLUS CEREUS: A CASE REPORT
	4CPS-037	INDIRECT COMPARISONS OF BIOLOGICAL TREATMENTS IN PSORIATIC ARTHRITIS
	4CPS-038	CHALLENGES RELATED TO TRANSITIONING FROM HOSPITAL TO TEMPORARY CARE AT A SKILLED NURSING FACILITY
	4CPS-039	CLINICAL AND ECONOMIC IMPACT OF MULTISWITCHING FROM ORIGINAL ADALIMUMAB TO BIOSIMILARS.
	4CPS-040	ELECTRONIC CLINICAL DECISION SUPPORT FOR PHARMACOTHERAPEUTIC INTERVENTIONS TO REDUCE ANTICHOLINERGIC BURDEN IN OLDER HOSPITALISED PATIENTS
	4CPS-041	ASSESSMENT OF QUALITY OF LIFE IN PATIENTS UNDERGOING ANTIMIGRAINE TREATMENT
	4CPS-042	OFF-LABEL USE OF USTEKINUMAB IN NONBULLOUS CONGENITAL ICHTHYOSIFORM ERYTHRODERMA: A CASE REPORT
	4CPS-043	DRUG-DRUG INTERACTIONS WITH NIRMATRELVIR/RITONAVIR FOR COVID-19 AND THE ROLE OF HOSPITAL PHARMACISTS
	4CPS-044	EFFECTIVENESS AND SAFETY OF DIFFERENT INITIAL DOSES OF ARIPIPRAZOLE INTRAMUSCULAR DEPOT
	4CPS-045	ECOLOGICAL AND CLINICAL IMPACT OF AN ANTIMICROBIAL STEWARDSHIP PROGRAMME ON THE INCIDENCE OF CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE
	4CPS-046	A QUALITATIVE STUDY OF FEASABILITY AND ACCEPTABILITY OF A PHARMACY PRIORITISATION TOOLKIT BY A FRAILTY FOCUSED MULTIDICIPLINARY TEAM IN AN ACUTE HOSPITAL EMERGECY DEPARTMENT
	4CPS-047	IMPACT OF CORTICOSTEROID ON THE EFFECTIVENESS OF IMMUNOTHERAPY
	4CPS-048	ANALYSIS OF PAXLOVID® FOR THE TREATMENT OF COVID-19 IN ARAGÓN, SPAIN
	4CPS-049	TELEPHARMACY AND NEW HEALTHCARE MODELS: CLOSER TO PATIENTS
	4CPS-050	ANALYSIS OF REAL-LIFE USE OF IBRUTINIB AFTER RELAPSE TO CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA
	4CPS-051	IMPACT OF THE NEW ANTIEPILEPTIC DRUG MONITORING PROGRAMME ON THE ACTIVITY OF THE PHARMACY AND NEUROLOGY DEPARTMENTS
	4CPS-052	LONG-TERM MONITORING OF UREA AS TREATMENT FOR HYPONATREMIA ASSOCIATED TO INADEQUATE SECRETION OF ANTIDIURETIC HORMONE (ISADH)
	4CPS-053	KOUNIS SYNDROME SECONDARY TO METAMIZOLE: A CASE REPORT
	4CPS-054	USE OF INTRATHECAL LIPOSOMAL-AMPHOTERICIN B FOR CANDIDA MENINGITIS: A CASE REPORT.
	4CPS-055	EFFECTIVENESS AND SAFETY OF RIBOCICLIB IN THE FIRST LINE OF LUMINAL METASTATIC BREAST CANCER.
	4CPS-056	A CLINICAL AND COST ANALYSIS OF MEDICINES RECONCILIATION BY CLINICAL PHARMACISTS ON HOSPITAL DISCHARGE
	4CPS-057	SEARCHING FOR A TREATMENT FOR PERIPHERAL TISSUE ISCHEMIA IN NEWBORNS. A CASE REPORT.
	4CPS-058	SYMBALOO AS DIGITAL TOOL FOR HEMOPHILIA
	4CPS-059	EFFICACY AND SAFETY OF EARLY SWITCH TO ORAL ANTIBIOTHERAPY IN PNEUMOLOGY: PROPENSITY SCORE-MATCHED ANALYSIS
	4CPS-060	EFFECTIVENESS AND ECONOMIC ANALYSIS OF WEIGHT-BASED VERSUS FIXED DOSING OF PEMBROLIZUMAB IN NON SMALL CELL LUNG CANCER
	4CPS-061	APPLICATION OF PROPORTION OF DAY COVERED (PDC) TO EVALUATE ADHERENCE AND PERSISTENCE TO TREATMENT WITH FINGOLIMOD IN PATIENTS WITH MULTIPLE SCLEROSIS
	4CPS-062	EVALUATION AND FOLOW-UP OF PEDIATRIC PATIENT WITH SHORT BOWEL SYNDROME ON TREATMENT WITH TEDUGLUTIDE: CASE REPORT
	4CPS-063	USING MACHINE LEARNING TO PREDICT PHARMACEUTICAL INTERVENTIONS IN A HOSPITAL SETTING
	4CPS-064	EFFECTIVENESS OF RIBOCICLIB AND ABEMACICLIB AS FIRST LINE TREATMENT FOR METASTATIC BREAST CANCER IN POST-MENOPAUSAL WOMEN.
	4CPS-065	SIMULATION OF THE IMPACT OF PHARMACOGENETIC MONITORING OF CYTOCHROME P450 2C19 IN PATIENTS ON CLOPIDOGREL TREATMENT
	4CPS-066	BIOLOGICAL TREATMENTS USED TO TREAT HIDRADENITIS SUPPURATIVA IN A TERTIARY HOSPITAL
	4CPS-067	A CROSS-SECTORAL PHARMACIST INTERVENTION FOR PATIENTS IN TRANSITION BETWEEN HOSPITAL AND GENERAL PRACTICE: A PILOT STUDY
	4CPS-068	CONDUCTION OF AN AUDIT TO REDUCE THE ECONOMIC LOSS DUE TO UNUTILIZED ONCOLOGICAL DRUG PREPARATIONS
	4CPS-069	EXPERIENCE OF ONCOHEMATOLOGY PATIENTS IN OUTPATIENT THERAPY WITH COMPREHENSIVE MEDICATION MANAGEMENT IN THE CONTEXT OF A COVID 19 PANDEMIC
	4CPS-070	THE CLINICAL PHARMACIST : AN ESSENTIAL ACTOR IN TIMES OF CRISIS
	4CPS-071	IMPACT OF INADEQUATE EMPIRICAL THERAPY ON THE MORTALITY RATE IN PSEUDOMONAS AERUGINOSA INFECTIONS
	4CPS-072	REAL-WORLD EXPERIENCE IN HEMOPHILLIA B PATIENTS AFTER SWITCHING TO FIX EXTENDED HALF LIFE USING PHARMACOKINETIC POBLACIONAL SOFTWARE AND MONOCOMPARTIMENTAL MODEL
	4CPS-073	ANALYSIS OF EFFECTIVENESS AND POSITIVE PREDICTIVE VALUE OF ANTIMICROBIAL STEWARDSHIP ALERTS USING A CLINICAL-DECISSION SUPPORT SYSTEM
	4CPS-074	EFFICACY AND SAFETY OF SOTROVIMAB: RESULTS OF A RETROSPECTIVE OBSERVATIONAL STUDY IN A FRENCH HOSPITAL
	4CPS-075	PERSISTENCE AND COST ANALYSIS OF SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIASIS
	4CPS-076	EFFECTIVENESS AND TOLERABILITY OF CYCLIN-DEPENDENT KINASE INHIBITOR TREATMENT IN METASTATIC BREAST CANCER: REAL-LIFE DATA.
	4CPS-077	CLINICAL-EPIDEMIOLOGICAL CHARACTERISTICS OF A COHORT OF PATIENTS TREATED WITH DORAVIRINE
	4CPS-078	ASSESSMENT OF THE QUALITY OF A HOSPITAL'S CLINICAL TRIAL INITIATION VISIT
	4CPS-079	COMPARATIVE ANALYSIS OF THE EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM ADMINISTERED BY INTERMITTENT INFUSION VERSUS CONTINUOUS INFUSION
	4CPS-080	OPTIMIZATION OF ANTIRETROVIRAL THERAPY: RESULTS AFTER SIMPLIFICATION TO BITHERAPY WITH DOLUTEGRAVIR/LAMIVUDINE OR DOLUTEGRAVIR/RILPIVIRINE.
	4CPS-081	EVALUATION OF EFFECTIVENESS, SAFETY AND ADHERENCE OF PRE-EXPOSURE PROPHYLAXIS AGAISNT HIV
	4CPS-082	MOST FREQUENT ERRORS IN THE INHALATION TECHNIQUE OF ASTHMATIC CHILDREN
	4CPS-083	CREATININE AND CYSTATIN-BASED ESTIMATED RENAL FUNCTION IN VANCOMYCIN MONITORING
	4CPS-084	EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER WITH VERY HIGH VS HIGH PD-L1 EXPRESSION
	4CPS-085	PHARMACEUTICAL INTERVENTIONS IN A NEONATOLOGY UNIT
	4CPS-086	COMPARISON OF A TRADITIONAL ELISA TECHNIQUE VERSUS A POINT-OF-CARE TECHNIQUE IN THE DETERMINATION OF ADALIMUMAB LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
	4CPS-087	PERSISTENCE IN THE METHADONE MAINTENANCE PROGRAMME AND ITS RELATIONSHIP WITH THE MEDICATION REGIMEN COMPLEXITY INDEX IN OPIOID DEPENDENT PATIENTS
	4CPS-088	CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND EFFICACY IN NON-SMALL CELL LUNG CANCER TREATED WITH NIVOLUMAB
	4CPS-089	CURRENT STATUS OF HEPATITIS C VIRUS INFECTION
	4CPS-090	A REVIEW OF PHARMACY HOMECARE SERVICES WITHIN A GROUP OF UK HOSPITAL PHARMACIES
	4CPS-091	WHAT YOU NEED TO KNOW ABOUT BRUGADA SYNDROME IF YOU ARE A HOSPITAL PHARMACIST
	4CPS-092	STATISTICAL RELATIONSHIP BETWEEN BIOMARKERS WITH PROGNOSTIC VALUE IN ANTI-PDL1 TREATMENTS IN CANCER PATIENTS
	4CPS-093	POLYPHARMACY AND INAPPROPRIATE DRUGS IN PATIENTS WITH OROPHARYNGEAL DYSPHAGIA
	4CPS-094	ANALYSIS OF INTERVENTIONS ON ANTIBIOTIC PRESCRIPTIONS BY THE ANTIMICROBIAL STEWARDSHIP PROGRAMS AT THE EMERGENCY DEPARTMENT
	4CPS-095	INFUSION AUDIT IN HEMATOLOGY: IMPORTANCE OF EVALUATION AND OPTIMIZATION OF PROFESSIONAL PRACTICES
	4CPS-096	EVOLUTION OF SELECTIVE IMMUNOMODULATE THERAPY IN SPECIAL SITUATIONS
	4CPS-097	COMPARATIVE EFFECTIVENESS OF RISANKIZUMAB AND SECUKINUMAB IN MODERATE TO SERIOUS PSORIASIS.
	4CPS-098	NIRMATRELVIR-RITONAVIR EFFECTIVENESS ANALYSIS AND INTERACTION PROFILE ANALYSIS
	4CPS-099	NINTEDANIB AND PIRFENIDONE IN IDIOPATHIC PULMONARY FIBROSIS: COMPARATIVE EFFECTIVENESS AND SAFETY IN A THIRD-LEVEL HOSPITAL
	4CPS-100	VALIDITY, RELIABILITY AND USER-PRACTICABILITY OF A CLASSIFICATION TOOL FOR DRUG-RELATED PROBLEMS AND PHARMACIST INTERVENTIONS WITHIN AN UPPER AUSTRIAN HOSPITAL TRUST
	4CPS-101	CAUSALITY OF ADVERSE DRUG REACTIONS IN HIV-PATIENTS TREATED WITH BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE
	4CPS-102	DRUG RELATED PROBLEMS SECONDARY TO HEPARIN TREATMENT IN PATIENTS DISCHARGED FROM THE EMERGENCY DEPARTMENT
	4CPS-103	PHARMACOKINETIC INTERACTION STUDY OF OSIMERTINIB AND DIGOXIN: A CASE REPORT
	4CPS-104	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN A UNIT DOSE AREA
	4CPS-105	CEFIDEROCOL TREATMENT IN COVID-19 POSITIVE PATIENTS CO-INFECTED WITH PAN-RESISTANT PSEUDOMONAS AERUGINOSA
	4CPS-106	BEDSIDE CHECK OF MEDICATION APPROPRIATENESS (BED-CMA) AS A RISK-BASED TOOL FOR BEDSIDE CLINICAL PHARMACY SERVICES: A PROOF-OF-CONCEPT STUDY AT THE TRAUMA SURGERY WARD
	4CPS-107	EFFECT OF PATIENT BODY WEIGHT ON THE PHARMACOKINETIC BEHAVIOR OF AMIKACIN
	4CPS-108	PATIENT AND PHYSICIANS'S SATISFACTION WITH CLINICAL PHARMACY SERVICES ON A HEMATOLOGY WARD IN A LARGE TERTIARY CARE HOSPITAL
	4CPS-109	THERAPEUTIC DRUG MONITORING OF VANCOMYCIN IN ONCOLOGIC AND HEMATOLOGIC PATIENTS: REAL-WORLD DATA
	4CPS-110	ASSOCIATION BETWEEN BASELINE CHARACTERISTICSTS AND FIRST LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER PATIENTS
	4CPS-111	IMPORTANCE OF IMPLEMENTING A CLINICAL PHARMACOKINETIC UNIT IN HOSPITAL PHARMACY SERVICE
	4CPS-112	SURVEY OF DIETARY SUPPLEMENT USE AND VACCINATION STATUS AMONG RHEUMATOID ARTHRITIS PATIENTS DURING THE COVID-19 PANDEMIC
	4CPS-113	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS AND ACTIVITY IN THE ARTHROPATHY PHARMACEUTICAL CARE PRACTICE IN A REGIONAL HOSPITAL
	4CPS-114	DEVELOPMENT AND PROSPECTIVE VALIDATION OF A PREDICTION MODEL TO IDENTIFY CLINICALLY RELEVANT MEDICATION DISCREPANCIES AT THE EMERGENCY DEPARTMENT
	4CPS-115	DEVELOPMENT AND IMPLEMENTATION OF A REVIEW PROGRAMME ASSISTED BY THE PHARMACIST TO IMPROVE THE ADEQUACY OF TREATMENT IN POLYMEDICATED PATIENTS IN HOSPITAL OUTPATIENT SETTING
	4CPS-116	THE EFFICIENCY AND COST-EFFECTIVENESS OF HEALTHCARE AND NUTRITIONAL INTERVENTIONS IN THE MANAGEMENT OF POST-STROKE OROPHARYNGEAL DYSPHAGIA, RESULTS OF A SYSTEMATIC REVIEW
	4CPS-117	USE OF ERYTHROMYCIN AS PROKINETIC IN CRITICALLY HOSPITALIZED PATIENTS
	4CPS-118	HEALTH OUTCOMES IN A COHORT OF HIV+ PATIENTS STRATIFIED USING THE KAISER PERMANENTE PYRAMID POPULATION-BASED RISK STRATIFICATION MODEL
	4CPS-119	PNEUMONOLOGY-PHARMACY COLLABORATION IN THE PHARMACOTHERAPEUTIC OPTIMIZATION OF MONOCLONAL ANTIBODIES IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA
	4CPS-120	ADVERSE EFFECTS OF ANTIRETROVIRALS: EXPERIENCE OF PATIENTS. «TALK ABOUT IT TO BETTER MANAGE IT»
	4CPS-121	ANALYSIS OF THE USE OF INTRAVENOUS IRON IN OUTPATIENTS
	4CPS-122	CLINICAL FOLLOW-UP IN PATIENTS WITH MIGRAINE AFTER DISCONTINUATION OF PROPHYLACTIC BIOLOGICAL TREATMENT: A REAL-WORLD EXPERIENCE
	4CPS-123	CASE-CONTROL STUDY ON THE ASSOCIATION BETWEEN NOSOCOMIAL BLOODSTREAM INFECTIONS AND GLUCOCORTICOIDS, TOCILIZUMAB, SYSTEMIC ANTIBIOTICS, MECHANICAL VENTILATION AND LENGTH OF HOSPITAL STAY IN COVID-19 HOSPITALISED PATIENTS
	4CPS-124	EFFICACY AND SAFETY OF ERENUMAB IN A SECOND-LEVEL HOSPITAL
	4CPS-125	PREEXPOSURE PROPHYLAXIS IN MEN AT HIGH RISK FOR HIV-1 INFECTION
	4CPS-126	LINEZOLID STUDY USE AND ASSESSMENT THE APPROPRIATENESS OF ITS PRESCRIPTION IN A REGIONAL HOSPITAL
	4CPS-127	PHARMACOKINETIC MONITORING OF VANCOMYCIN, GENTAMICIN AND AMIKACIN IN PAEDIATRIC POPULATION
	4CPS-128	CLINICAL PRACTICE: ANTI-VEGF THERAPY FOR RESISTANT MACULAR EDEMA.
	4CPS-129	REAL-LIFE EFFECTIVENESS AND SAFETY OF NIRAPARIB AND OLAPARIB IN HIGH-GRADE OVARIAN CANCER
	4CPS-130	EVALUATION OF TIXAGEVIMAB-CILGAVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-19
	4CPS-131	SOCIAL FUNCTION OF THE TELEPHARMACY: A SOCIOECONOMIC ANALYSIS
	4CPS-132	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS REGARDING ADMISSION RECONCILIATION
	4CPS-133	SAFETY AND EFFECTIVENESS OF GUSELKUMAB ON MODERATE TO SEVERE PLAQUE PSORIASIS
	4CPS-134	PERSISTENCE AND SHIFT IN THE TREATMENT OF PSORIASIS IN THE PERIOD 2019 - 2021
	4CPS-135	MELANOMA ADJUVANT THERAPY: from trials to clinical practice215
	4CPS-136	STANDARD FIRST DAY OF LIFE CENTRAL PARENTERAL NUTRITION, EXPERIENCE IN REAL CLINICAL PRACTICE
	4CPS-137	EVALUATING THE POTENTIAL CLINICAL AND ECONOMIC IMPACT OF CHEMOTHERAPY PRESCRIBING BY PHARMACISTS AT A UNIVERSITY TEACHING HOSPITAL
	4CPS-138	USE OF SODIUM ZIRCONIUM CYCLOSILICATE IN HYPERKALEMIC EMERGENCIES
	4CPS-139	THE PHARMACEUTICAL NEWSLETTER AS AN INFORMATION TOOL: USEFUL OR FUTILE ?
	4CPS-140	MEDICAL CANNABIS: PRESCRIPTION ANALYSIS IN TERMS OF FORMULATION AND THERAPEUTIC NEED IN AN HOSPITAL PHARMACY
	4CPS-141	PHARMACEUTICAL INTERVENTIONS IN A MEDICAL EMERGENCY DEPARTMENT: 6-MONTHS EXPERIENCE
	4CPS-142	EVALUATION OF PREMEDICATION USE IN ADVERSE DRUG REACTIONS OCCURENCE IN PATIENTS WHO RECEIVED INFLIXIMAB TO TREAT INFLAMMATORY BOWEL DISEASE
	4CPS-143	CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA FOLLOWING IMMUNE CHECKPOINT INHIBITION FOR SOLID TUMORS: TWO CASE REPORTS AND LITERATURE STATE OF THE ART.
	4CPS-144	EXPERIENCE OF USING REMDESIVIR IN THE TREATMENT OF PATIENTS WITH SARS-COV2 INFECTION
	4CPS-145	CONSENSUS VALIDATION OF A SCREENING TOOL FOR CARDIOVASCULAR PHARMACOTHERAPY IN GERIATRIC PATIENTS: THE RASP_CARDIO LIST
	4CPS-146	‘REAL WORLD’ EXPERIENCE OFELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN THE TREATMENT OF CYSTIC FIBROSIS: EFFECTIVENESS AND SAFETY EVALUATION
	4CPS-147	REAL WORLD DATA (RWD) ANALYSIS ON USE OF IMMUNECHECKPOINT INHIBITORS (ICI) FOR NON-SMALL CELL LUNG CANCER (NSCLC)
	4CPS-148	USE OF ANTIVIRALS AUTHORIZED FOR THE TREATMENT OF COVID-19 IN PATIENTS NOT SUBJECT TO HOSPITAL ADMISSION
	4CPS-149	PAIN MANAGEMENT IN MENTAL HEALTH.
	4CPS-150	THE ROLE OF CLINICAL PHARMACIST IN EMERGENCY DEPARTMENT
	4CPS-151	ACETYLSALICYLIC ACID DESENSITIZATION IN PATIENTS WITH CORONARY ARTERY SYNDROME: LITERATURE REVIEW, RETROSPECTIVE ANALYSIS AND PATIENT FOLLOW-UP PROCEDURE IN AN ITALIAN CARDIOLOGICAL CENTER
	4CPS-152	PERSISTENT CYTOPENIA AFTER CAR-T CELLS: TREATMENT WITH ELTROMBOPAG. A CASE REPORT.
	4CPS-153	OFF-LABEL USE OF KETAMINE FOR RESISTANT DEPRESSION: ROLE OF THE HOSPITAL PHARMACIST
	4CPS-154	IFOSFAMIDE-INDUCED HEMORRHAGIC CYSTITS: INCIDENCE IN A PATIENT SAMPLE AND POSSIBLE CHEMIOTHERAPY PROTOCOL REVIEW
	4CPS-155	CREATION AND VALIDATION OF A MEDICATION REVIEW SUPPORT TOOL FOR POTASSIUM CHLORIDE INJECTION (KCl-inj) PRESCRIPTIONS
	4CPS-156	ANALYSIS OF EFECTIVENESS AND COSTS OF DRUG THERAPY PRESCRIBED IN SPECIAL SITUATIONS IN OUR HOSPITAL
	4CPS-157	COMPARISON OF THE EFFECTIVENESS BETWEEN INTERLEUKIN-23 INHIBITORS FOR TREATMENT OF PSORIASIS IN A THIRD LEVEL HOSPITAL
	4CPS-158	IMPROVEMENT IN PATIENT CARE BY PHARMACIST PHONE CALL AFTER STARTING TREATMENT
	4CPS-159	ESTIMATING RENAL FUNCTION FOR DRUG DOSING: CORRELATION BETWEEN CKD-EPI AND COCKCROFT-GAULT IN AN ELDERLY POPULATION
	4CPS-160	REAL-WORLD PERSISTENCE WITH DOLUTEGRAVIR/LAMIVUDINE VERSUS BICTEGRAVIR/EMTRICITABINA/TENOFOVIR ALAFENAMIDE AMONG HUMAN IMMUNODEFICIENCY VIRUS PATIENTS
	4CPS-161	NEGATIVE PRESSURE WOUND THERAPY IMPORTANCE IN WOUND CARE
	4CPS-162	TRIPLE WHAMMY DRUG-DRUG INTERACTION: CLINICAL RELEVANCE AND RESULTS OF PHARMACEUTICAL INTERVENTION.
	4CPS-163	CYTOCHROME P450 2C19 GENOTYPING FOR PERSONALISATION OF PROTON PUMP INHIBITOR THERAPY
	4CPS-164	ADEQUACY REVIEW IN THE USE OF DAPAGLIFLOZIN FOR THE TREATMENT OF HEART FAILURE.
	4CPS-165	ADAPTATION OF MARKETED PARENTERAL NUTRITION TO THE NEEDS OF A HOSPITAL.
	4CPS-166	IMPLEMENTATION OF A LINEZOLID PHARMACOKINETIC MONITORING PROGRAMME
	4CPS-167	CURRENT TRENDS IN THE USE OF CHECK-POINT INHIBITORS FOR NON-SMALL CELL LUNG CANCER
	4CPS-168	RESULTS OF THE USE OF GALCANEZUMAB IN ROUTINE CLINICAL PRACTICE
	4CPS-169	PHYSICOCHEMICAL CHARACTERIZATION OF ORAL LIQUID FORMS AND REVIEW OF THE LITERATURE FOR SAFE AND EFFECTIVE ADMINISTRATION BY ENTERAL FEEDING TUBES
	4CPS-170	THE HOSPITAL PHARMACIST ROLE IN MULTIDISCIPLINARY TEAM DURING THE VACCINATION CAMPAIGN
	4CPS-171	METHADONE DRUG-DRUG INTERACTIONS POTENTIALLY RELATED TO CARDIOVASCULAR EVENTS IN CLINICAL PRACTICE
	4CPS-172	BRODALUMAB'S EFFECTIVENESS ON MODERATE TO SEVERE PLAQUE PSORIASIS IN REAL PRACTISE
	4CPS-173	EVALUATION OF INCLUSION CRITERIA OF OUTPATIENTS INCLUDED AT HOSPITAL MEDICATION DISPENSING PROGRAMME THROUGH COMMUNITY PHARMACIES
	4CPS-174	EFFECTIVITY AND SAFETY OF CYCLIN-DEPENDENT KINASE INHIBITORS IN METASTATIC BREAST CANCER PATIENTS
	4CPS-175	SEPSIS CODE: IMPROVING OUTCOMES FOR PATIENTS WITH SEPSIS
	4CPS-176	EVALUATION OF NIRMATRELVIR/RITONAVIR USE AND EFFECTIVENESS
	4CPS-177	OPTIMIZATION OF THE THERAPEUTIC MANAGEMENT OF PATIENTS ON ECMO IN THE PEDIATRIC INTENSIVE CARE UNIT
	4CPS-178	DURABILITY OF TREATMENT AND REASONS FOR DISCONTINUATION OF DIMETHYL FUMARATE AND TERIFLUNOMIDE IN PATIENTS WITH MULTIPLE SCLEROSIS
	4CPS-179	REVERSAL OF ANTICOAGULATION IN ORTHOGERIATRIC PATIENTS WITH HIP FRACTURE REQUIRING EARLY SURGICAL INTERVENTION
	4CPS-180	VANCOMYCIN: CONCORDANCE OF DOSAGE ADJUSTMENT ACCORDING TO MINIMUM PLASMA CONCENTRATION AND AREA UNDER THE CURVE/MINIMUM INHIBITORY CONCENTRATION
	4CPS-181	FOLLOW-UP OF EXPOSED NEWBORNS TO HIV IN PREGNANCY IN A TERTIARY HOSPITAL
	4CPS-182	EXPERIENCE OF DISCONTINUATION TYROSINE KINASE INHIBITORS THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CLINICAL PRACTICE
	4CPS-183	EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN REAL LIFE SETTING
	4CPS-184	WHAT IS THE ADDITIONNAL VALUE OF PHARMACEUTICAL INTERVENTIONS ON [123I]-METAIODOBENZYLGUANIDINE SCINTIGRAPHY?
	4CPS-185	COMPOUNDED INSULIN EYE DROPS: POPULATION CHARACTERISTICS, USE IN CLINICAL PRACTICE AND SAFETY
	4CPS-186	EFFECTIVENESS AND SAFETY OF CILGAVIMAB/TIXAGEVIMAB IN PRE-EXPOSURE PROPHYLAXIS OF COVID-19
	4CPS-187	PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH MONOCLONAL ANTIBODIES FOR PRE-EXPOSURE PROPHYLAXIS OF COVID-19
	4CPS-188	QUALITY OF LIFE IN PATIENTS ON GALCANEZUMAB LONG TERM TREATMENT
	4CPS-189	ANALYSIS OF MEDICATION PERSISTANCE IN MIGRAINE PATIENTS TREATED WITH ANTI-CGRP MONOCLONAL ANTIBODIES
	4CPS-190	ANALYSIS OF IBRUTINIB DOSE REDUCTION IN PATIENTS DIAGNOSED WITH CHRONIC LYMPHOCYTIC LEUKEMIA. ARE WE DOING IT RIGHT?
	4CPS-191	IMPACT OF THE COVID-19 PANDEMIC ON THE ADHERENCE OF HIV PATIENTS
	4CPS-192	ANALYSIS OF ADHERENCE AND ASSOCIATED RISK FACTORS IN MULTIPLE SCLEROSIS PATIENTS UNDER DISEASE-MODIFYING THERAPY
	4CPS-193	SUITABILITY OF THE DUAL ANTIPLATELET THERAPY TO THE GUIDELINES OF EUROPEAN SOCIETY OF CARDIOLOGY IN ACUTE CORONARY SYNDROME
	4CPS-194	BASELINE AUDIT OF POTENTIAL TO OPTIMISE THERAPY THROUGH USE OF SGLT2i IN A COHORT OF PATIENT ADMITTED WITH AN ACUTE MYOCARDIAL INFARCTION
	4CPS-195	E-LUNGING: EVALUATION OF AN E-LEARNING PROGRAM INTENDED FOR HEALTHCARE PROFESSIONALS REGARDING THE MEDICATION OF LUNG TRANSPLANT PATIENTS
	4CPS-196	POTENTIALLY INAPPROPIATE MEDICATIONS AND POTENTIALLY PRESCRIBING OMISSIONS IN OLDER PEOPLE LIVING WITH HIV
	4CPS-197	CONCOMITANT USE OF PROTON PUMP INHIBITORS AND PALBOCICLIB: ¿IS THERE A REAL IMPACT ON RESPONSE?
	4CPS-198	ANALYSIS OF ANTIPSYCHOTIC DRUGS USE AT A SPANISH TERTIARY HOSPITAL
	4CPS-199	PHARMACO-ECONOMIC IMPACT OF DRUG INTOXICATIONS IN CHILDREN
	4CPS-200	SUSTAINING A PHARMACEUTICAL DECISION SUPPORT SYSTEM BY DETERMINING THE CLINICAL RISK’S LEVEL OF DETECTED DRUG-RELATED PROBLEMS
	4CPS-201	PHARMACEUTICAL CARE TO OPTIMIZE TREATMENT FOR ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A PRISON
	4CPS-202	THE USEFULNESS OF A PHARMACY RESIDENT STAGE IN THE CRITICAL CARE UNIT
	4CPS-203	ANTIBIOTIC STEWARDSHIP PROGRAMME INTERVENTIONS IN A THIRD LEVEL HOSPITAL IN SPAIN: A ONE-YEAR REVIEW
	4CPS-204	NATIONAL SURVEY ON CLONIDINE PRESCRIBING PRACTICES IN COMPLEX TRAUMA IN CHILD PSYCHIATRY
	4CPS-205	PHARMACIST’S INTERVENTION IN THE THERAPEUTIC MANAGEMENT OF PATIENTS WITH HEART FAILURE – AN OPPORTUNITY FOR IMPROVEMENT
	4CPS-206	EVALUATION OF IRON CARBOXYMALTOSE VS IRON SUCROSE ADMINISTRATION FOR THE CONTROL OF ANAEMIA IN HOSPITALISED PATIENTS
	4CPS-207	PHARMACEUTlCAL INTERVENTIONS IN AN INTENSIVE CARE UNIT OF EMERGENCY TRAUMA
	4CPS-208	TELEPHARMACY INTERVENTIONS IN PATIENTS WITH CHRONIC DISEASES
	4CPS-209	EXPERIENCE OF THE NOCEBO EFFECT IN PATIENTS WITH SWITCH TO BIOSIMILARS IN RHEUMATOID ARTHRITIS.
	4CPS-210	EFFICACY OF MONOCLONAL ANTIBODIES TO PREVENT PROGRESSION TO SEVERE COVID-19 DISEASE: REAL-LIFE DATA OF A UNIVERSITY HOSPITAL
	4CPS-211	DESIGN AND VALIDATION OF A QUESTIONNAIRE IN ARABIC LANGUAGE EVALUATING CHRONIC RENAL FAILURE PATIENTS'S KNOWLEDGE
	4CPS-212	SPECIALIST PHARMACIST-LED MULTIDISCIPLINARY CARE PATHWAY FOR OPTIMISING LIPID THERAPY – SIX MONTHS INTERIM ANALYSIS
	4CPS-213	CHARACTERISTICS OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN VERSUS KAWAZAKI ON CLINICAL ASPECTS, SPECIFICITIES AND TREATMENT
	4CPS-214	REAL-LIFE RESULTS ON THE USE OF TRASTUZUMAB EMTANSINE IN HER2-POSITIVE METASTATIC BREAST CANCER
	4CPS-215	DESCRIPTION OF THE PRE-EXPOSURE PROPHYLAXIS COVERAGE AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS.
	4CPS-216	OFF-LABEL USE OF RECOMBINANT HUMAN ERYTHROPOIETIN IN JEHOVAH'S WITNESS PATIENTS WITH HIP FRACTURE SUBJECTED TO MAJOR ORTHOPAEDIC SURGERY: A THREE CASES REPORT
	4CPS-217	THE USE OF CYSTIC FIBROSIS CONDUCTANCE REGULATOR MODULATORS IN PATIENTS WITH RARE MUTATION
	4CPS-218	TNF GENE POLYMORPHISMS PREDICTORS OF RESPONSE TO ANTI-TNF DRUGS IN PATIENTS DIAGNOSED WITH MODERATE-SEVERE PSORIASIS
	4CPS-219	AGAMENON-SEOM MODEL FOR THE PREDICTION OF SURVIVAL IN PATIENTS WITH HER2-POSITIVE ADVANCED ESOPHAGOGASTRIC ADENOCARCINOMA RECEIVING TRASTUZUMAB-BASED FIRST-LINE TREATMENT
	4CPS-220	COMPARATIVE ANALYSIS OF SKIN TOXICITY ON PATIENTS WITH METASTATIC COLON CANCER TREATED WITH EPIDERMAL GROWTH RECEPTOR BLOCKING DRUGS.
	4CPS-221	ASSESSMENT OF CLINICAL BENEFIT OF CANCER TREATMENTS ACCORDING TO THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY SCALE
	4CPS-222	HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED > 55 YEARS WITH ACUTE MYELOID LEUKAEMIA
	4CPS-223	BOTULINUM TOXIN TYPE A: THE NON-INVASIVE SUCCESS FOR OVERACTIVE BLADDERS
	4CPS-224	IMPACT OF AUGMENTED RENAL CLEARANCE ON ANTIMICROBIAL DOSING IN SEVERELY BURNED PATIENTS
	4CPS-225	HEALTH IMPACT OF TREATMENT FOR INFLAMMATORY BOWEL DISEASE WITH BIOLOGICAL AGENTS FROM THE PATIENT’S PERSPECTIVE: A CROSS-SECTIONAL STUDY USING PATIENT REPORTED OUTCOME MEASURES (PROMs)
	4CPS-226	CONTINUOUS INFUSION OF VANCOMICYN: WHO ARE THE PATIENT CANDIDATES AND HOW SAFE IT IS?
	4CPS-227	REAL WORLD EVIDENCE OF THE USE OF DEFIBROTIDE FOR PROPHYLAXIS OF VENO-OCCLUSIVE DISEASE AFTER POST-HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN CHILDREN
	4CPS-228	HIGH DOSE PHENOBARBITAL COMA IN PAEDIATRIC REFRACTORY STATUS EPILEPTICUS
	4CPS-229	THE ADDED VALUE OF A NATIONAL ELECTRONIC HEALTH RECORD FOR THE BEST POSSIBLE MEDICATION HISTORY OBTAINED BY A CLINICAL PHARMACIST
	4CPS-230	ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS AGED <60 YEARS WITH ACUTE MYELOID LEUKEMIA
	4CPS-231	EVALUATION OF CLINICAL DATA OF PATIENTS TREATED WITH ANTI-PCSK9 DRUGS IN TWO HEALTH DISTRICTS
	4CPS-232	COMPARATIVE EFFICACY OF RISANKIZUMAB AND GUSELKUMAB IN MODERATE TO SEVERE PLAQUE PSORIASIS
	4CPS-233	PD-L1 EXPRESSION AND HISTOLOGICAL TYPE AS PREDICTORS OF RESPONSE IN METASTASIC NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH PEMBROLIZUMAB IN FIRST LINE
	4CPS-234	DEVELOPMENT AND VALIDATION OF A RAPID HIGH PERFORMANCE CHROMATOGRAPHY METHOD (HPLC) FOR THE DETERMINATION OF LINEZOLID IN HUMAN PLASMA
	4CPS-235	IMPACT OF TELEPHARMACY ON BIOLOGIC THERAPIES ADHERENCE AND CLINICAL OUTCOMES IN PATIENTS WITH PSORIASIS
	4CPS-236	LOSS TO FOLLOW-UP FACTORS OF PEOPLE LIVING WITH HIV
	4CPS-237	HYPERKALEMIA AND RISK FACTORS: SCREENING AND ASSESSSMENT IN HOSPITAL PATIENTS.
	4CPS-238	PROFILE OF ELDERLY PATIENTS AT HIGH FALL RISK AND POLYPHARMACY IN THE EMERGENCY DEPARTMENT.
	4CPS-239	POPULATION PHARMACOKINETICS OF ISAVUCONAZOLE BASED ON PHAMACOGENETICS IN IMMUNOSUPPRESSED PATIENTS
	4CPS-240	FINGOLIMOD: ANALYSIS OF USE AND SAFETY IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
	4CPS-241	FINAL VALIDITY OF A TOOL FOR RATING SIGNIFICANCE OF PHARMACISTS’ CLINICAL CONTRIBUTIONS IN HOSPITAL
	4CPS-242	ISAVUCONAZOLE TREATMENT IN TWO PEDIATRIC PATIENTS DURING EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT: THE ROLE OF THERAPEUTIC DRUG MONITORING.
	4CPS-243	DELAYED HIV TREATMENT AND FACTORS ASSOCIATED
	4CPS-244	ANALYSIS AND COMPARISON OF OLANZAPINE ADMINISTRATION IN SMOKING AND NON-SMOKING PATIENTS
	4CPS-245	PREVENTION OF REFEEDING SYNDROME IN PATIENTS ON PARENTERAL NUTRITION: A REVIEW OF APPROPRIATENESS
	4CPS-246	TREATMENT AND NURSING CARE OF MUCORMYCOSIS IN PAEDIATRICS: A CASE REPORT
	4CPS-247	INITIATIVES TO IMPROVE THE MANAGEMENT OF PATIENTS WITH HEREDITARY ANGIOEDEMA BY HOSPITAL PHARMACY
	4CPS-248	THERAPEUTIC DRUG MONITORING OF LINEZOLID IN SOFT-TISSUE AND OSTEOARTICULAR INFECTIONS: A RETROSPECTIVE ANALYSIS
	4CPS-249	RELATIONSHIP BETWEEN RENAL FUNCTION AND ERTAPENEM PLASMA CONCENTRATION IN ADULT PATIENTS.
	4CPS-250	EXPERIENCE OF TECOVIRIMAT AND CIDOFOVIR USE IN A PATIENT WITH MONKEYPOX: A CASE REPORT
	4CPS-251	HEREDITARY ANGIOEDEMA: IMPACT OF THE BURDEN OF DISEASE IN SPAIN
	4CPS-252	OPTIMIZATION OF ERTAPENEM POSOLOGY IN A CRITICALLY ILL PATIENT BY THERAPEUTIC DRUG MONITORING: A CASE REPORT
	4CPS-253	DESCRIPTIVE STUDY OF THE ONCOLOGY AND HAEMATOLOGY POPULATION, DIAGNOSIS, AND IMMUNOTHERAPY IN PATIENTS OVER 65 YEARS OLD IN A THIRD LEVEL HOSPITAL
	4CPS-254	DAPAGLIFOZIN PRESCRIPTION PRACTICE IN PATIENTS WITH CHRONIC HEART FAILURE
	4CPS-255	ANTIPARKINSONIAN MEDICATION RECONCILIATION: HOW PREVENTING MEDICATION ERRORS PROMOTES THERAPEUTIC QUALITY AND SAFETY
	4CPS-256	ENHANCING THE SAFETY OF INJECTABLE CYTOTOXIC CHEMOTHERAPY AT A TERTIARY CARE HOSPITAL: A RETROSPECTIVE ANALYSIS OF PHARMACISTS’ INTERVENTIONS IN CHEMOTHERAPY PREPARATION SERVICES
	4CPS-257	PREOPERATIVE INTRAVENOUS IRON TO TREAT ANEMIA BEFORE MAJOR ORTHOPEDIC SURGERY
	4CPS-258	PHARMACOKINETICS ALTERATIONS IN FIVE CRITICALLY ILL PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION RECEIVING ISAVUCONAZOL
	4CPS-259	MANAGEMENT OF VORICONAZOLE-INDUCED LIVER TOXICITY IN A PEDIATRIC PATIENT
	4CPS-260	PERSISTENCE, SAFETY AND ASSOCIATED LYMPHOPENIA OF DIMETHYL FUMARATE IN RELAPSING REMITTING MULTIPLE SCLEROSIS, REAL WORLD DATA
	4CPS-261	ANALYSIS OF DRUG INTERACTIONS BETWEEN ORAL ONCOLOGICAL TREATMENT OF PROSTATE CANCER AND CHRONIC MEDICATION.
	4CPS-262	A NOVEL ARTIFICIAL INTELLIGENCE-BASED TOOL TO ASSESS ANTICHOLINERGIC BURDEN: A SURVEY
	4CPS-263	THE PHARMACIST’S ROLE IN OPTIMIZING SURGICAL ANTIBACTERIAL PROPHYLAXIS (SAP)

Section 5: Patient Safety and Quality Assurance
PDF document	Poster number	Poster Title
	5PSQ-001	EFFICACY AND SAFETY OF THE COMBINATION OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA: A CASE REPORT
	5PSQ-002	PHARMACIST IN SECURING DRUG CIRCUIT : FROM PRESCRIPTION TO ADMINISTRATION (ANALYSIS AND ACTIONS)
	5PSQ-003	PERFORMANCE OF A COLD MAINTENANCE DEVICE DURING THE IMPLEMENTATION OF A PNEUMATIC CIRCUIT
	5PSQ-004	EPCLUSA RELATED SLEEPINESS: A CASE REPORT
	5PSQ-005	ANALYSIS OF ANTI-ANGIOGENESIS-RELATED ADVERSE EVENTS ASSOCIATED WITH VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS (VEGFR-TKIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
	5PSQ-006	IMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS' KNOWLEDGE: A 7-MONTHS ANALYSIS
	5PSQ-007	IMPACT OF PUIZZLE, A PLAYFUL EDUCATIONAL TOOL ON HIGH-ALERT MEDICATIONS ON HEALTHCARE PROFESSIONALS' KNOWLEDGE: WHAT'S NEW AND WHAT'S LEFT?
	5PSQ-008	A DIGITAL ASSISTANT TO SUPPORT PATIENTS IN PREPARING MEDICATION RECONCILIATION: PATIENT EXPERIENCES.
	5PSQ-009	EFFECTIVENESS AND SAFETY OF MONOCLONAL ANTIBODY SWITCHING IN MIGRAINE PATIENTS
	5PSQ-010	DIGOXIN ADJUSTMENT: COMPARATIVE ANALYSIS OF THREE PHARMACOKINETIC SOFTWARE
	5PSQ-011	PHARMACOKINETIC EVALUATION OF DRUGS WITH A NARROW THERAPEUTIC RANGE AND THEIR INFLUENCE ON CLINICAL DECISION
	5PSQ-012	CASE REPORT: INHALED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR MILD-TO-MODERATE AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS - 24 MONTHS OF FOLLOW-UP
	5PSQ-013	PALBOCICLIB IN METASTATIC BREAST CANCER TREATMENT: NEUTROPENIA MANAGEMENT IN CLINICAL PRACTICE.
	5PSQ-014	IMPACT OF HISTAMINE-2 ANTAGONIST SHORTAGE ON THE INCIDENCE OF HYPERSENSITIVITY REACTIONS TO PACLITAXEL - TOWARDS CRISIS MANAGEMENT AND A PREMEDICATION RECONSIDERATION IN FRANCE (PACLIREACT STUDY)
	5PSQ-015	PERSISTENCE OF TREATMENT WITH JAK INHIBITORS IN RHEUMATOID ARTHRITIS IN PATIENTS ALREADY TREATED WITH THEM
	5PSQ-016	HUMAN FACTORS ROLE IN MEDICATION ERRORS: DILUTING INTRAVENOUS MEDICATIONS AT HOSPITAL WARDS - A STUDY BASED ON INCIDENT REPORTS
	5PSQ-017	IMMUNE-MEDIATED ADVERSE EFFECTS OF CHIMERIC ANTIGEN RECEPTOR T CELLS (CAR-T) THERAPY IN REAL LIFE POPULATION: WE CONTINUE TO LEARN.
	5PSQ-018	PRESCRIBING ERRORS IN CHILDREN: WHAT IS THE IMPACT OF A COMPUTERIZED PHYSICIAN ORDER ENTRY?
	5PSQ-019	ANALYSIS OF THE USE OF IDARUCIZUMAB IN A TERTIARY HOSPITAL
	5PSQ-020	ANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS TO INCREASE THE SAFETY AND ADEQUACY OF THEIR TREATMENT
	5PSQ-021	AUTOMATION MEETS TRACEABILITY TO OPTIMIZE DRUGS AND MEDICAL DEVICES LOGISTICS GUARANTEEING PATIENT SAFETY AND HOSPITAL STAFF WELL-BEING
	5PSQ-022	ANALYSIS OF HEALTHCARE VISITS TO EMERGENCY SERVICES FROM PATIENTS WITH PAINFUL VASCULAR ULCERS TREATED WITH TOPICAL SEVOFLURANE
	5PSQ-023	SEVERE PHOTOTOXICITY REACTION ASSOCIATED WITH VANDETANIB: A CASE REPORT
	5PSQ-024	HAZARD VULNERABILITY ANALYSIS (HVA): EVALUATION OF RISK IN EXPERIMENTAL ONCOLOGICAL DRUGS COMPOUNDING
	5PSQ-025	IMPACT AND EVALUATION OF PHARMACOKINETIC MONITORING IN PRIMARY CARE.
	5PSQ-026	MEDICATION-RELATED OSTEONECROSIS OF THE JAWS AND CDK4/6 INHIBITORS
	5PSQ-027	APPROPRIATENESS OF PRESCRIPTION OF TRICYCLIC ANTIDEPRESSANTS ACCORDING TO STOPP CRITERIA
	5PSQ-028	CDK 4/6 INHIBITORS - ANALYSIS OF POTENTIAL DRUG INTERACTIONS
	5PSQ-029	PERCEIVED EXPERIENCE OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) AFTER IMPLEMENTING A TELEPHARMACY PROGRAMME
	5PSQ-030	SAFETY AND SECURITY OF CICLOSPORIN EYE DROPS IN PATIENTS WITH XEROPHTHALMIA
	5PSQ-031	ANALYSIS OF THE USE OF ISAVUCONAZOLE IN CRITICALLY ILL PATIENTS WHEN THE USE OF VORICONAZOLE IS INDICATED
	5PSQ-032	PHARMACIST INTEGRATION IN THE MULTIDISCIPLINARY EMERGENCY TEAM
	5PSQ-033	ANTIVIRAL TREATMENT DISCONTINUATION IN PATIENTS WITH HEPATITIS B
	5PSQ-034	FIXED VS WEIGHT-BASED DOSING OF PEMBROLIZUMAB FOR PATIENTS UNDER 80 KG, BASED ON OBSERVED ADRS IN ONE CANCER SETTING
	5PSQ-035	MASS UNIFORMITY OF HARD CAPSULES: ROYAL SPANISH PHARMACOPOEIA VS UNITED STATES PHARMACOPOEIA
	5PSQ-036	MEDICATION ERRORS RELATED TO HIGH-ALERT MEDICATIONS IN A TERTIARY CARE PEDIATRIC HOSPITAL – AN ANALYSIS OF REGISTER-BASED DATA
	5PSQ-037	IMPORTANCE AND IMPACT OF PHARMACEUTICAL RECONCILIATION AT DISCHARGE IN THE ELDERLY PATIENT WITH POLYMEDICATION
	5PSQ-038	DRUG RELATED VISITS TO THE EMERGENCY DEPARTMENT IN NURSING HOME PATIENTS
	5PSQ-039	RAF-KINASI PATHWAY INHIBITORS IN TREATMENT OF METASTATIC MELANOMA: WHEN COMPLIANCE DOESN’T MATCH WITH TOLERANCE.
	5PSQ-040	ANALYSIS OF THE IMPACT OF THE COVID-19 PANDEMIC ON PSYCHOTROPIC DRUG USE
	5PSQ-041	STERILE INTRAOCULAR INFLAMMATION AFTER INTRAVITREAL AFLIBERCEPT
	5PSQ-042	PREVALENCE OF MEDICATION PRESCRIPTION WITH A POTENTIAL NEGATIVE EFFECT ON SWALLOWING IN OUTPATIENTS WITH COGNITIVE IMPAIRMENT AND A DIAGNOSIS OF DYSPHAGIA.
	5PSQ-043	UNSUPPORTED PRESCRIPTION OF POLYVALENT IMMUNOGLOBULINS IN A UNIVERSITY HOSPITAL CENTER: FREQUENCY AND COST
	5PSQ-044	REAL-LIFE SAFETY AND SATISFACTION OF CFTR PROTEIN MODULATORS IN CYSTIC FIBROSIS
	5PSQ-045	IMPACT OF PHARMACEUTICAL INTERVENTIONS IN CRITICAL PATIENTS
	5PSQ-046	FMEA (FAILURE MODE AND EFFECT ANALYSIS) APPLICATION TO PARENTERAL NUTRITION BAGS MANUFACTURING PROCESS: ROLE OF HOSPITAL PHARMACIST
	5PSQ-047	PRECAUTIONARY CANCELLATION: TOOL TO IMPROVE PATIENT SAFETY
	5PSQ-048	WHAT DO ONCOLOGISTS AND PHARMACISTS THINK AND WANT FROM A CAHM-DRUG INTERACTION CHECKER? A BROADSCALE SURVEY TO ASSESS EXPECTATIONS.
	5PSQ-049	ASSESSMENT AND OPTIMISATION OF THE MANAGEMENT OF HIGH RISK MEDICINES IN A GENERAL HOSPITAL
	5PSQ-050	ANALYSIS OF THE USE OF USTEKINUMAB FOR CROHN DISEASE IN THE REAL CLINICAL PRACTICE
	5PSQ-051	PARKINSONISM INDUCED BY TAKING TRAZODONE AS A HYPNOTIC: A CASE REPORT
	5PSQ-052	CHANGES IN POLYMEDICATED PATIENTS’ PRESCRIPTIONS AFTER OUTPATIENT HOSPITAL CONSULTATIONS IN REAL LIFE SITUATIONS
	5PSQ-053	DESIGN OF A PRIORIZATION SYSTEM BY COMPLEXITY OF THE REVIEW IN POLYMEDICATED PATIENTS: POTENTIAL INADECUACY INDEX
	5PSQ-054	ASSESSEMENT OF OCCUPATIONAL PRACTICES: ANALYSIS OF THE PRESCRIPTIONS OF TRANSCATHETER AORTICVALVE IMPLANTATION (TAVI)
	5PSQ-055	SAFETY TESTING ASSESSMENT FOR THE ADHERENCE OF DOSE REDUCTION IN ONCOLOGY TREATMENT FOLLOWING CLINICAL GUIDELINES RECOMMENDATIONS IN PATIENTS PRIOR RECEIVING FLUOROPYRIMIDINES (5-FLUOROURACIL, CAPECITABINE AND TEGAFUR)
	5PSQ-056	HETEROGENEITY OF DEXMEDETOMIDINE TREATMENT EFFECT ON MORTALITY ACCORDING TO AGE
	5PSQ-057	EFFICACY AND SAFETY OF ADALIMUMAB IN THE TREATMENT OF INFLAMMATORY FACIAL GRANULOMA SECONDARY TO SILICONE
	5PSQ-058	MANAGEMENT OF SOLID ORAL PHARMACEUTICAL FORMS WITH UNIT DOSE
	5PSQ-059	REAL-WORLD CLINICAL DATA OF PALBOCICLIB AND RIBOCICLIB IN BREAST CANCER PATIENT
	5PSQ-060	GLUTEN IN MEDICINES. A PRESCRIPTION HELPING TOOL.
	5PSQ-061	NEW-ONSET MULTIPLE SCLEROSIS ASSOCIATED WITH ADALIMUMAB TREATMENT: ABOUT TWO CASE REPORTS
	5PSQ-062	REVIEW AND DEPRESCRIPTION OF MEDICATION IN POLYMEDICATED PATIENTS WITH PSYCHOACTIVE DRUGS.
	5PSQ-063	A CROSS-SECTIONAL STUDY ON THE POTENTIALLY INAPROPIATE PRESCRIBED AND CONTRAINDICATED HIGH-RISK MEDICATION IN HOSPITALIZED CHRONIC COMPLEX PATIENTS
	5PSQ-064	CONCOMITANT TREATMENT WITH ATEZOLIZUMAB AND ENZALUTAMIDE FOR METASTASTIC NON-SMALL-CELL LUNG CANCER AND METASTASTIC PROSTATE CANCER: A CASE REPORT
	5PSQ-065	BE A HUMAN, NOT A CASE REPORT! HOSPITAL PHARMACISTS MAKE THE DIFFERENCE
	5PSQ-066	ADEQUACY TO PROTOCOL OF USE OF TOCILIZUMAB FOR MANAGEMENT OF COVD-19 DISEASE
	5PSQ-067	TRACKING THE OVERAL IN USE AND STRESS STABILITY OF ROMIPLISTIM (N-PLATE®) BY THE EVALUATION OF A SELECTED SET OF CRITICAL QUALITY ATTRIBUTES
	5PSQ-068	DIARRHEA OCCURRENCE ANALYSIS IN IDIOPATHIC PULMONARY FIBROSIS PATIENTS
	5PSQ-069	ANALYSIS AND MONITORING OF ERRORS ASSOCIATED WITH ELECTRONIC PRESCRIPTION SYSTEMS: PRESCRIPTIONS WITH INCORRECT DRUG SCHEDULES.
	5PSQ-070	PHARMACEUTICAL CARE IN AN ONCO-HEMATOLOGICAL CLINICAL TRIALS UNIT
	5PSQ-071	ANALYSIS OF MEDICATION PROVIDED BY PATIENTS
	5PSQ-072	ANALYSIS OF THE DURATION AND COMPLICATIONS ASSOCIATED WITH PERIPHERAL PARENTERAL NUTRITION: A COHORT STUDY.
	5PSQ-073	IS THERE A SAFETY DIFFERENCE? JANUS KINASE INHIBITORS IN REAL CLINICAL PRACTICE
	5PSQ-074	INTERACTIONS DETECTED WITH THE USE OF NIRMATRELVIR/RITONAVIR IN A TERTIARY HOSPITAL
	5PSQ-075	PROPOSAL FOR THE ADJUSTMENT AND OPTIMISATION OF THE MEDICATION PROVIDED BY THE PATIENT
	5PSQ-076	PATIENTS’ SATISFACTION AFTER CHANGING FROM 150MG TO 300MG SECUKINUMAB PEN PRESENTATION
	5PSQ-077	CYCLIN DEPENDENT KINASES 4 AND 6 INHIBITORS - REAL-WORLD DATA ANALYSIS
	5PSQ-078	ANALYSIS OF CASIRIVIMAB AND IMDEVIMAB USE IN OUTPATIENTS WITH COVID-19
	5PSQ-079	FONDAPARINUX IN AN INFANT WITH SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA. A CASE REPORT.
	5PSQ-080	IDENTIFICATION OF PHARMACOLOGICAL INTERACTIONS BETWEEN IVACAFTOR/TEZACAFTOR/ELEXACAFTOR AND DIETARY SUPPLEMENTS/HERBS IN PATIENTS WITH CYSTIC FIBROSIS IN AN OUTPATIENT PHARMACEUTICAL CARE UNIT
	5PSQ-081	ASSESSMENT OF THE IMPACT OF THE PHARMACEUTICAL INTERVENTION IN MEDICATION RECONCILIATION AT PATIENT ADMISSION IN A SURGICAL PRE-HOSPITALIZATION CLINIC
	5PSQ-082	GRAVIMETRIC CONTROL OF PARENTERAL NUTRITION IN NEONATOLOGY AND PEDIATRICS.
	5PSQ-083	FOUR YEARS OF A PHARMACEUTICAL CARE PROGRAMME IN PATIENTS UNDERGOING CARDIAC SURGERY
	5PSQ-084	ASSESSING QUALITY OF LIFE OF PATIENTS WITH SEVERE ASTHMA MEASURED BY PATIENT REPORTED OUTCOMES
	5PSQ-085	MEDICATION ADMINISTRATION IN PATIENTS WITH DYSPHAGIA: SEARCHING FOR THE BEST PHARMACEUTICAL FORM
	5PSQ-086	ANALYSIS OF POTENCIALLY INAPPROPRIATE PRESCRIPTION IN A NURSING HOME
	5PSQ-087	EVALUATION OF THE EFFECTIVENESS OF LAMIVUDINE IN THE PROPHYLAXIS OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS WITH HAEMATOLOGICAL DISEASES
	5PSQ-088	EXPLORING THE NEED FOR A CHECK OF COMPOUNDING APPROPRIATENESS SERVICE: EVALUATION OF SPONTANEOUS CHECKS BEFORE COMPOUNDING AT A LARGE TERTIARY CARE HOSPITAL
	5PSQ-089	CHRONIC NON-CANCER PAIN, WHAT ABOUT THIS PATIENTS?
	5PSQ-090	STUDY OF THE USE OF RESTRICTED ANTIBIOTICS DURING COVID-19 PANDEMIC: CEFTAROLINE, CEFTAZIDIME/AVIBACTAM AND CEFTOLOZANE/TAZOBACTAM.
	5PSQ-091	TRIFECTA™ BIOPROSTHESES : EVALUATION OF THE SAFETY BASED ON THE STUDY OF DEGENERATIONS ACCORDING TO THE VARC-3 CLASSIFICATION
	5PSQ-092	PHARMACOVIGILANCE OF BIOLOGICAL THERAPIES FROM THE OUTPATIENT DEPARTMENT
	5PSQ-093	PHARMACEUTICAL INTERVENTION AFTER INAPPROPRIATE PRESCRIPTION OF ZOLPIDEM
	5PSQ-094	TOXICITY IN PATIENTS TREATED WITH VENETOCLAX. A SAFETY STUDY IN REAL-WORLD PRACTICE
	5PSQ-095	CARDIAC CONDUCTION DISORDERS ASSOCIATED WITH THE USE OF TRICYCLIC ANTIDEPRESSANTS IN THE ELDERLY
	5PSQ-096	A PROSPECTIVE OBSERVATIONAL STUDY OF MEDICATION PRESCRIBING ERRORS IN AN EMERGENCY DEPARTMENT.
	5PSQ-097	HEALTH ALERT OF TOFACITINIB AND PHARMACEUTICAL INTERVENTION
	5PSQ-098	SAFETY AND PERSISTENCE OF ANTI-FIBROTIC DRUGS IN INTERSTITIAL LUNG DISEASES
	5PSQ-099	ADEQUACY OF SOTROVIMAB PRESCRIPTION IN SARS-CoV-2 INFECTION IN A UNIVERSITY HOSPITAL
	5PSQ-100	UTILITY OF SOCIAL MEDIA AS A SOURCE OF PAEDIATRIC DRUG SAFETY, A SYSTEMATIC REVIEW
	5PSQ-101	ANALYSIS OF HIP PROSTHESES OVER A YEAR
	5PSQ-102	SAFETY EVALUATION OF MIDLINE CATHETERS USED FOR ANTIBIOTIC THERAPY
	5PSQ-103	PARENTAL UNMET NEEDS ON PAEDIATRIC DRUGS EXPRESSED IN FORUMS
	5PSQ-104	ERRORS IN ACENOCOUMAROL RECONCILIATION IN PATIENTS ADMITTED FROM THE EMERGENCY DEPARTMENT
	5PSQ-105	DEVELOPMENT OF HYPOMAGNESEMIA IN CRITICAL PATIENTS TREATED WITH ISAVUCONAZOLE
	5PSQ-106	SAFETY PERCEIVED BY PROFESSIONALS AFTER THE INNOVATION OF THE MEDICATION USE CIRCUIT IN A NEONATAL INTENSIVE CARE UNIT
	5PSQ-107	SAFETY ASSESSMENT OF ERENUMAB AND GALCANEZUMAB IN CLINICAL PRACTICE
	5PSQ-108	COMPUTERIZED PHYSICIAN ORDER ENTRY WITH CLINICAL DECISION SUPPORT IN PREVENTING WRONG DOSE ERRORS IN PEDIATRIC MEDICATION ORDERS: A SYSTEMATIC REVIEW
	5PSQ-109	RANSOMWARE ATTACK ON A CYTOTOXIC PREPARATION UNIT (CPU): WHAT NOW?
	5PSQ-110	IMPACT OF THE USE OF TRANSPARENT ADHESIVE DRESSINGS ON INFECTIONS IN PERITONEAL DIALYSIS
	5PSQ-111	MEDICATION ERRORS, THEIR PERCEPTION, ANALYSIS, AND PROPOSAL OF SOLUTIONS IN A PUBLIC HOSPITAL
	5PSQ-112	RELATIONSHIP BETWEEN EFFECTIVENESS AND IMMUNE-MEDIATED TOXICITY OF IMMUNE CHECK-POINT INHIBITORS IN ADVANCED NON-SMALL CELL LUNG CANCER
	5PSQ-113	REAL-LIFE EFFECTIVENESS, SAFETY AND ADHERENCE OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS
	5PSQ-114	PERSISTENCE AND LEVEL OF CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS TREATED WITH GUSELKUMAB
	5PSQ-115	DEPRESCRIBING LONG-TERM TREATMENTS WITH BIPHOSPHONATES. PHARMACEUTICAL INTERVENTION BRINGS VALUE.
	5PSQ-116	PERSISTENCE OF INHIBITORS OF INTERLEUKIN-23 (anti-IL-23) FOR THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS (msPs) IN THE ROUTINE CLINICAL PRACTICE CONDITIONS.
	5PSQ-117	EVALUATION OF CARDIOTOXICITY BY OSIMERTINIB IN CLINICAL PRACTICE
	5PSQ-118	PATIENTS´ EXPERIENCE WITH SUBCUTANEOUS INJECTION SELF-ADMINISTRATION AND THE ROLE OF VIRTUAL REALITY
	5PSQ-119	A NEW PHARMACEUTICAL CARE PROGRAMME FOR COVID-19 PATIENTS TREATED WITH PAXLOVID® : IMPLEMENTATION AND SAFETY OUTCOMES REPORTED
	5PSQ-120	ANALYSIS OF THE PHARMACEUTICAL INTERVENTIONS PERFORMED ON ONCOHEMATOLOGICAL PATIENTS THROUGH AN ONCOHEMATOLOGY PHARMACY CONSULTATION
	5PSQ-121	CYTOKINE RELEASE SYNDROME RELATED TO THE TREATMENT WITH TECLISTAMAB: A CASE REPORT
	5PSQ-122	COVID-19 VACCINE VIGILANCE: COMPARATIVE STUDY BETWEEN HOSPITAL, REGIONAL AND NATIONAL DATA
	5PSQ-123	IMPACT OF PHARMACOTHERAPEUTIC COMPLEXITY ON ADHERENCE TO ANTIRETROVIRAL TREATMENT IN OLDER ADULTS WITH HIV
	5PSQ-124	EFFECTIVENESS AND SAFETY OF ANTIRETROVIRAL TREATMENT SIMPLIFICATION TO DOLUTEGRAVIR+LAMIVUDINE OR DOLUTEGRAVIR+RILPIVIRINE IN OLDER ADULTS WITH HUMAN IMMUNODEFICIENCY VIRUS
	5PSQ-125	BRIDGING ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION AFTER A TRANSURETHRAL RESECTION: PATIENT MANAGEMENT IS DONE APPROPRIATELY?
	5PSQ-126	EFFICACY AND SAFETY OF OMALIZUMAB, MEPOLIZUMAB AND BENRALIZUMAB IN PATIENTS WITH SEVERE UNCONTROLLED ASTHMA
	5PSQ-127	PHARMACOLOGICAL RISK FACTORS FOR DRUG-DRUG INTERACTIONS IN PEOPLE LIVING WITH HIV: A SYSTEMATIC REVIEW
	5PSQ-128	THROMBOPROPHYLAXIS IN THE EMERGENCY DEPARTMENT. ADEQUACY OF THE PRESCRIPTION.
	5PSQ-129	SWITCHING BETWEEN ANTI-CALCITONIN GENE RELATED PEPTIDE MONOCLONAL ANTIBODIES IN MIGRAINE
	5PSQ-130	OFF-LABEL USE OF CIDOFOVIR INTRALESIONAL INJECTIONS IN EXTENSIVE ANOGENITAL CONDYLOMATOSIS: A CASE REPORT
	5PSQ-131	LETERMOVIR, GANCICLOVIR AND IMMUNOGLOBULINS COMBINATION TREATMENT IN AN IMMUNOCOMPROMISED PATIENT WITH CYTOMEGALOVIRUS INFECTION: A CASE REPORT
	5PSQ-132	PHARMACOGENETIC-GUIDED TREATMENT IN PATIENTS WITH DYHYDROPIRYMIDINE DEHYDROGENASE DEFICIENCY
	5PSQ-133	PHARMACISTS - GENERAL PRACTIONERS (GPs) COLLABORATION TO IDENTIFY DRUG-RELATED PROBLEMS (DRPs) IN PATIENTS IN POLYTHERAPY
	5PSQ-134	UNIT DOSE IN A CYBERATTACK SCENARIO
	5PSQ-135	HAS AN ANTIMICROBIAL STEWARDSHIP PROGRAMME HAD AN IMPACT ON THE ANTIBIOTIC CONSUMPTION?
	5PSQ-136	ANALYSIS OF ANTIRETROVIRAL THERAPY POTENCY IN HIV- NAÏVE PATIENTS
	5PSQ-137	ANALYSIS OF THE DPYD GENE MUTATIONS IN CANCER PATIENTS WHO ARE CANDIDATES FOR TREATMENT WITH FLUOROPYRIMIDINES
	5PSQ-138	CHEMOTHERAPY ERRORS DETECTED DURING PHARMACEUTICAL VALIDATION
	5PSQ-139	USING A TEXT-MINING APPROACH TO IDENTIFY THE CONTEXT VARIABLES LANGUAGE BARRIER, LIVING ALONE, COGNITIVE FRAILTY AND NON-ADHERENCE FROM ELECTRONIC HEALTH RECORDS (EHRs)
	5PSQ-140	FREQUENCY OF BLEEDING EVENTS REQUIRING HOSPITALIZATION IN PATIENTS UNDERGOING HOME TREATMENT WITH DIRECT-ACTING ORAL ANTICOAGULANTS (DOACs)
	5PSQ-141	FALLS IN ELDERLY PATIENTS AND CHRONIC CONSUMPTION OF ANXIOLYTIC BENZODIAZEPINES.
	5PSQ-142	EVALUATION OF ADEQUACY, ADHERENCE AND SAFETY OF HUMAN IMMUNODEFICIENCY VIRUS POST-EXPOSURE TREATMENT
	5PSQ-143	THE ROLE OF THE PHARMACIST IN INCREASING HEALTH VIGILANCE AMONG HEALTH PROFESSIONALS: QUINCKE'S EDEMA FOLLOWING THE ADMINISTRATION OF RITUXIMAB
	5PSQ-144	ELECTRONIC PATIENT-REPORTED OUTCOME (PROM) MEASUREMENT USING PRO-CTCAE®QUESTIONNAIRE TO IMPROVE QUALITY OF LIFE ASSESSMENT AND HEALTHCARE RESOURCES MANAGEMENT IN PATIENTS WITH LYMPHOMA RECEIVING INTRAVENOUS CHEMOTHERAPY
	5PSQ-145	A PATIENT SATISFACTION SURVEY ON UNIT DOSE DRUG DISTRIBUTION IN HOSPITAL

Section 6: Education and Research
PDF document	Poster number	Poster Title
	6ER-001	THE USE OF GAMIFICATION TO EVALUATE PUBLIC UNDERSTANDING OF ADVERSE DRUG REACTIONS
	6ER-002	WHAT's ANOTHER PEER? EXPLORING THE USE OF NEAR PEER TEACHING OF MEDICATION HISTORY TAKING IN PHARMACY UNDERGRADUATES IN THE UK
	6ER-003	THE CLIMATE EMERGENCY, HOW CAN PHARMACY MAKE A DIFFERENCE?
	6ER-004	EFFECTIVENESS AND SAFETY OF COVID-19 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED DISEASES ON BIOLOGICAL THERAPY
	6ER-005	EFFECTS OF ADHERENCE TO THE MEDITERRANEAN DIET IN PATIENTS WITH AUTOIMMUNE DISEASES
	6ER-006	CURRENT PERFORMANCE OF HOSPITAL PHARMACY SPECIALISTS TRAINED AT A TERTIARY HOSPITAL IN SPAIN
	6ER-007	PHYSICO-CHEMICAL PARAMETERS OF TOBACCO OIL AND PREPARATION OF A DOSAGE FORM BASED ON IT
	6ER-008	CORRELATES OF ONE-YEAR MORTALITY AMONG PATIENTS LIVING WITH HIV ACCORDING TO THE STRATIFICATION LEVEL OF THE PHARMACEUTICAL CARE MODEL
	6ER-009	COMPARATIVE EFFICACY OF ABEMACICLIB AND PALBOCICLIB AS ADJUVANT TREATMENT IN PATIENTS WITH EARLY BREAST CANCER
	6ER-010	EVOLUTION OF ONCOHAEMATOLOGICAL CLINICAL TRIALS FROM 2016 TO 2021: EXPERIENCE FROM A TERTIARY HOSPITAL
	6ER-011	EFFICACY OF THERAPIES IN NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS: A SYSTEMATIC REVIEW
	6ER-012	TREATMENT DECISIONS ACCORDING TO 1-YEAR RISK MORTALITY IN PULMONARY ARTERIAL HYPERTENSION PATIENTS. A MULTICENTRE RETROSPECTIVE STUDY.
	6ER-013	1 YEAR-MORTALITY RISK ASSESSMENT IN PULMONARY ARTERIAL HYPERTENSION PATIENTS. A MULTICENTRE RETROSPECTIVE STUDY.
	6ER-014	EFFECTIVENESS AND SAFETY OF THE ADMINISTRATION OF MURPHY’S ENEMA FOR THE TREATMENT OF REFRACTORY CONSTIPATION IN A TERTIARY HOSPITAL
	6ER-015	AZACITIDINE IN THE TREATMENT OF JUVENILE MYELOMONOCYTIC LEUKAEMIA: AN UP-TO-DATE PHARMACY PROTOCOL
	6ER-016	IDENTIFICATION OF NEW GENES OF EARLY RESPONSE TO ANTI-TNFS BY RNASEQ IN PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
	6ER-017	STRUCTURED OBJECTIVE CLINICAL EVALUATION FOR PHARMACY STUDENTS ON INTERNSHIPS AT THE HOSPITAL
	6ER-018	OFF-LABEL USE OF USTEKINUMAB IN REFRACTORY EPIDERMOLYTIC ICHTHYOSIS: A CASE REPORT
	6ER-019	THE STUDENT PHARMACIST EXPERIENCE OF ENHANCED CLINICAL PLACEMENTS
	6ER-020	PRESCRIPTION AND USE OF LIPOSOMAL AMPHOTERICIN B DURING THE COVID-19 PANDEMIC
	6ER-021	RETROSPECTIVE OF DRUG INNOVATION DURING THE SARS-Cov2 PANDEMIC : DEVELOPMENT OF A GAME-BASED TRAINING
	6ER-022	CLINICAL IMPACT OF THE USE OF GLUCOCORTICOIDS FOR THE TREATMENT OF COVID-19 IN INTERMEDIATE RESPIRATORY CARE UNITS
	6ER-023	THE ASSOCIATION BETWEEN NADROPARIN DOSE AND ANTI-XA LEVELS IN RENAL INSUFFICIENCY: A MULTICENTER STUDY
	6ER-024	COMPARISON OF REDUCTIONS IN MONTHLY MIGRAINE DAYS BETWEEN NEW SMALL MOLECULE CGRP RECEPTOR ANTAGONISTS (GEPANTS) AND MONOCLONAL ANTIBODIES TARGETING CGRP/CGRP RECEPTOR
	6ER-025	EFECTIVENESS AND SAFETY OF 20% AUTOLOGOUS SERUM EYE DROPS IN PATIENTS WITH CORNEAL SURFACE PATHOLOGIES
	6ER-026	SPECTRUM OF HEART FAILURE IN 16 SUB-SAHARAN AFRICAN COUNTRIES: TREATMENTS AND IN-HOSPITAL OUTCOME
	6ER-027	ASSESSMENT OF ATTITUDES AND PERCEIVED SKILLFULNESS OF PHARMACY STUDENTS IN CARING FOR UNDERSERVED POPULATIONS
	6ER-028	ASSESSMENT OF SYMPTOMS AND SIGNS SEVERITY IN PSORIASIS PATIENTS
	6ER-029	EYE DROPS OF INTERFERON ALPHA-2B TO TREAT OCULAR PATHOLOGIES
	6ER-030	USING A PHARMACIST-LED ASTHMA SERVICE TO ASSESS THE CONCORDANCE BETWEEN PATIENT-REPORTED ICS ADHERENCE AND OBJECTIVE E-MONITORING OF ICS THERAPY
	6ER-031	KWOLEDGE ABOUT HUMAN IMMUNODEFICIENCY VIRUS (HIV) TRANSMISSION IN PEOPLE LIVING WITH HIV IN ANTIRETROVIRAL THERAPY
	6ER-032	HOW CAN DUTCH UNIVERSITY HOSPITALS CONTRIBUTE TO AFFORDABLE MEDICINES AND COST CONTAINMENT OF TOTAL HOSPITAL DRUG EXPENDITURE: A DELPHI STUDY
	6ER-033	PEMBROLIZUMAB AND ATEZOLIZUMAB AS POSSIBLE EQUIVALENT FIRST-LINE THERAPEUTIC ALTERNATIVES IN PDL1-EXPRESSING TRIPLE-NEGATIVE BREAST CANCER
	6ER-034	USE OF CLOSED SYSTEM TRANSFER DEVICES WITH INVESTIGATIONAL DRUG PRODUCTS

26th Congress of the EAHP

National Poster Prize Winners
PDF document	Poster number	Poster Title
	NP-01	The appropriateness review FOR HOSPITAL MEDICATION ORDERS IN FINLAND
	NP-02	Usage of falls-risk-increasing drugs among patients with high risk of falls in the nursing ward of Tartu University Hospital
	NP-03	From basic to advanced computerized IV to oral switch for paracetamol and antibiotics: an interrupted time series analysis
	NP-04	MONITORING OF GRAM-NEGATIVE (G-) MULTIDRUG RESISTANT (MDR) PATIENS AT POLICLINICO UMBERTO I OF ROME WITH THE AIM OF CONTROLLING HEALTHCARE ASSOCIATED INFECTIONS, COUNTERACTING THE PHENOMENON OF ANTIMICROBIAL RESISTANCE AND...
	NP-05	INTRAVESICAL EPIRUBICIN ADMINISTRATION IN A UROLOGY DEPARTMENT
	NP-06	RELATIONSHIP BETWEEN SERUM VEDOLIZUMAB CONCENTRATIONS IN INDUCTION PHASE AND EARLY AND SUSTAINED RESPONSE ON PATIENTS WITH ULCERATIVE COLITIS
	NP-08	Integrating pharmacogenetic information into medication reviews – an interprofessional challenge

Section 1: Introductory Statements and Governance
PDF document	Poster number	Poster Title
	1ISG-003	IMPACT OF TELEPHARMACY AND COMMUNITY PHARMACY REMOTE-DISPENSING ON PATIENTS ON ORAL ANTINEOPLASTIC AGENTS
	1ISG-004	ASSESSMENT OF CUSTOMER SATISFACTION WITH HOSPITAL PHARMACY SERVICES IN ESTONIA
	1ISG-006	ESTIMATION OF DRUG COST AVOIDANCE IN CLINICAL TRIALS OF NON-SMALL CELL LUNG CANCER
	1ISG-007	ECONOMIC SAVINGS FROM WEIGHT-BASED DOSING OF PEMBROLIZUMAB: WHAT IS THE IMPACT IN A TERTIARY HOSPITAL?
	1ISG-008	OPTIMISATION PROGRAMME OF OMALIZUMAB TREATMENT FOR CHRONIC IDIOPATHIC URTICARIA
	1ISG-009	IMPLEMENTATION AND EVALUATION OF TELEPHARMACY DURING COVID-19 PANDEMIC IN AN ACADEMIC MEDICAL CITY : PAVING THE WAY FOR TELEPHARMACY
	1ISG-012	ECONOMIC EVALUATION OF DOSE BANDING IN INMUNOTHERAPY: NIVOLUMAB AND PEMBROLIZUMAB
	1ISG-013	Users’ expectations and opinions on a computerised physician order entry (CPOE) system before and after its implementation

Section 2: Selection, Procurement and Distribution
PDF document	Poster number	Poster Title
	2SPD-001	HOW CAN WE BEST MANAGE SUPPLY SHORTAGES OF EXCLUSIVELY HUMAN MOLECULES FOR SUBSTITUTION ? THE EXAMPLE OF IMMUNOGLOBULINS
	2SPD-003	TELEPHARMACY IN ONCO-HEMATOLOGIC PATIENTS: A SEVEN MONTH EXPERIENCE
	2SPD-005	SIGNIFICANT DISCONTINUATION RATES IN PATIENTS INITIATING OR SWITCHING FROM CT-P13: A RETROSPECTIVE COHORT STUDY IN A UNIVERSITY HOSPITAL
	2SPD-006	DEVELOPMENT OF A PRIORITATION PROTOCOL FOR THE USE OF IMMUNOGLBULINS IN VIEW OF THE GLOBAL SUPPLY PROBLEM
	2SPD-008	NETWORK META-ANALYSIS OF IMMUNOTHERAPIES IN UNTREATED ADVANCED OR METASTARIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA
	2SPD-011	RIVAROXABAN VERSUS ENOXAPARIN IN TRAUMATOLOGY: A PHARMACO-ECONOMIC STUDY
	2SPD-012	IMMUNOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY IN REAL LIFE
	2SPD-013	INCREASE IN HEALTHCARE COSTS WITH FIDAXOMICIN INSTEAD OF VANCOMYCINFOR CLOSTRIDIUM DIFFICLIE TREATMENT
	2SPD-014	APPROPRIATENESS OF USTEKINUMAB THERAPY PRESCRIPTION AND REAL-LIFE CONDITION USE IN CROHN’S DISEASE
	2SPD-015	LOGISTICS AUTOMATION AND PROCESS REENGINEERING: IMPACT ON INTER-HOSPITAL LOAN MANAGEMENT
	2SPD-016	APPLICATION OF FAILURE MODE AND EFFECT ANALYSIS TO IMPROVE CYTOSTATIC DRUG STOCK MANAGEMENT
	2SPD-017	ANALYSIS AND MONITORING OF THE WORKLOAD AND FINANCIAL BURDEN OF DISPENSING HIGHCOST MEDICINES WITH ITEM-BASED REIMBURSEMENT IN HUNGARIAN HOSPITAL PHARMACIES
	2SPD-019	INVENTORY MANAGEMENT DURING THE COVID-19 PANDEMIC: OUR CASE FOR THE THIRD WAVE
	2SPD-020	INTRODUCTION OF A NEW PRESENTATION OF HYALURONIC ACID FOR INTRAARTICULAR INFILTRATION
	2SPD-021	ASSESSMENT OF FORECAST ACCURACY FOR CONTRACTUAL PURCHASES
	2SPD-022	RELEVANCE OF UNIVERSAL KIT COMPOSITION AND ECONOMIC VALUE OF NON-USED MEDICAL DEVICES
	2SPD-023	CHOOSING THE RIGHT FORECASTING METHOD: WHICH PRACTICE IS BEST FOR OUR CASE?
	2SPD-024	RETROSPECTIVE EVALUATION OF THE SAFETY STOCK LEVEL DETERMINED FOR THE PANDEMIC IN TERMS OF SERVICE LEVEL
	2SPD-025	ACALABRUTINIB + OBINUTUZUMAB VERSUS IBRUTINIB + OBINUTUZUMAB AS FIRST LINEIN CHRONIC LYMPHOCYTIC LEUKEMIA
	2SPD-027	Medication storage temperatures inside emergency vehicles A pilot study in a temperate climate country
	2SPD-029	STABILITY OF NIVOLUMAB SOLUTIONS AFTER TRANSPORT THROUGH PNEUMATIC TUBE SYSTEMS
	2SPD-030	How to assess the impact of medicines shortages in the European Union?
	2SPD-031	THE ECONOMIC IMPACT OF ANTIMICROBIAL SHORTAGES IN ANTIMICROBIAL STEWARDSHIP PROGRAMMES
	2SPD-032	DRUG EXCHANGE NETWORK
	2SPD-033	Making the case for Prefilled Syringes (PFS): Development and utilisation of an economic model
	2SPD-034	METHODOLOGICAL ANALYSIS OF PHARMACOECONOMIC STUDIES IN CAR-T: A SYSTEMATIC REVIEW
	2SPD-035	COST MINIMISATION ANALYSIS IN CLINICAL PRACTICE OF RIBOCICLIB VERSUS PALBOCICLIB IN THE TREATMENT OF METASTASTIC BREAST CANCER

Section 3: Production and Compounding
PDF document	Poster number	Poster Title
	3PC-001	CHOLESTEROL 2%/SIMVASTATIN 1% OINTMENT FOR THE TREATMENT OF POROKERATOSIS PTYCHOTROPICA: A CASE REPORT
	3PC-002	GLASS AMPOULES AND DRUG FILTRATION: ¿HOW MUCH DO WE KNOW ABOUT IT?
	3PC-003	SODIUM THIOSULPHATE GEL 25% FOR THE TREATMENT OF CALCIPHYLAXIS
	3PC-004	INSULIN EYE DROP FORMULATION: EFFECTIVENESS, SAFETY AND PATIENT SATISFACTION
	3PC-005	SELECTION OF AN OSMOLARITY VALIDATION MODEL FOR NOMINATIVE PARENTERAL NUTRITION
	3PC-006	EVALUATION OF PARENTERAL NUTRITION COMPOUNDING THROUGH A CHECKLIST
	3PC-008	TIMES AND ERRORS FOR DISPENSING NARCOTICS DRUGS IN AUTOMATED SYSTEM VERSUS MANUAL SYSTEM
	3PC-009	STANOZOLOL RAPID HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) QUANTIFICATION METHOD FOR QUALITY CONTROL
	3PC-010	Assessment of Chemfort (OnGuard, US) Syringe Adaptor Lock Fitted With Luer Lock Syringes to Container Integrity Standards (NHS, UK) Supporting Dose Banding of Cytotoxic Drugs
	3PC-011	STUDY OF THE CONTAINERCONTENT INTERACTION BETWEEN ETOPOPHOS POLYVINYL CHLORIDE (PVC) PERFUSION
	3PC-012	IMPACT OF PRELIMINARY WIPING OF EQUIPMENT INTRODUCED INTO A CLEANROOM ON THE CONTROL OF THE ENVIRONMENT
	3PC-013	PHARMACEUTICAL COMPOUNDING IN PAEDIATRIC PATCH TESTING: ARE WE SURE ABOUT THE ACTUAL ACTIVE INGREDIENT CONCENTRATION?
	3PC-014	EVALUATION OF THE MICROBIOLOGICAL QUALITY OF NONSTERILE DRUGS PREPARED IN A HOSPITAL PHARMACY
	3PC-016	VANCOMYCIN EYE DROPS AT 50 MG/ML : PHYSICOCHEMICAL STABILITY, IMPACT OF PACKAGING AND STORAGE CONDITIONS
	3PC-017	Assessing the stability of Sandoz rituximab biosimilar after exposure to out-of-fridge conditions for 21 days
	3PC-018	COMPATIBILITY AND 30-DAY STABILITY OF FOUR INTRAVENOUS MIXTURES FOR MULTIMODAL ANALGESIA
	3PC-019	EVALUATION OF THE IMPACT OF MACHINE-AIDED DEBLISTERING IN UNIT DOSE BLISTER PRODUCTION ON THE FUNCTIONALITY OF TABLET COATING
	3PC-020	CHEMICAL STABILITY AND PHYSICAL COMPATIBILITY OF INSULIN EYE DROPS USED IN CLINICAL PRACTICE
	3PC-021	DESIGN AND ELABORATION OF METRONIDAZOLE 1% TOPICAL SOLUTION FOR TREATMENT OF ULCERS INFECTED BY ANAEROBIC BACTERIA
	3PC-022	PH STABILITY OF TETRACAINE SOLUTIONS FOR SURFACE ANAESTHESIA
	3PC-023	Investigation of Leachable Compounds In water for injection used in hospital pharmacy
	3PC-024	IMPACT OF PH MODIFICATION ON THE AGGREGATION OF NIVOLUMAB (OPDIVO) IN CLINICAL SOLUTIONS AT 1 AND 5 MG/ML MEASURED BY DYNAMIC LIGHT SCATTERING (DLS) AND SIZEEXCLUSION HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-DIODE ARRAY DETECTION (SE/HPLC-DAD)
	3PC-026	Rainer Trittler, Brigitte Altmann, Manuel Garcia-Käufer, Richard Gminski, Martin J. Hug
	3PC-027	DIGITALIZATION SUPPORT SYSTEM FOR INTRAVENOUS MIXTURES ELABORATION IN A BIOLOGICAL SAFETY CABINET
	3PC-028	PHARMACEUTICAL INTERVENTIONS IN PAEDIATRIC PARENTERAL NUTRITION
	3PC-029	STUDY OF PSMA11-68GA ADSORPTION ON MEDICAL DEVICES USED FOR RADIOSYNTHESIS AND MEDIA FILL TEST
	3PC-030	Different substrates for orodispersible films: You have the choice!
	3PC-031	PHYSICOCHEMICAL STABILITY OF helen.linxweiler@unimedizin-mainz.de DILUTED ‘THIOTEPA RIEMSER’ INFUSION SOLUTIONS IN PREFILLED 5% GLUCOSE INFUSION BAGS
	3PC-032	Optimising Analgosedation in the Intensive Care Unit during the SARS-COV-2 Pandemic
	3PC-033	Y-site Compatibility of Intravenous Nefopam with Medications Commonly Used in Intensive Care Units
	3PC-034	DEVELOPMENT AND VALIDATION OF A METHOD FOR THE DETERMINATION OF VANCOMYCIN EYE DROPS BY ULTRAVIOLET-VISIBLE SPECTROPHOTOMETRY
	3PC-035	Minimising Waste In Oncology

Section 4: Clinical Pharmacy Services
PDF document	Poster number	Poster Title
	4CPS-002	COVID-19 HOSPITAL VACCINATION CENTER: PATIENT AND NURSE SATISFACTION
	4CPS-003	OUTPATIENT-REPORTED EXPERIENCE IN HOSPITAL PHARMACY AMBULATORY CARE DURING THE COVID19 PANDEMIC
	4CPS-004	IMPACT OF THE SARS-COV PANDEMIC ON THE TRAINING OF HOSPITAL PHARMACY RESIDENTS
	4CPS-005	Evaluating pharmaceutical logistics automated technologies in the hospital setting: a Health Technology Assessment (HTA) approach
	4CPS-006	EVALUATION STUDY OF THE CHAGE IN ADMINISTRATION TIMING OF FIXED COMBINATION: NETUPITANT AND PALONOSETRON IN ONCOHEMATOLOGIC PATIENTS WITH HIGH DOSES OF CARBOPLATIN
	4CPS-008	The role of the pharmacist in the management of Intravenous fluids & electrolytes in adult patients
	4CPS-011	ASSESSMENT OF KNOWLEDGE, ATTITUDES AND PRACTICES REGARDING ANTIBIOTIC RECONSTITUTION AMONG HEALTHCARE PROFESSIONALS IN 12 SOUTHEASTERN EUROPEAN HOSPITALS: A MULTICENTRE CROSS-SECTIONAL STUDY
	4CPS-013	MERGING THE MEDICATION RECONCILIATION AND THE HOSPITALIZATION REPORT TO FORM THE LIAISON LETTER IN A DEPARTMENT OF OTOLARYNGOLOGY
	4CPS-014	CLINICAL RELEVANCE OF PHARMACISTS' INTERVENTIONS IN THE ACUTE WARD
	4CPS-015	SATISFACTION AND INDIRECT IMPACT OF AN OUTPATIENTS’ TELEPHARMACY PROGRAMME
	4CPS-016	Factors influencing the attitudes and opinions of Czech physicians and citizens toward influenza vaccination in Czech pharmacies
	4CPS-017	THE DECISION-MAKING PROCESS IN HEALTH POLICY IMPACTS CLINICAL PRACTICES: A QUALITATIVE STUDY
	4CPS-018	Perceptions of young people regarding pharmaceutical care provided by pharmacists
	4CPS-019	REACTOGENICITY OF THE BNT162B2 (PFIZERBIONTECH) MRNA VACCINE AGAINST COVID-19 IN TERTIARY HOSPITAL WORKERS
	4CPS-020	COMPARISON OF DEPRESCRIBING STRATEGIES: LESSCHRON CRITERIA VERSUS THE GOOD PALLIATIVEGERIATRIC ALGORITHM IN A NURSING HOME
	4CPS-021	POST-STERNOTOMY MEDIASTINITIS: A MEDICOECONOMIC STUDY COMPARING TWO PREVENTIVE STRATEGIES IN CARDIAC SURGERY
	4CPS-022	To vaccinate or not to vaccinate : Impact of a public health action on vaccine hesitancy
	4CPS-023	INDIVIDUALIZATION OF TREATMENT WITH TOCILIZUMAB IN GRAVES ORBITHOPATHY
	4CPS-024	PHARMACEUTICAL INTERVIEWS DEDICATED TO VACCINATION: WHAT ROLE FOR THE CLINICAL PHARMACIST IN MONITORING THE VACCINATION COVERAGE OF AT-RISK PATIENTS ?
	4CPS-025	Adequacy of hepatitis B reactivation prophylaxis in patients treated with rituximab
	4CPS-026	OPTIMISATION OF DIRECT ORAL ANTICOAGULANT TREATMENTS: ANALYSIS OF PRESCRIPTIONS AND PHARMACEUTICAL INTERVIEWS (PI)
	4CPS-027	DESENSITISATION PROTOCOL FOR LIPOSOMAL AMPHOTHERICIN B: A CASE REPORT
	4CPS-028	EFFECTIVENESS AND SAFETY OF CENOBAMATE: EXPERIENCE IN A THIRD-LEVEL HOSPITAL
	4CPS-029	PEMBROLIZUMAB, NIVOLUMAB AND ATEZOLIZUMAB: INCREMENTAL COST-EFFECTIVENESS RATIO
	4CPS-030	SELECTIVE DECONTAMINATION OF THE GASTROINTESTINAL TRACT IN PREVENTING VENTILATOR-ASSOCIATED PNEUMONIA IN AN INTENSIVE CARE UNIT
	4CPS-031	EFFICACY AND SAFETY OF HIGH-DOSE TWICE WEEKLY SEBELIPASE ALFA IN SEVERE-ONSET WOLMAN DISEASE: A CASE REPORT
	4CPS-032	Medication errors in prescribing antithrombotics for patients admitted to the hospital in the weekend. A pilot-study
	4CPS-033	Development and evaluation of an amitriptyline topical form for the treatment of cancer-related neuropathy
	4CPS-034	DEPRESCRIBING ORAL IRON IN ELDERLY PATIENTS: EXPERIENCE FROM A NURSING HOME ASSOCIATED WITH A THIRD LEVEL HOSPITAL
	4CPS-035	PHARMACIST-LED MEDICATION RECONCILIATION AT DISCHARGE SHALL NOT BE SUFFICIENT TO REDUCE UNPLANNED HEALTHCARE UTILIZATION: HEAR THE PATIENT EXPERIENCE!
	4CPS-036	IS OUR PROTOCOL FOR THE USE OF TOCILIZUMAB IN COVID PATIENTS ADEQUATE?
	4CPS-037	The 5P-study: Patient and healthcare Provider Perspectives on Potential Preventability of hospital admission for acute exacerbations of Chronic Obstructive Pulmonary Disease
	4CPS-038	Intrapleural colistin for pleural empyema caused by extensively drug-resistant Pseudomonas aeruginosa: A case report
	4CPS-039	EFFECTIVENESS OF ERENUMAB AND GALCANEZUMAB IN THE TREATMENT OF MIGRAINE
	4CPS-040	INTERINDIVIDUAL VARIABILITY OF LINEZOLID IN CRITICALLY ILL PATIENTS
	4CPS-041	SACUBITRIL/ VALSARTAN PRESCRIPTION PRACTICE IN PATIENTS WITH CHRONIC HEART FAILURE
	4CPS-042	PHARMACOKINETIC MONITORING OF TACROLIMUS IN RENAL TRANSPLANT PATIENTS
	4CPS-043	EFFECTIVENESS, SAFETY AND ADHERENCE OF GUSELKUMAB IN MODERATE TO SEVERE PSORIASIS
	4CPS-044	PATIENTS’ PERCEPTIONS OF HEALTHCARE ASSOCIATED-INFECTIONS AND USE OF ANTIBIOTICS IN SURGICAL CONTEXT
	4CPS-045	HEALTHCARE EVALUATION OF HOSPITAL PHARMACY SERVICES BY PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES: A MULTICENTRE STUDY
	4CPS-046	CARDIOVASCULAR RISK OF HIV PATIENTS
	4CPS-048	IMPROVING SAFETY IN THE USE OF MONOCLONAL ANTIBODIES IN PATIENTS WITH MIGRAINE: AN INTERDISCIPLINARY STUDY
	4CPS-049	MANAGEMENT OF PAN-RESISTANT STENOTROPHOMONAS MALTOPHILIA
	4CPS-050	USE OF GALCANEZUMAB IN PATIENTS WITH MIGRAINE IN A TERTIARY HOSPITAL: HEALTH RESULTS
	4CPS-051	PHARMACOKINETICS ALTERATIONS IN TWO CRITICALLY ILL PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION RECEIVING ISAVUCONAZOL
	4CPS-053	GALCANEZUMAB IN PROPHYLAXIS OF REFRACTORY HIGH-FREQUENCY EPISODIC MIGRAINE IN CLINICAL PRACTICE
	4CPS-054	ANALYSIS OF REAL-WORLD DATA FOR ERENUMAB UTILISATION AND PATIENT-RELATED OUTCOMES
	4CPS-055	SUCCESSFUL SOFOSBUVIR/VELPATASVIR TREATMENT IN A HEPATITIS C PATIENT RECEIVING CHRONIC ANTIEPILEPTIC THERAPY: A CASE REPORT
	4CPS-056	POLYPHARMACY AND POTENTIALLY INAPPROPIATE MEDICATIONS IN OLDER PEOPLE LIVING WITH HIV
	4CPS-057	DISCONTINUATION OF PROTON PUMP INHIBITORS DURING HOSPITALISATION: A RANDOMISED CONTROLLED TRIAL
	4CPS-058	REAL-WORLD EXPERIENCE WITH PROLONGED TEDIZOLID TREATMENT: EFFECTIVENESS AND SAFETY
	4CPS-059	CASE REPORT OF SEVERE HYPERBILIRRUBINEMIA IN A PATIENT CARRYING POLYMORPHISMS IN CES1P1, CDA, SLC22A7 AND ENOSF1 TREATED WITH FLUOROPYRIMIDINES
	4CPS-060	INFLUENCE OF GENETIC POLYMORPHISMS ON THE RESPONSE AND TOXICITY OF CAPECITABINE THERAPY IN PATIENTS WITH BREAST CANCER
	4CPS-061	IMPACT OF PHARMACOGENETICS ON THE TOXICITY OF HIGH-DOSE METHOTREXATE IN A PAEDIATRIC POPULATION
	4CPS-062	RITUXIMAB PHARMACOKINETICS CHARACTERIZATION IN PLASMA AND URINE IN A PATIENT WITH NEPHOTIC SYNDROME
	4CPS-063	ERENUMAB VERSUS GALCANEZUMAB, EFFECTIVENESS IN REAL-LIFE EXPERIENCE
	4CPS-064	QUALITY OF LIFE STUDY: GALCANEZUMAB IN THE TREATMENT OF MIGRAINE
	4CPS-065	SAFETY OF BEVACIZUMAB BIOSIMILAR IN CLINICAL PRACTICE IN NEW AND SWITCHED TREATMENTS
	4CPS-067	PHARMACIST INTERVENTIONS IN SEQUENTIAL ANTIMICROBIAL THERAPY INSIDE AN ANTIMICROBIAL STEWARDSHIP PROGRAMME (ASP)
	4CPS-068	IMPACT OF PHARMACOGENETICS IN SEVERE ALLERGIC ASTHMA PATIENTS TREATED WITH OMALIZUMAB
	4CPS-069	INFLUENCE OF GENETIC VARIANTS IN THE VITAMIN D HYDROXYLATION PATHWAY AS A RESPONSE FACTOR TO PLATINUM-BASED CHEMOTHERAPY IN NONSMALL CELL LUNG CANCER
	4CPS-070	STUDY OF CARDIOVASCULAR TOXICITY ASSOCIATED WITH IBRUTINIB TREATMENT
	4CPS-071	CYP27B1 GENETIC VARIANTS’ INFLUENCE IN NEPHROTOXICITY DUE TO PLATINUMBASED CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER
	4CPS-072	BEZLOTOXUMAB FOR THE PREVENTION OF CLOSTRIDIOIDES DIFFICILE RECURRENCE: STUDY IN THE REAL WORLD
	4CPS-073	DESENSITISATION TO IBRUTINIB IN A PATIENT WITH SERIOUS LATE REACTION: A CASE REPORT
	4CPS-075	EVALUATION OF THE COST OF MANAGING ADVERSE EVENTS RELATED TO CYTOTOXIC DRUGS IN CHILDREN
	4CPS-077	GENETICVARIANTSAFFECTINGBISOPROLOL RESPONSEINCARDIOVASCULARDISEASES
	4CPS-078	MOTIVATIONAL INTERVIEWING IN CLINICAL PHARMACIST INTERVENTIONS: A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS
	4CPS-079	ANALYSIS OF CURRENT RESEARCH IN WEAREABLES : TOWARD A MORE DIGITAL HEALTH
	4CPS-080	EFFICACY AND SAFETY OF THE CONTINUOUS INFUSION OF VANCOMYCIN IN PAEDIATRIC PATIENTS: A SYSTEMATIC REVIEW
	4CPS-081	SUBCUTANEOUS FUROSEMIDE INFUSION USING ELASTOMERIC INFUSION PUMPS IN A TERTIARY HOSPITAL
	4CPS-082	ENVIRONMENTAL POLLUTION WITH QUINOLONES IN SPAIN
	4CPS-083	Cost-effectiveness analysis of adalimumab and its clinical alternatives in immunemediated inflammatory diseases in Spain
	4CPS-085	STABILITY OF MEROPENEM AND PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION FOR HOME ADMINISTRATION
	4CPS-086	Inhaled sedation with halogenated agents in the Intensive Care Unit: A literature mini-review
	4CPS-087	THE USE OF PATIENT-REPORTED OUTCOME INSTRUMENTS IN IMMUNE CHECKPOINT INHIBITOR THERAPY FOR CANCER IN CLINICAL PRACTICE: A SYSTEMATIC REVIEW
	4CPS-088	INDIRECT COMPARISON OF NIVOLUMAB, PEMBROLIZUMAB AND CAMRELIZUMAB IN PATIENTS WITH UNRESECTABLE AND/OR ADVANCED SQUAMOUS CELL CARCINOMA OF ESOPHAGUS IN SECOND-LINE SETTING
	4CPS-089	RISANKIZUMAB IN REFRACTORY HIDRADENITIS SUPPURATIVA TO ANTI-TNFa A CASE REPORT
	4CPS-090	EFFICACY AND SAFETY OF PANGENOTYPS TREATMENTS IN HCV PATIENTS
	4CPS-091	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS RELATED TO HIGH-RISK-DRUGS IN THE EMERGENCY DEPARTMENT
	4CPS-092	BIOLOGICAL THERAPIES FOR THE TREATMENT OF PSORIASIS: EFFECTIVENESS, SAFETY AND ECONOMIC IMPACT OF OPTIMISATION STRATEGIES
	4CPS-093	DRUG-INDUCED SOMNOLENCE IN FRAILTY PATIENTS ATTENDED IN AN EMERGENCY DEPARTMENT
	4CPS-095	APPROPRIATENESS OF EMPIRICAL ANTIBIOTIC THERAPY FOR CERVICITIS AND URETHRITIS PRESCRIBED AT THE EMERGENCY DEPARTMENT
	4CPS-099	CLINICALLY RELEVANT DRUG-DRUG INTERACTION EVENTS IN PATIENTS WITH ABIRATERONE, ENZALUTAMIDE OR APALUTAMIDE TREATMENT
	4CPS-100	INTRADIALYTIC PARENTERAL NUTRITION EFFECTS ON ALBUMIN LEVELS IN MALNOURISHED HAEMODIALYSIS PATIENTS
	4CPS-101	BIOLOGIC AGENTS IN RHEUMATOLOGICAL DISEASES: IMPACT OF ‘TREAT TO TARGET’ IN CLINICAL PRACTICE
	4CPS-102	Drug-related hospital admissions in older adults: comparison of the Naranjo algorithm and an adjusted version of the Kramer algorithm
	4CPS-103	IMPROVING MEDICATION RECONCILIATION REPORTS: EVALUATION THROUGH QUALITY AUDITS
	4CPS-104	PERSISTENCE WITH DISEASE-MODIFYING THERAPY IN MULTIPLE SCLEROSIS PATIENTS
	4CPS-105	CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH HIV INFECTION WITH ANTIRETROVIRAL TREATMENT
	4CPS-106	SAFETY OF ADJUVANT TRASTUZUMAB EMTANSINA FOR RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER
	4CPS-107	IMMUNOTHERAPY IN SEVERE UNCONTROLLED ASTHMA: EFFECTIVENESS AND SAFETY IN CLINICAL PRACTICE
	4CPS-108	BIOMARKERS EVOLUTION IN PATIENTS WITH SARSCOV-2 PNEUMONIA TREATED WITH BARICITINIB
	4CPS-109	DESCRIPTIVE ANALYSIS OF PATIENTS CO-INFECTED WITH HIV AND HEPATITIS C VIRUS (HCV) TREATED WITH ANTIVIRALS FOR HCV AND ITS EFFICACY IN A PRISON FROM 2002 TO 2020
	4CPS-110	INITIAL EXPERIENCE OF THE USE OF CEFIDEROCOL FOR MULTIDRUG RESISTANT INFECTIONS IN A UNIVERSITY HOSPITAL
	4CPS-111	RUXOLITINIB FOR REFRACTORY GRAFT-VERSUS-HOST DISEASE IN PAEDIATRIC PATIENTS
	4CPS-112	VORICONAZOLE THERAPEUTIC DRUG MONITORING: RELATIONSHIP WITH LIVER TOXICITY
	4CPS-113	REAL-LIFE DATA ON THE USE OF ABIRATERONE/ ENZALUTAMIDE IN CASTRATION-RESISTANT PROSTATE CANCER
	4CPS-114	INTEGRATION OF A PHARMACIST INTO A GERIATRIC DEPARTMENT
	4CPS-115	NABPACLITAXEL PLUS GEMCITABINE VERSUS FOLFIRINOX IN METASTATIC PANCREATIC CANCER: REAL WORLD DATA EXPERIENCE
	4CPS-116	ASSOCIATON OF DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY WITH CAPECITABINE TOLERANCE
	4CPS-117	APPROPRIATENESS OF ANTIBIOTIC PRESCRIPTIONS IN A LONG-TERM CARE FACILITY
	4CPS-119	REAL-WORLD EXPERIENCE WITH PCSK9 INHIBITORS PROTOCOL FOR HYPERCHOLESTEROLEMIA
	4CPS-120	ADVERSE DRUG REACTION (ADR) NOTICATIONS’ IMPACT ON PATIENTS FOLLOWED AT AN AMBULATORY CARE PHARMACY UNIT
	4CPS-121	CLINICAL PHARMACIST INTERVENTIONS IN THE EMERGENCY DEPARTMENT AND THEIR IMPACT ON PREVENTABLE ADVERSE DRUG EVENTS
	4CPS-122	OVERVIEW OF THE IMPACT OF PENICILLIN ALLERGY LABELS ON ANTIBIOTIC USE IN THE EMERGENCY DEPARTMENT
	4CPS-123	PERFORMANCE OF MOST COMMONLY USED EQUATIONS TO ESTIMATE GLOMERULAR FILTRATION RATE IN CRITICALLY ILL PATIENTS
	4CPS-124	COST OPTIMISATION PLAN IN IMMUNOTHERAPY
	4CPS-125	SINGLE-AGENT BEVACIZUMAB IN OFF-LABEL TREATMENT OF RECURRENT OR REFRACTORY GLIOMA
	4CPS-126	REAL-WORLD PERSISTENCE WITH FAMPRIDINE AMONG MULTIPLE SCLEROSIS PATIENTS
	4CPS-127	THERAPEUTIC DRUG MONITORING WITH BIOLOGICAL DRUGS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
	4CPS-129	ADJUST DOSES OF ANTIBIOTICS IN PATIENTS WITH RENAL INSUFFICIENCY
	4CPS-130	Analysis of the Different Cardioversion Strategies in the Emergency Department in a Secondary Hospital
	4CPS-131	SWITCHING AND DISCONTINUATION OF DISEASE-MODIFYING TREATMENTS IN MULTIPLE SCLEROSIS PATIENTS: EXPERIENCE IN AN UNIVERSITY HOSPITAL
	4CPS-133	ANALYSIS AND EVALUATION OF PHARMACEUTICAL INTERVENTIONS PERFORMED IN THE EMERGENCY DEPARTMENT
	4CPS-134	OPTIMIZATION OF DENOSUMAB PRESCRIPTION IN OSTEOPOROSIS PATIENTS
	4CPS-136	PERSISTENCE OF FIRST-LINE BIOLOGICAL THERAPY IN PATIENTS WITH CROHN’S DISEASE
	4CPS-137	Prospective analysis of clinical pharmacist interventions for QT drug-drug interactions alongside clinical decision support
	4CPS-138	THERAPEUTIC DRUG MONITORING OF INTRAVENOUSBUSULFANINPAEDIATRICPATIENTS
	4CPS-140	ANTIMICROBIAL STEWARDSHIP PROGRAM IN ONCOLOGY PATIENTS THROUGH A MULTIDISCIPLINARY TEAM
	4CPS-141	ASSESSMENT OF TEDIZOLID FOR USE IN GRAM-POSITIVE BACTERIAL INFECTIONS BACKGROUND: REAL WORLD DATA
	4CPS-142	EFFECTIVENESS AND SAFETY OF ATEZOLIZUMAB IN METASTATIC UROTHELIAL CARCINOMA
	4CPS-145	EFFECTIVENESS AND SAFETY OF BARICITINIB AND TOFACITINIB IN REUMATOID ARTHRITIS IN CLINICAL PRACTICE
	4CPS-146	Development and validation of a rapid High Performance Liquid Cromatography method (HPLC) for the determination of triazoles in human plasma
	4CPS-147	EXPERIENCE OF USE OF BIOLOGICAL ANTIMIGRAINE TREATMENTS IN CLINICAL PRACTICE
	4CPS-148	Use of remdesivir in severe Sars-CoV-2 pneumonia in critically and non-critically ill patients
	4CPS-149	HOSPITAL AT HOME COVID UNIT: MULTIDISCIPLINARY STRATEGIES
	4CPS-150	Ability to assess acute kidney injury in patients admitted to hospital
	4CPS-152	CHARACTERIZATION OF A COMPOUNDED VORICONAZOLE SOLUTION FOR NEBULIZATION AND DESCRIPTION OF ITS USE IN THE CLINICAL SETTING
	4CPS-154	STEVENS–JOHNSON SYNDROME IN A PREGNANT WOMAN CAUSED BY PYRIMETHAMINE AND SULFADIZINE
	4CPS-155	APPROPRIATENESS OF PHARMACOTHERAPY IN NURSING HOMES: PHARMACY AND GERIATRICS SERVICES COORDINATION PROJECT
	4CPS-156	ANTIMICROBIAL STEWARDSHIP PROGRAMME IN A GENERAL SURGERY SERVICE: ROLE OF THE PHARMACIST
	4CPS-157	IMPACT OF COVID-19 PANDEMIC ON PATIENTS TREATED WITH BIOLOGICAL DRUGS AND ENZYME REPLACEMENT THERAPIES
	4CPS-161	BUDGETARY IMPACT OF PCSK9I DOSES REGIMEN OPTIMISATION
	4CPS-162	CYTOKINE RELEASE SYNDROME IN ONCOHAEMATOLOGICAL PATIENTS TREATED WITH TOCILIZUMAB
	4CPS-163	EARLY EXPERIENCES IN SWITCHING BETWEEN MONOCLONAL ANTIBODIES IN CHRONIC MIGRAINE PREVENTIVE THERAPY
	4CPS-164	DURABILITY OF ORAL DUAL ANTIRETROVIRAL THERAPY IN HIV PATIENTS
	4CPS-165	HAS COVID AFFECTED THE TREATMENT OF ONCOLOGY PATIENTS?: A DESCRIPTIVE STUDY OF TREATMENTS FROM 2019 TO 2021
	4CPS-166	ASSOCIATION BETWEEN IMMUNE-RELATED EFFECTS AND EFFECTIVENESS OF FIRST-LINE PEMBROLIZUMAB IN ADVANCED NON-SMALL CELL LUNG CANCER
	4CPS-167	SODIUM AND MAGNESIUM ALTERATIONS IN THE CRITICAL PATIENT WITH SARS-CoV-2 AND PARENTERAL NUTRITION
	4CPS-170	Review of new biomarkers that predict the pharmacokinetics of biologic drugs in inflammatory bowel disease
	4CPS-171	EFFECT OF LIPIDIC COMPOSITION OF PARENTERAL NUTRITION ON THE DEVELOPMENT OF HYPERTRIGLYCERIDAEMIA AND CHOLESTASIS
	4CPS-172	POSACONAZOL THERAPEUTIC DRUG MONITORING IN A PAEDIATRIC TERTIARY HOSPITAL
	4CPS-173	PHARMACEUTICAL INTERVENTION IN BROAD-SPECTRUM ANTIBIOTIC PRESCRIPTION IN HOSPITALIZED PATIENTS
	4CPS-174	EFFECTIVENESS OF OBETICOLIC ACID TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS E
	4CPS-175	MEDICATION REGIMEN COMPLEXITY INDEX AMONG SOLID ORGAN TRANSPLANT PATIENTS
	4CPS-176	ORAL IVERMECTIN EFFECTIVENESS IN THE TREATMENT OF PERMETHRIN-RESISTANT SCABIES: A DESCRIPTIVE AND RETROSPECTIVE OBSERVATIONAL STUDY
	4CPS-177	A QUALITATIVE STUDY ON PHARMACIST PRESCRIBING FOR PATIENTS WITH CHRONIC KIDNEY DISEASE
	4CPS-178	THERAPEUTIC DRUG MONITORINGOF GENTAMICIN AFTER PRE-DIALYSIS ADMINISTRATION
	4CPS-179	“Description and Follow-up of the Use of Emtricitabin/ Tenofovir for HIV Pre-Exposure Prophylaxis
	4CPS-182	INCREASE IN THE PRESCRIPTION OF BENZODIAZEPINES IN THE CONTEXT OF THE SARSCOV-2 PANDEMIC
	4CPS-183	Prevention of coronavirus contamination from the environment using an air-cleaning closed system drug-transfer device
	4CPS-185	A toll for Hospital Pharmacist Interventions optimization
	4CPS-186	2020 ANTIMICROBIAL CONSUMPTION INDICATORS: ANALYSIS COMPARED WITH PREVIOUS YEARS
	4CPS-187	Pharmacist-clinician Collaborative Study for Prospective Identification of Drug Interactions on HIV Patients
	ACPS-189	ASSOCIATION BETWEEN THE DEVELOPMENT OF IMMUNE-RELATED ADVERSE EVENTS AND THE EFFECTIVENESS OF IPILIMUMAB IN ADVANCED MELANOMA
	4CPS-190	TELEPHARMACY: A PILOT EXPERIENCE IN TIMES OF COVID-19 IN A TERTIARY HOSPITAL
	4CPS-191	SWITCH TO BENRALIZUMAB FOR SEVERE EOSINOPHILIC ASTHMA
	4CPS-192	IMPACT OF THE SARS-COV-2 PANDEMIC ON THE USE OF ANTIFUNGALS IN AN INTENSIVE CARE UNIT IN A THIRD-LEVEL HOSPITAL
	4CPS-193	Selection of clinical rules for the screening of high-risk situations in paediatric medicine
	4CPS-194	CLINICAL IMPACT OF A PHARMACIST-LED DISCHARGE MEDICATION REVIEW SERVICE: AN ANALYSIS OF PREVALENCE AND ACCEPTANCE OF INTERVENTIONS
	4CPS-195	Medication-related readmissions: documentation and communication to the next healthcare providers and patients
	4CPS-197	Evaluation of adherence to cystic fibrosis transmembrane conductance protein modulator drugs
	4CPS-198	THE IMPACT OF A PHARMACIST-LED MEDICATION REVIEW ON THE MEDICINE RISK SCORE: A NONRANDOMISED CONTROLLED STUDY
	4CPS-199	EVALUATION OF FREMANEZUMAB RESPONSE IN MIGRAINE PROPHYLAXIS
	4CPS-200	EFFECTIVENESS OF ERENUMAB AND GALCANEZUMAB IN THE PREVENTION OF MIGRAINE
	4CPS-201	Audit on the prescription and administration of Parkinson’s Disease medication on admission to hospital
	4CPS-202	OPTIMISATION OF SUBCUTANEOUS BIOLOGICAL THERAPIES IN RHEUMATIC AND DERMATOLOGICAL DISEASES
	4CPS-203	COMPARISON OF PIRFENIDONE VERSUS NINTENDANIB IN IDIOPATHIC PULMONARY FIBROSIS
	4CPS-204	AN EXPLORATION OF PATIENTS’ PERCEPTIONS OF COLORECTAL CANCER AND ITS MANAGEMENT: A QUALITATIVE STUDY AT INITIATION OF TREATMENT WITH CHEMOTHERAPY
	4CPS-206	RIBOCICLIB AS FIRST LINE FOR METASTASIC BREAST CANCER: ANALISIS OF USE AND SECURITY
	4CPS-207	IMPROVING THE SAFETY OF PHARMACOTHERAPY IN PAEDIATRIC HAEMATO-ONCOLOGY BY CLINICAL PHARMACY SERVICES
	4CPS-209	Benefit of Medication Reviews by a Renal Pharmacist in the Setting of a Computerized Physician Order Entry System
	4CPS-210	IMPACT OF THE ANTIBIOTIC THERAPY USED DURING THE SARS-COV-2 PANDEMIC ON THE INCIDENCE OF CLOSTRIDIOIDES DIFFICILE INFECTION
	4CPS-211	Reduction of flushing volume and incompatibilities by a clinical pharmacist in a paediatric intensive care unit
	4CPS-212	INSTRUCTIONS GIVEN BY THE ANAESTHETIST ON THE MANAGEMENT OF CHRONIC TREATMENTS PREOPERATIVELY: WHAT DOES THE PATIENT REALLY UNDERSTAND AND RETAIN? AN OBSERVATIONAL STUDY
	4CPS-213	A COMPARATIVE RISK ANALYSIS COMPARING THE CONVENTIONAL AND FULLY AUTOMATED MANAGEMENT OF CLINICAL TRIALS IN AN ONCOLOGY PHARMACY
	4CPS-214	EXPERIENCE OF USE OF CANNABIDIOL IN PAEDIATRIC PATIENTS
	4CPS-215	PERSISTENCE AND THERAPEUTIC ADHERENCE TO FIRST GENERATION JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS
	4CPS-217	CLINICAL, ECONOMIC AND ORGANISATIONAL IMPACT OF PHARMACISTS’ INTERVENTIONS IN ONCOLOGICAL CARE PATIENTS
	4CPS-218	EVALUATION OF THE IMPACT OF INCORPORATING A PHARMACIST INTO A HOSPITAL EMERGENCY DEPARTMENT
	4CPS-221	POTENTIALLY INAPPROPRIATE MEDICINES IN OLDER PATIENTS
	4CPS-222	ADHERENCE IN POLYMEDICATED ELDERLY PATIENTS ADMITTED TO A TRAUMA WARD
	4CPS-223	ADHERENCE TO ABIRATERONE AND CORTICOID IN PATIENTS WITH PROSTATE CANCER
	4CPS-224	IMPACT OF PROACTIVE MEDICATION RECONCILIATION PRIOR TO PRE-ANAESTHESIC CONSULTATION
	4CPS-225	Integration of a clinical pharmacist in a therapeutic education team for diabetic patients: an initiative that is worth gold!
	4CPS-226	THE ROLE OF THE CLINICAL PHARMACIST IN THE SCREENING OF CANDIDATES FOR ONCOHAEMATOLOGICAL CLINICAL TRIALS
	4CPS-227	Feedback from a French region on the use of e - Therapeutic Patient Education during the health crisis: high-speed interviews!
	4CPS-229	Implementation of an interprofessional pre-operative medication management program in cardiac surgery – a pre post quality improvement study
	4CPS-231	ARE WE SUSTAINABLE? A BASELINE QUESTIONNAIRE REGARDING THE ENVIRONMENTAL IMPACT OF PHARMACY PRACTICE ACROSS THE COUNTRY
	4CPS-232	Pharmacist-led medication review unveiled more medication-related problems in possibly medication-related hospitalisations than in unlikely medication-related hospitalisations in elderly patients
	4CPS-233	THERAPEUTIC SWITCH OF ANTIRETROVIRAL TREATMENTS: EFFICACY, TOLERABILITY AND REASON FOR CHANGE
	4CPS-234	IMPACT OF AN INTENSIVE MONITORING PROGRAM ON METHOTREXATE ELIMINATION
	4CPS-235	PROFILE OF USE OF PHARMACOTHERAPY IN PSORIASIS, BIOLOGICAL DRUGS AND BIOSIMILARS
	4CPS-237	MEASURING ADHERENCE TO ANTIRETROVIRAL TREATMENT: CORRELATION AND CONCORDANCE BETWEEN TWO INDIRECT METHODS
	4CPS-239	IMPACT OF KNOWLEDGE ABOUT HUMAN IMMUNODEFICIENCY VIRUS (HIV) TRANSMISSION ON THE QUALIY OF LIFE OF PEOPLE LIVING WITH HIV
	4CPS-240	DEVELOPMENT OF A 25% BENZYL BENZOATE LOTION FOR A CASE OF RESISTANT NORWEGIAN SCABIES
	4CPS-241	Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Tenofovir alafenamide, Emtricitabine and Bictegravir in a Real-Life Cohort of HIV-Infected Adults
	4CPS-242	HUMAN IMMUNODEFICIENCY VIRUS PRE-EXPOSURE PROPHYLAXIS: ANALYSIS, FOLLOW-UP AND PANDEMIC EFFECT
	4CPS-243	INFLUENCE OF VENOVENOUS EXTRACORPOREAL MEMBRANE OXYGENATION ON THE PHARMACOKINETICS OF VANCOMYCIN IN ADULTS: CAN AN OPTIMAL PHARMACODYNAMIC TARGET BE ACHIEVED?
	4CPS-244	CARDIOVASCULAR, RENAL AND BONE EVALUATION OF A HIV POPULATION OVER 60 YEARS OLD
	4CPS-245	INAPPROPRIATE ANTIBIOTIC DOSAGE ADJUSTMENTS IN PATIENTS WITH RENAL IMPAIRMENT: A CROSS-SECTIONAL ANALYSIS
	4CPS-246	MEDICATION-RELATED ADMISSION WAS MORE FREQUENT IN ELDERLY PATIENTS HOSPITALISED IN AN ORTHOPEDIC UNIT THAN IN AN EMERGENCY DEPARTMENT IN TWO FRENCH HOSPITALS
	4CPS-247	EVALUATION OF THE CLINICAL IMPACT OF MEDICATION RECONCILIATION ON ADMISSION USING THE CLEO TOOL
	4CPS-249	ELTROMBOPAG FOR TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA ASSOCIATED WITH COVID-19 VACCINE: A CASE REPORT
	4CPS-250	HOME DELIVERY FOR OUTPATIENTS WITH IMMUNEMEDIATED DISEASES: EXPERIENCE AND PATIENT SATISFACTION
	4CPS-251	INFLUENCE OF POLYPHARMACY AND COMORBIDITIES IN THE QUALITY OF LIFE OF PATIENTS WHO SUFFER HIP FRACTURE
	4CPS-252	ORAL AND INTRAVENOUS IRON IN THE TREATMENT OF PERIOPERATIVE ANAEMIA
	4CPS-253	DIFFERENCES BETWEEN PHARMACEUTICAL INTERVENTIONS PERFORMED ON ANTIMICROBIALS IN MEDICAL AND SURGICAL SERVICES
	4CPS-257	EFFECTIVENESS AND SAFETY OF NINTEDANIB AND PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
	4CPS-258	ACTIVATION, ADHERENCE AND HEALTH OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS TREATED WITH BIOLOGICAL DRUGS
	4CPS-259	ANALYSIS OF THE ANTICHOLINERGIC LOAD IN POLYMEDICATED ELDERLY PATIENTS WHO HAVE SUFFERED A FALL
	4CPS-260	PERSISTENCE AND SAFETY OF CALCITONIN GENERELATED PEPTIDE INHIBITORS IN CHRONIC MIGRAINE
	4CPS-262	EVALUATION OF DRY EYE SEVERITY AND THERAPEUTIC ADHERENCE OF PATIENTS ON AUTOLOGOUS SERUM EYE DROPS
	4CPS-263	EVALUATION OF THE EFFECTIVENESS AND SAFETY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS TOCILIZUMAB
	4CPS-264	ANALYSIS OF MEDICAL TREATMENT, RISK FACTORS AND RECURRENCE OF CLOSTRIDIOIDES DIFFICILE NOSOCOMIAL DIARRHOEA
	4CPS-265	CHRONIC COMPLEX PALLIATIVE PAEDIATRIC PATIENT AT-HOME CARE UNIT: PHARMACOTHERAPEUTIC PROFILE AND ANALYSIS OF SIALORRHEA TREATMENT
	4CPS-266	Detection and follow-up of drug related problems for patients with cardiovascular disease: A study of the Medicine Start Service in hospital pharmacies
	4CPS-267	Design, implementation, and evaluation of a medication counselling service provided by pharmacists using teach-back at hospital discharge
	4CPS-269	ANALYSIS OF RECURRENCES AND RISK FACTORS IN INFECTION BY CLOSTRIDIUM DIFFICILE
	4CPS-270	Investigating the Use of Patient Frailty to Guide Pharmacist-led Medication Review
	4CPS-271	ADHERENCE TO MEPOLIZUMAB AND BENRALIZUMAB IN REAL CLINICAL PRACTICE
	4CPS-272	INTEGRATION OF THE HOSPITAL PHARMACIST INTO A MULTIDISCIPLINARY DYSPHAGIA SCREENING TEAM IN AN INTERMEDIATE AND LONG STAY HOSPITAL
	4CPS-273	IMPACT OF A SPECIALIST PHARMACIST ON HEPATOPANCREATICO-BILIARY (HPB) SURGICAL WARD ROUNDS AT A LARGE TERTIARY LIVER CENTRE
	4CPS-274	Evaluation of pharmaceutical interventions documented by a pharmacy technician: Where do pharmacy technicians have the biggest impact to avoid drug-related problems?

Section 5: Patient Safety and Quality Assurance
PDF document	Poster number	Poster Title
	5PSQ-002	ADVERSE EVENTS REPORTED AFTER ADMINISTRATION OF BNT162B2 AND MRNA-1273 COVID-19 VACCINES AMONG HEALTHCARE-WORKERS
	5PSQ-003	DEVELOPMENT AND APPLICABILITY OF THE MEDHIPPRO-Q: A QUESTIONNAIRE ASSESSING MEDICAL DOCTORS’ EXPERIENCE WITH MEDICATION MANAGEMENT IN THE HIP FRACTURE PATIENT PATHWAY
	5PSQ-004	ANALYSIS OF ADVERSE DRUG REACTIONS OF DISEASE -MODIFYING TREATMENTS IN MULTIPLE SCLEROSIS
	5PSQ-006	DOSING LOW MOLECULAR WEIGHT HEPARINS IN RENAL IMPAIRMENT: A NATIONWIDE SURVEY
	5PSQ-008	ASSESSMENT OF PATIENTCONTROLLED ANALGESIA (PCA) PRACTICES IN A PUBLIC HOSPITAL
	5PSQ-009	Patient Safety and Medication Safety Culture in a Hospital Pharmacy Department: A Mixed Methods Study
	5PSQ-010	Identification of incorrect dosing of direct oral anticoagulants: an important intervention to improve patient safety
	5PSQ-011	INTRAVENOUS POTASSIUM CHLORIDE: HOSPITALWIDE EVALUATION AND BENEFITS OF A VIDEO COURSE
	5PSQ-012	ARE 12 MONTHS OF TREATMENT WITH MONOCLONAL ANTIBODIES SUFFICIENT FOR MIGRAINE ATTACK PREVENTION?
	5PSQ-013	ANTINEOPLASTIC DRUGS AND THROMBOSIS: ANALYSIS OF A COHORT OF PATIENTS WITH CANCER-ASSOCIATED THROMBOSIS
	5PSQ-014	SAFETY AND TOLERANCE PROFILE OF NIVOLUMAB AND PEMBROLIZUMAB
	5PSQ-015	ANTIBIOTIC DESENSITIZATION IN PATIENTS WHO WERE PREVIOUSLY TREATED WITH POTENTIALLY ALLERGY-TRIGGERING MOLECULES
	5PSQ-016	ACE INHIBITORS AND ARBs AS RISK FACTORS FOR COVID-19 INFECTION: FAKE NEWS OR EVIDENCE-BASED MEDICINE?
	5PSQ-017	MAPPING OF PHARMACOLOGICAL RISK FACTORS AND COMORBIDITY IN PATIENTS WITH SEVERE COVID-19: A RETROSPECTIVE OBSERVATIONAL CASE-CONTROL STUDY
	5PSQ-018	ANALYSIS OF THE USE OF FONDAPARINUX IN SUSPECTED HEPARIN-INDUCED THROMBOCYTOPENIA
	5PSQ-019	ASSESSMENT OF THE LEVEL OF KNOWLEDGE AND MOTIVATION IN A HOSPITAL CENTER STAFF FOR GETTING VACCINATED AGAINST SARS-CoV-2
	5PSQ-021	Patient´s and physician´s acceptance of a pharmacist-led intervention to reduce anticholinergic burden
	5PSQ-022	DESENSITISATION PROTOCOL FOR ADALIMUMAB IN ARTHROPATHIC PSORIASIS: A CASE REPORT
	5PSQ-023	Neutropenia as an indicator of trifluridinetipiracil efficacy in metastatic colorectal cancer
	5PSQ-024	Effectiveness and safety of durvalumab in the treatment of unresectable locally advanced non small cell lung cancer (LANSCLC)
	5PSQ-025	ANTICHOLINERGIC RISK IN OLDER PEOPLE LIVING WITH HIV
	5PSQ-026	CLINICAL IMPORTANCE OF GENETIC VARIANTS IN CAPECITABINE BIOACTIVATION PATHWAY FOR THE PREDICTION OF RESPONSE IN COLORECTAL CANCER PATIENTS
	5PSQ-027	Misuse assesment and risks of NSAIDs prescriptions for elderly patients in surgical units
	5PSQ-028	ASSESSMENT OF SUSPICION OF ALLERGY TO CORONAVIRUS DISEASE 2019 VACCINE BY SKIN TESTING: RESULTS FROM A MONOCENTRIC COHORT
	5PSQ-029	EVALUATION OF THE EFFICACY AND SAFETY OF ERENUMAB IN THE PROFILAXIS OF CHRONIC AND EPISODIC MIGRAINE
	5PSQ-030	USE OF CEFIDEROCOL FOR MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII IN PATIENTS WITH SARS-COV-2: TWO CASE REPORTS
	5PSQ-031	EVALUATION OF THE SAFETY AND TOLERANCE OF THE COMMERCIAL PRESENTATION OF CICLOSPORINE 0.1% COLLYRIUM
	5PSQ-032	COMPLIANCE ANALYSIS OF PEDIATRIC ANTICANCER DRUG DOSING
	5PSQ-033	Positive Impact of an Implemented Ward Pharmacist in a Multiprofessional Cancer Care Team in Germany
	5PSQ-034	HOMOGENEITY OF OPINION EXPERT ON CLEO SCALE WHEN APPLIED TO 50 MODELED PHARMACEUTICAL INTERVENTIONS
	5PSQ-035	INTENSIFICATING THERAPY WITH USTEKINUMAB IN NON-FIRST LINE CROHN’S DISEASE: CLINICAL EXPERIENCE, SAFETY AND EFFECTIVENESS IN THE “REAL WORLD”
	5PSQ-036	IMPROVEMENT IN POSTOPERATIVE PAIN CONTROL BY THE INTRODUCTION OF ELASTOMETRIC LOCAL ANAESTHESIC LEVOBUPIVACAINE PUMPS IN PATIENTS UNDERGOING ARTHROPLASTY
	5PSQ-038	DEPRESCRIBING INTERVENTIONS PERFORMED BY HOSPITAL PHARMACISTS REDUCE POTENTIALLY INAPPROPRIATE MEDICATION AT HOSPITAL DISCHARGE
	5PSQ-040	PHARMACEUTICALS IN HOSPITAL WASTEWATER: A REVIEW
	5PSQ-041	SAFETY AND EFFICACY OF HIGH DOSES OF IRINOTECAN IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FOLFIRI SCHEME BASED ON UGT1A1 GENOTYPE: A SYSTEMATIC REVIEW
	5PSQ-042	TOXICITY OF REMDESIVIR AS TREATMENT OF NON-CRITICALLY ILL COVID-19 PATIENTS
	5PSQ-043	BENZODIAZEPINES AND HYPNOTIC ANTIPSYCHOTICS IN A PSYCHIATRIC HOSPITAL
	5PSQ-044	CONCILIATION AND PHARMACEUTICAL CARE ON DISCHARGE IN THE PSYCHIATRIC PATIENT
	5PSQ-045	ANALYSIS OF ANTIPSYCHOTIC POLYTHERAPY IN A PSYCHIATRIC HOSPITAL
	5PSQ-046	IMPACT OF THE COVID-19 PANDEMIC ON A NOTIFICATION AND LEARNING SYSTEM FOR PATIENT SAFETY IN A PSYCHIATRIC HOSPITAL
	5PSQ-048	ANALYSIS OF THE UNIT DOSE SYSTEM OF MEDICATION DISTRIBUTION IN MENTAL HEALTH PHARMACY
	5PSQ-049	STARTING POINT TO PROMOTE A POTENTIALLY INAPPROPRIATE PRESCRIPTION ASSESSMENT PROJECT
	5PSQ-051	COST-EFFECTIVENESS OF A PRESURGICAL PHARMACEUTICAL CARE CONSULTATION
	5PSQ-053	INFLUENCE OF AUGMENTED RENAL CLEARANCE IN THE LOWER INCIDENCE OF LINEZOLID-RELATED HAEMATOLOGICAL TOXICITY
	5PSQ-054	ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH ANTIANGIOGENIC DRUGS: A RARE BUT SERIOUS COMPLICATION
	5PSQ-055	LONG-TERM EFFECTIVENESS OF ADALIMUMAB IN SECONDLINE OF BIOLOGICAL THERAPY IN ULCERATIVE COLITIS AND INFLUENCE OF THE FIRST-LINE TREATMENT
	5PSQ-056	LOT QUALITY ASSURANCE SAMPLING (LQAS) OF A TELEPHARMACY PROGRAMME FROM THE HOSPITAL PHARMACY TO THE OUTPATIENT THROUGH THE COMMUNITY PHARMACY
	5PSQ-057	ACTIVE PHARMACOVIGILANCE OF PATIROMER IN A CENTRAL HOSPITAL PHARMACEUTICAL CONSULTATION SETTING
	5PSQ-058	EFFICACY AND MARGINAL COST OF TREATMENT WITH TOCILIZUMAB IN COVID-19 PATIENTS
	5PSQ-059	CHARACTERISATION OF MEDICATION ERRORS IN A PUBLIC HOSPITAL
	5PSQ-060	LONG-TERM EFFECTIVENESS OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA IN CLINICAL PRACTICE
	5PSQ-062	REAL CLINICAL PRACTICE RESULTS OF INTERLEUKIN23 BLOCKERS IN REFRACTORY PSORIASIS
	5PSQ-063	PERSISTENCE OF TYROSINE KINASE INHIBITORS IN ADVANCED RENAL CELL CARCINOMA
	5PSQ-065	INMUNOTHERAPY: RECOGNISING AND TREATING ADVERSE EFFECTS
	5PSQ-066	PATIENT OUTCOMES AFTER THE IMPLEMENTATION OF A HUMANISED ENHANCED RECOVERY AFTER KNEE JOINT REPLACEMENT SURGERY PROGRAMME
	5PSQ-067	ARE POLY (ADP-RIBOSE) POLYMERASE INHIBITORS WELL TOLERATED BY OUR PATIENTS? A SAFETY STUDY IN REAL-WORD PRACTICE
	5PSQ-068	INCIDENCE OF POST-ARTESUNATE-INDUCED HAMOLYSIS AFTER SEVERE MALARIA
	5PSQ-069	DOES THE TREATMENT LINE HAVE AN IMPACT ON THE TOXICITY PRODUCED BY OFF-LABEL ONCOLOGICAL TREATMENTS?
	5PSQ-070	USEFULNESS OF PHARMACEUTICAL VALIDATION IN CHEMOTHERAPY PRESCRIPTION
	5PSQ-071	REAL-WORLD RESULTS OF EFFECTIVENESS AND SECURITY OF ERENUMAB AND GALCANEZUMAB IN MIGRAINE PATIENTS
	5PSQ-074	COVID-19 VACCINES: ADVERSE EVENTS AFTER A SECOND DOSE OF PFIZER OR ASTRAZENECA VACCINES IN HEALTHCARE WORKERS WHO RECEIVED A FIRST DOSE OF ASTRAZENECA VACCINE
	5PSQ-076	EVALUATION AND MONITORING OF BIOCHEMICAL PARAMETERS IN PATIENTS ON PARENTERAL NUTRITION
	5PSQ-077	BEVACIZUMAB BIOSIMILARUSE IN OPHTHALMOLOGY
	5PSQ-078	THROMBOEMBOLIC PROPHYLAXIS IN PATIENTS TREATED WITH ORAL IMMUNOMODULATORS IN MULTIPLE MYELOMA
	5PSQ-080	ERTAPENEM-INDUCED NEUROTOXICITY: ROLE OF PLASMA CONCENTRATION MONITORING
	5PSQ-081	IMPACT OF PHARMACY INTERVENTION ON REDUCTION OF MEDICATION-RELATED PROBLEMS IN ELDERLY PATIENTS IN A NURSING HOME
	5PSQ-082	EFFECTIVENESS IN REAL LIFE OF BIOLOGICAL DRUGS USED IN MIGRAINE PROPHYLAXIS
	5PSQ-083	USE OF ISAVUCONAZOLE IN PATIENTS WITH COVID19 IN AN INTENSIVE CARE UNIT
	5PSQ-084	HOME DELIVERY AND TELEPHARMACY PROGRAMME: SATISFACTION OF PATIENTS
	5PSQ-085	REAL-WORLD SAFETY AND TOLERABILITY OF PALBOCICLIB AS FIRST-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER
	5PSQ-086	EVALUATION OF THE EFFECTIVENESS OF BEZLOTOXUMAB ON PREVENTION OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION
	5PSQ-087	LONG-TERM DUAL ANTIPLATELET THERAPY: CONTROVERSY CONTINUES
	5PSQ-088	ANTI SARS-CoV-2 MONOCLONAL ANTIBODIES: FROM CLINICAL TRIAL TO REAL WORLD EVIDENCE
	5PSQ-090	USE OF MONOCLONAL ANTIBODIES AGAINST THE CALCITONIN GENERELATED PEPTIDE PATHWAY IN CHRONIC MIGRAINE IN CLINICAL PRACTICE
	5PSQ-091	DALBAVANCIN ADMINISTRATION IN OUTPATIENTS TO REDUCE HOSPITAL STAY IN SELECTED PATIENTS
	5PSQ-092	TREATMENT OF METASTATIC HER2+ BREAST CANCER: USE OF TRASTUZUMAB BIOSIMILARS IN COMBINATION WITH PERTUZUMAB
	5PSQ-093	PERSISTENCE OF TREATMENT WITH INTERLEUKIN -17 INHIBITORS IN SKIN DISORDERS
	5PSQ-094	REASONS FOR DISCONTINUATION OF SELECTIVE IMMUNOSUPPRESSIVE BIOLOGICAL TREATMENTS AGAINST PSORIASIS
	5PSQ-095	COMPARISON BETWEEN THE MAXIMUM RECOMMENDED DOSE OF AZATHIOPRINE ACCORDING TO THE ENZYMATIC ACTIVITY OF THIOPURINE METHYLTRANSFERASE AND 6-THIOGUANINE LEVELS WITH THE MAXIMUM TOLERATED DOSE
	5PSQ-097	USE AND PERSISTENCE OF FIRST-LINE BIOLOGICAL TREATMENTS FOR PSORIASIS
	5PSQ-098	EXPERIENCE IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION
	5PSQ-101	MEDICATION ERRORS IN UNIT-DOSE DRUG DISTRIBUTION SYSTEM: QUALITY CONTROL
	5PSQ-103	DEVELOPMENT AND TESTING OF A SMARTPHONEBASED SOLID ORAL DOSAGE FORM IMAGE RECOGNITION SYSTEM BY MACHINE LEARNING TO SUPPORT THE IDENTIFICATION OF DISPENSING ERRORS
	5PSQ-104	VOLUNTARY ELECTRONIC REPORTING OF MEDICATION ERRORS AND ADVERSE DRUGS EVENTS DURING THE FIRST YEAR OF THE COVID-19 PANDEMIC
	5PSQ-105	INSULIN PERFUSION IN NEONATOLOGY. WHICH ONE IS THE SAFEST?
	5PSQ-106	IMPLEMENTATION OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMP) RECONSTITUTION IN A UNIVERSITY TEACHING HOSPITAL IN FRANCE : PROPOSAL OF A DECISION-MAKING ALGORITHM
	5PSQ-107	SECURIZING OF TISAGENLECLEUCEL THAWING AND DELIVERING
	5PSQ-108	SECURIZING OF TISAGENLECLEUCEL (KYMRIAH®) STORAGE
	5PSQ-110	OMEPRAZOLE DEPRESCRIPTION PROJECT IN A SOCIAL HEALTH CENTER WITH A DEPOSIT OF MEDICINES ASSOCIATED WITH A HOSPITAL PHARMACY SERVICE
	5PSQ-111	PHARMACEUTICAL INTERVENTION: AVOIDING INTERACTIONS BETWEEN ANTIRETROVIRALS AND VITAMIN SUPPLEMENTS/ ANTIACIDS
	5PSQ-112	HIDDEN HARM? ASSESSING MAGNITUDE AND COSTS OF INTRAVENOUS THERAPY ADMINISTRATION ERRORS VIA SMART PUMP REPORTS
	5PSQ-115	ANALYSIS OF MEDICATION ERRORS INVOLVING HIGH-RISK PATIENTS IN THE PERIOPERATIVE SETTING
	5PSQ-116	Medication-related follow-up of older patients after hospital discharge: a multicentre retrospective chart review
	5PSQ-117	DETERMINATION OF GENETIC POLYMORPHISMS IN THE DIHYDROPYRIMIDINE DEHYDROGENASE GENE IN A PATIENT WITH GASTRIC ADENOCARCINOMA TREATED WITH FLUOROPYRIMIDINES: A CASE REPORT
	5PSQ-118	LITHIUM THERAPY ON HOSPITAL ADMISSION
	5PSQ-120	IMPACT OF THE COVID-19 PANDEMIC ON THE USE OF ANTIMICROBIALS IN PRIMARY AND HOSPITAL CARE
	5PSQ-121	IMPORTANCE OF CONCILIATION IN IMMUNOSUPPRESSANT TREATMENT
	5PSQ-122	EXPERIENCE OF BARICITINIB-REMDESIVIR USE IN PATIENTS WITH SARS-COV-2 INFECTION
	5PSQ-123	ORPHAN OFF-LABEL DRUG: IS IT REALLY COMMON PRACTICE?
	5PSQ-124	THE ROLE OF THE CLINICAL PHARMACIST AVOIDING MEDICATION ERRORS IN A CLINICAL RESEARCH ONCO-HEMATOLOGIC UNIT
	5PSQ-125	THE IDENTIFICATION OF HEALTH CONSEQUENCES ASSOCIATED WITH COUNTERFEIT MEDICINE AND ILLEGAL HEALTH PRODUCT APPLICATION USING PHARMACOVIGILANCE DATA
	5PSQ-128	CLINICAL INTERVENTIONS IN THE AREA OF INPATIENT PRESCRIPTIONS PERFORMED BY HOSPITAL PHARMACY RESIDENT
	5PSQ-130	DOSE BANDING OF INTRAVENOUS 5-FLUOROURACIL, OXALIPLATIN, PACLITAXEL AND GEMCITABIN: EVALUATION OF EFFICIENCY AND SAFETY SUBSEQUENT TO AN IMPLEMENTATION PROGRAMME
	5PSQ-131	PARENTERAL NUTRITION IN ACUTE PANCREATITIS: A REVIEW OF APPROPRIATENESS
	5PSQ-132	ANALYSIS OF CHEMICAL CONTAMINATION BY HAZARDOUS DRUGS WITH SEMIQUANTITATIVE SYSTEM IN A TERTIARY HOSPITAL
	5PSQ-133	ANALYSIS OF REAL-LIFE DATA: OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL OF NIVOLUMAB AND ATEZOLIZUMAB IN NOT SMALL CELLS LUNG CANCER
	5PSQ-134	PATIENTS’ SATISFACTION TOWARD PHARMACEUTICAL CARE AT A UNIVERSITY HOSPITAL
	5PSQ-135	NEW SECURITY WARNINGS FOR TOFACITINIB: ANALYSIS OF PATIENTS IN RISK
	5PSQ-137	MEDICATION ERRORS RELATING TO ISOAPPEARANCES IN THE EMERGENCY ROOM
	5PSQ-138	IMPACT OF HIGH TEMPERATURE, SHAKING AND LIGHT ON QUALITY OF THE THERAPEUTIC PEPTIDE TEDUGLUTIDE (REVESTIVE®) EVALUATED BY LC/MS/MS (ORBITRAP) PEPTIDE MAPPING ANALYSIS AND STRESS
	5PSQ-139	ANTICHOLINERGIC RISK EVALUATION IN HOSPITALISED PATIENTS
	5PSQ-140	PATIENT SAFETY CLIMATE IN A HOSPITAL PHARMACY DEPARTMENT
	5PSQ-141	Personalized therapy for interstitial lung diseases in caused by ABCA3 mutations
	5PSQ-144	Development and validation of clinical rules to address risk prescriptions
	5PSQ-145	MEDICINAL PLANTS USE AMONG TUNISIAN PATIENTS: PREVALENCE AND PERCEPTION
	5PSQ-146	RISK MAPPING OF DRUG MANAGEMENT IN A PRISON
	5PSQ-147	A SYSTEMATIC RISK ANALYSIS METHOD APPLIED TO THE MEDICAL DEVICES MANAGEMENT PROCESS IN A HOSPITAL PHARMACY
	5PSQ-148	TANDEM PROJECT: TRANSITIONS OF CARE AND MEDICATION RECONCILIATION IN HIGH-RISK PATIENTS
	5PSQ-149	DURVALUMAB FOR THE TREATMENT OF NONSMALL CELL LUNG CANCER: REAL-WORLD EXPERIENCE
	5PSQ-150	Implementation of a Programme for Optimising the Use of Antibiotics (PROA) in the Paediatrics Emergency Care Unit of a third level hospital
	5PSQ-151	OPTIMIZATION OF THE SUBCUTANEOUS ADMINISTRATION OF DARATUMUMAB
	5PSQ-152	EFFECTIVENESS AND SAFETY OF ERENUMAB IN MIGRAINE PROPHYLAXIS
	5PSQ-153	PERSISTENCE AND REASONS FOR DISCONTINUATION OF TREATMENT WITH APREMILAST IN DERMATHOLOGICAL DISEASES
	5PSQ-154	Impact of the COVID-19 Pandemic on Antimicrobial Consumption and Antimicrobial Resistance
	5PSQ-155	HOW IS CHEMOTHERAPY USED AT THE END OF LIFE IN A SECONDARY HOSPITAL?
	5PSQ-156	REASONS FOR SECUKINUMAB TREATMENT DISCONTINUATION
	5PSQ-157	SEVERE NEUROTOXICITY OF ORAL IVERMECTIN: A SYSTEMATIC REVIEW OF CASES AND CASE SERIES
	5PSQ-158	Food and drink management as part of medicaton administration safety

Section 6: Education and Research
PDF document	Poster number	Poster Title
	6ER-001	CAN PHARMACISTS IMPROVE THEIR PATIENT COMMUNICATION BY READING FICTION?
	6ER-002	Applying reflective Multicriteria Decision Analysis to understand the value of therapeutic alternatives in the management of anaemia in gynaecologic surgery
	6ER-005	REDUCING INVASIVE DEVICE-RELATED BLOODSTREAM INFECTIONS: A CHALLENGE FOR THE PREVENTION OF HEALTH-CARE ASSOCIATED INFECTIONS
	6ER-006	PARACETAMOL VERSUS IBUPROFEN FOR TREATMENT OF PERSISTENT DUCTUS ARTERIOSUS CLOSURE IN PRETERM INFANTS: IBUPAR-TRIAL
	6ER-007	REAL-WORLD EFFECTIVENESS OF GENE THERAPY ONASEMNOGENE ABEPARVOVEC (ZOLGENSMA) FOR SPINAL MUSCULAR ATROPHY: A REVIEW
	6ER-008	DEVELOPMENT OF A RISK-SHARING MODEL BASED ON THE CLINICAL PERFORMANCE OF ONASEMNOGENE ABEPARVOVEC (ZOLGENSMA)
	6ER-011	COTRIMOXAZOL: HOW FOLATE SUPPLEMENTATION COULD AFFECT TREATMENT EFFICACY
	6ER-012	EFFECTIVENESS OF IL-23 INHIBITORS IN PATIENTS WITH MODERATE–SEVERE CHRONIC PLAQUE PSORIASIS
	6ER-013	ANALYSIS OF PATIENTS’ MORTALITY IN SARS-COV-2 INFECTION DURING THE FIRST MONTH OF HOSPITAL ADMISSION
	6ER-014	ANALYSIS OF THE EVOLUTION OF INTERLEUKIN-6 IN COVID-19 PATIENTS AFTER BEING TREATED WITH DEXAMETHASONE
	6ER-015	MUTATIONS IN THE FACTOR VIII GENE IN OUR HAEMOPHILIA A POPULATION
	6ER-017	PREVENTION OF EXTRAVASATION BY THE LOCAL APPLICATION OF HYBRID AEROGEL MICROPARTICLES AS DRUG DELIVERY SYSTEMS FOR CERVICAL CANCER CHEMOTHERAPY
	6ER-018	USE OF ELTROMBOPAG IN ROUTINE CLINICAL PRACTICE
	6ER-019	DETERMINATION OF DOXORUBICIN FROM THE EFLUATE OF CELLS USING THE DRUGLOG® SYSTEM
	6ER-020	The occurrence of fluid overload in critically ill patients: is there a need for fluid stewardship?
	6ER-021	EVALUATION OF COVID MORTALITY DURING HOSPITAL ADMISSION IN PATIENTS RECEIVING ONCOLOGIC TREATMENT
	6ER-022	PHARMACOLOGICAL FACTORS RELATED TO HOSPITAL ADMISSIONS IN POLYMEDICATED ELDERLY PATIENS
	6ER-023	STUDY OF THE USE OF CEFTAZIDIMA-AVIBACTAM IN A THIRDLEVEL UNIVERSITY HOSPITAL
	6ER-024	POTENTIALLY DRUG-RELATED PROBLEMS IN A POLYMEDICATED POPULATION
	6ER-025	Real-life use of remdesivir in hospitalized COVID-19 patients with severe pneumonia: an observational study from an Italian University Hospital
	6ER-026	EFFECTIVENESS AND SAFETY OF APREMILAST IN A THIRD-LEVEL HOSPITAL
	6ER-027	BLOOD CYTOKINE EVALUATION IN PATIENTS WITH INTRAVITREAL RANIBIZUMAB FOR NEOVASCULAR AGE RELATED MACULAR DEGENERATION
	6ER-027	BLOOD CYTOKINE EVALUATION IN PATIENTS WITH INTRAVITREAL RANIBIZUMAB FOR NEOVASCULAR AGE RELATED MACULAR DEGENERATION
	6ER-028	MARKET EXCLUSIVITY EXPIRY HAS LIMITED EFFECT ON PRICES OF BRAND-NAME ORPHAN DRUGS
	6ER-029	Game-based training: play instead of reading boring procedures!

25th Anniversary EAHP Congress - Hospital Pharmacy 5.0 - the future of patient care (2021)

National Poster Prize Winners
PDF document	Poster number	Poster Title
	NP-001	IMPACT OF AN ORAL NUTRITION PROTOCOL IN PATIENTS TREATED WITH ELECTIVE RADICAL CYSTECTOMY: A LONG TERM FOLLOW-UP (submitted in 2019)
	NP-002	MEDICATION SAFETY IN PATIENTS TREATED WITH ORAL ANTITUMOR AGENTS: A PROSPECTIVE, RANDOMIZED INVESTIGATION TO IMPROVE PATIENT SAFETY AND WELL-BEING BY INTENSIFIED CLINICAL PHARMACEUTICAL/ PHARMACOLOGICAL CARE (submitted in 2019)
	NP-003	STEADY-STATE PHARMACOKINETICS AND EARLY SAFETY DATA IN HIV-INFECTED AFRICAN CHILDREN WEIGHING ≥25KG AFTER SWITCHING TO 50MG FILM-COATED DOLUTEGRAVIR TABLETS IN THE ODYSSEY TRIAL (submitted in 2019)
	NP-004	INITIATION OF A CLINICAL PHARMACIST LED, PROSPECTIVE AUDIT ON ANTIBIOTIC PRESCRIBING (submitted in 2019)
	NP-005	IMPLEMENTING MEDICATION RECONCILIATION ON HOSPITAL ADMISSION: A MULTICENTER PILOT STUDY IN ESTONIA AND FINLAND (submitted in 2019)
	NP-006	A PAIR OF PHARMACY TECHNICIAN / NURSE TO TRAIN ON THE ANTI-RETURN VALVES (submitted in 2019)
	NP-007	A MIXED METHODS EVALUATION OF THE CROSS-SECTOR PHARMACIST VOCATIONAL TRAINING FOUNDATION PROGRAMME: IS THE TRAINING PROGRAMME FIT FOR PURPOSE? (submitted in 2019)
	NP-008	MONITORING OF PRESCRIPTIONS ON PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) IN MEDICAL PATIENTS IN BEATRIZ ÂNGELO HOSPITAL (submitted in 2019)
	NP-009	THE IMPACT OF TNFa INHIBITORS ON GLUCOCORTICOIDS USE AMONG PATIENTS WITH ARTHRITIDES (submitted in 2019)
	NP-010	CLINICAL AND PHARMACOKINETIC RESULTS AFTER THE SWITCH TO INFLIXIMAB BIOSIMILAR IN INFLAMMATORY BOWEL DISEASE: 2 YEARS OF REAL-LIFE EXPERIENCE (submitted in 2019)
	NP-011	MEDICATION RECONCILIATION IN AN EMERGENCY DEPARTMENT – PROCESS ASSESSMENT FOR A MORE EFFICIENT SERVICE (submitted in 2019)
	NP-012	COST EFFECTIVENESS ANALYSIS AND INDIRECT COMPARISON CAN SUPPORT THE PRICE’ DEFINITION OF A DRUG? THE CASE OF ENCORAFENIB AND BINIMETINIB IN METASTATIC MELANOMA, THE PHARMACIST’POINT OF VIEW (submitted in 2019)
	NP-013	THE NEOCHECK PROJECT: DEVELOPMENT OF A PRESCRIPTION-SCREENING TOOL SPECIFIC TO NEONATOLOGY (submitted in 2019)
	NP-014	MEDICINE BOXES FOR DISTRIBUTION OF PAID PHARMACEUTICALS TO OUTPATIENTS IN THE FUTURE (submitted in 2019)
	NP-015	QUALITY ASSESSMENT OF 3D PRINTED SILDENAFIL AND FUROSEMIDE TABLETS FOR THE PAEDIATRIC POPULATION USING AN INNOVATIVE EXTRUSIONBASED TECHNIQUE
	NP-016	EPIDEMIOLOGY AND RESISTANCE MAP TO AID ANTIBIOTIC GUIDELINE DEVELOPMENT SINGLE CENTRE RETROSPECTIVE STUDY FROM AN EMERGENCY DEPARTMENT
	NP-017	RISK ASSESSMENT OF OCCUPATIONAL EXPOSURE TO CYTOTOXIC DRUGS IN AN OUTPATIENT HOSPITAL PHARMACY
	NP-018	BUILDING CAPACITY WITHIN A HEPATITIS C TREATMENT MODEL. THE VALIDATION PROCESS FOR A HEPATITIS C PRE-TREATMENT PHARMACIST ASSESSMENT COMPLEX INTERVENTION TOOLKIT
	NP-019	DEVELOPMENT OF A CONVERSION FACTOR BETWEEN DEFINED DAILY DOSES OF ADULTS AND NEONATES
	NP-020	ANTINEOPLASTIC AND OTHER HAZARDOUS DRUGS: RISK POTENTIAL AND EXPOSURE – LESS IS MORE!

Section 1: Introductory Statements and Governance
PDF document	Poster number	Poster Title
	1ISG-001	CAN RIVAROXABAN BECOME COST SAVING COMPARED WITH VITAMIN K ANTAGONISTS IN THE TREATMENT OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN FRANCE? (submitted in 2019)
	1ISG-002	BIOLOGICAL DRUGS FOR THE TREATMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS: A COST ANALYSIS AND AN APPLICATION OF A CORRELATION ANALYSIS TO INVESTIGATE COST EFFECTIVENESS (submitted in 2019)
	1ISG-003	STUDY OF THE USE OF INTRAVENOUS IMMUNOGLOBULINS DURING THE FOURTH QUARTER OF 2018 AND ANALYSIS OF ITS OFF-LABEL USE (submitted in 2019)
	1ISG-004	ECONOMIC COMPARISON OF THERAPEUTIC ALTERNATIVES FOR FIRSTLINE OF TREATMENT MULTIPLE MYELOMA (submitted in 2019)
	1ISG-005	ABC-VEN CROSSTAB ANALYSIS: A DECISION MAKING SYSTEM APPLIED FOR ANTICANCER MEDICINES (submitted in 2019)
	1ISG-006	EFFECTIVENESS EVALUATION OF HIGHCOST DRUGS FOR ADVANCED NON-SMALL-CELL LUNG CANCER: REAL WORLD EVIDENCE, COMPLIANCE WITH CLINICAL PRACTICE GUIDELINES AND ECONOMIC EVALUATION (submitted in 2019)
	1ISG-007	NEW CANCER DRUGS APPROVALS IN PORTUGAL (submitted in 2019)
	1ISG-008	COST EFFICACY ANALYSIS OF ABIRATERONE IN NEWLY DIAGNOSED HIGH RISK METASTATIC CASTRATION SENSITIVE PROSTATE CANCER (submitted in 2019)
	1ISG-009	BUDGET IMPACT ANALYSIS OF A NATALIZUMAB EXTENDED INTERVAL DOSING REGIMEN (submitted in 2019)
	1ISG-010	INTRODUCTION OF RITUXIMAB BIOSIMILAR: AN OPPORTUNITY TO IMPROVE HEALTH SYSTEM EFFICIENCY? (submitted in 2019)
	1ISG-011	ASSESSMENT OF ASTHMA DIAGNOSED POPULATION ELIGIBLE FOR NEW MONOCLONAL ANTIBODY THERAPY AND RELATED COST IN THE VENETO REGION (submitted in 2019)
	1ISG-012	NATIONAL REPORTING SYSTEM FOR DRUG SHORTAGES : CLASSIFICATION AND TRENDS IN REPORTED CAUSES FROM 2015 TO 2018 (submitted in 2019)
	1ISG-013	SMARTPHONE APPLICATIONS FOR PATIENTS DIAGNOSED WITH GENITOURINARY TUMOURS: ANALYSIS OF THE QUALITY USING THE MOBILE APPLICATION RATING SCALE (submitted in 2019)
	1ISG-014	COST EFFECTIVENESS ANALYSIS OF PATIENTS' SELF-ADMINISTRATION OF MEDICATION (SAM) DURING HOSPITALISATION IN A CARDIOLOGY UNIT (submitted in 2019)
	1ISG-015	EVALUATION OF BISPECTRAL INDEX MONITORING IN GENERAL ANAESTHESIA THROUGH A HEALTH TECHNOLOGY ASSESSMENT METHOD: A POSSIBLE INTRODUCTION IN CLINICAL PRACTICE IN AN ITALIAN HOSPITAL? (submitted in 2019)
	1ISG-016	ENVISIONING SUSTAINABILITY IN PERSONALISED MEDICINE: FONDO AIFA 5% AND THE ITALIAN EXAMPLE (submitted in 2019)
	1ISG-017	IMPACT OF SUPPLY PROBLEMS IN A HOSPITAL PHARMACY SERVICE (submitted in 2019)
	1ISG-018	APPLICATION OF A TIME SLOT MODEL IN ONCOLOGY: DELIVERY PLANNING AND PROCESS OPTIMISATION (submitted in 2019)
	1ISG-019	HOSPITAL PHARMACISTS AGED <45 YEARS: AN EMPLOYMENT STATUS AND JOB SATISFACTION SURVEY IN ITALY (submitted in 2019)
	1ISG-020	COST SAVINGS IMPACT OF BIOSIMILARS: A LOCAL EXPERIENCE ON TRASTUZUMAB
	1ISG-021	INDIRECT COMPARISON OF BRIGATINIB VERSUS ALECTINIB IN THE ALK-POSITIVE NON-SMALL CELL LUNG CANCER
	1ISG-022	ECONOMIC ANALYSIS AFTER THE INCORPORATION OF BEVACIZUMAB BIOSIMILAR IN A THIRD LEVEL HOSPITAL
	1ISG-023	PHARMACOECONOMIC ANALYSIS OF REFERENCE BEVACIZUMAB: OPPORTUNITY FOR IMPROVED EFFICIENCY
	1ISG-024	BIOLOGICAL DRUGS IN THE TREATMENT OF IMMUNE MEDIATED INFLAMMATORY DISEASES: MONITORING OF PRESCRIPTION APPROPRIATENESS
	1ISG-025	BUDGET IMPACT ANALYSIS OF BIOSIMILAR ADALIMUMAB VERSUS REFERENCE ADALIMUMAB
	1ISG-026	MULTIDISCIPLINARY DOCTOR-PHARMACIST COLLABORATION IN THE MANAGEMENT OF REFUNDS POLICIES OF OPHTHALMIC DRUGS AT SANT'ANDREA HOSPITAL , VERCELLI
	1ISG-027	CARBON FOOTPRINT OF A STERILISATION UNIT
	1ISG-028	BECOMING OF GRADUATE HOSPITAL PHARMACISTS: A FRENCH NATIONAL SURVEY
	1ISG-029	CRANIOPLASTY: A REVIEW OF CUSTOMISED CRANIOPLASTY IMPLANTS
	1ISG-030	ECONOMIC IMPACT OF BIOLOGICAL MEDICINES ON A THIRD LEVEL HOSPITAL

Section 2: Selection, Procurement and Distribution
PDF document	Poster number	Poster Title
	2SPD-001	IMPLEMENTATION OF HOME DELIVERY AND TELEPHARMACY SYSTEMS IN A THIRD LEVEL HOSPITAL (submitted in 2019)
	2SPD-002	IMPROVEMENT IN AN ANTIMICROBIAL STEWARDSHIP PROGRAMME AFTER IMPLEMENTING A SCREENING ALERT SYSTEM (submitted in 2019)
	2SPD-003	ECONOMIC IMPACT OF THE INTRODUCTION OF LAMIVUDINE PLUS DOLUTEGRAVIR BITHERAPY IN HIV NAIVE PATIENTS (submitted in 2019)
	2SPD-004	EFFICIENCY OF PRECISION DOSING WITH INTRAVENOUS IMMUNOGLOBULINS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES (submitted in 2019)
	2SPD-005	ECONOMIC ANALYSIS OF OSIMERTINIB IN PREVIOUSLY UNTREATED EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (submitted in 2019)
	2SPD-006	ASSESSMENT OF REGORAFENIB, RAMUCIRUMAB AND CABOZANTINIB AS SECONDLINE THERAPY IN HEPATOCARCINOMA AND ALFA-FETOPROTEIN VALUE ≥400 NG/ML (submitted in 2019)
	2SPD-007	OUT OF SUPPLY OF CHEMOTHERAPY INJECTABLE MEDICINES OVER 9 MONTHS: PATIENT IMPACT (submitted in 2019)
	2SPD-008	IMPACT OF FRENCH EXPERIMENT FOR INCENTIVISING ETANERCEPT BIOSIMILAR USE AFTER 10 MONTHS (submitted in 2019)
	2SPD-009	COST MINIMISATION STUDY OF THE BIOLOGICAL TREATMENT OF INFLAMMATORY BOWEL DISEASE: USTEKINUMAB VERSUS VEDOLIZUMAB (submitted in 2019)
	2SPD-010	ECONOMIC IMPACT OF SWITCHING THE ADMINISTRATION ROUTE OF TOCILIZUMAB IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (submitted in 2019)
	2SPD-011	TRANS-INTERFACE GAIN SHARE PROGRAMME FOR BIOSSIMILAR INFLIXIMAB (submitted in 2019)
	2SPD-012	COST MINIMISATION STUDY IN SEVERE ASTHMA TREATMENT (submitted in 2019)
	2SPD-013	APPLICATION OF THE ABC ANALYSIS METHOD FOR OPTIMIZING THE STOCK MANAGEMENT OF MEDICAL DEVICES IN COMMON USE (submitted in 2019)
	2SPD-014	EVALUATING THE METHODOLOGICAL QUALITY OF PIVOTAL CLINICAL TRIALS´S PUBLICATIONS FOR ORPHAN DRUGS AUTHORISED IN 2018. ARE THEY RELIABLE? (submitted in 2019)
	2SPD-015	COST OF STOCKOUT. A GROWING PROBLEM (submitted in 2019)
	2SPD-016	FUTURE DISTRIBUTION MODELTS FOR PAID PHARMACEUTICALS: THE PATIENT'S PERSPECTIVE (submitted in 2019)
	2SPD-017	IMPACT OF THE IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE AT THE LISBON PORTUGUESE INSTITUTE OF ONCOLOGY (FG, EPE) (submitted in 2019)
	2SPD-018	FOUR YEAR STUDY OF DRUGS SHORTAGES IN TWO PUBLIC HOSPITALS (submitted in 2019)
	2SPD-019	FOUR YEARS OF SHORTAGES REGARDING THE ANATOMIC, THERAPEUTIC AND CHEMICAL CLASSIFICATION (submitted in 2019)
	2SPD-020	IMPACT OF MEDICINE SHORTAGES ON AN OUTPATIENT CLINIC OF A GENERAL HOSPITAL (submitted in 2019)
	2SPD-021	SURVEY OF DRUG SHORTAGES IN HUNGARIAN HOSPITALS (submitted in 2019)
	2SPD-022	DRUG SHORTAGES AND DRUG UNAVAILABILITY: ANALYSIS FROM AN ITALIAN HOSPITAL (submitted in 2019)
	2SPD-023	HOW MUCH DOES FALSIFIED MEDICINES DIRECTIVE ACTUALLY COSTS? DETAILED COST EVALUATION OF SERIALISATION IN A REPRESENTATIVE SAMPLE OF HUNGARIAN HOSPITAL PHARMACIES (submitted in 2019)
	2SPD-024	SHORTAGES OF MEDICINES IN HOSPITAL: RESULTS OF A SURVEY ON THE PERCEPTION OF HEALTH WORKERS IN THE WARDS VSV REAL WORLD (submitted in 2019)
	2SPD-025	APPLICATION OF HAZARD VULNERABILITY ANALYSIS TO EVALUATE THE RISK LEVEL OF MEDICINE SHORTAGES (submitted in 2019)
	2SPD-026	MANAGEMENT OF DRUG SHORTAGES (submitted in 2019)
	2SPD-027	ECONOMIC IMPACT OF DRUG SHORTAGES (submitted in 2019)
	2SPD-028	REFERENCING A MIDLINE: HOW TO MAKE A CHOICE? (submitted in 2019)
	2SPD-029	OFF-LABEL DRUGS: USE ANALYSIS AND PHARMACOEPIDEMIOLOGY IN A COVID CENTRE IN ROME
	2SPD-030	POSITIONING OF DORAVIRINE IN THE PHARMACOTHERAPEUTIC GUIDE OF A THIRD LEVEL HOSPITAL.
	2SPD-031	SUBGROUP ANALYSIS ABOUT EFFICACY OF EARLY USE OF REMDESIVIR IN COVID-19
	2SPD-032	NETWORK META-ANALYSIS OF THERAPEUTIC ALTERNATIVES IN UNTREATED METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER
	2SPD-033	EVALUATION OF DOCETAXEL IN LOW AND HIGH BURDEN METASTATIC HORMONE SENSITIVE PROSTATE CANCER
	2SPD-034	USE OF DARATUMUMAB BASED TREATMENTS IN PATIENTS WITH MULTIPLE MYELOMA AND HEPATIC IMPAIRMENT
	2SPD-035	BIOLOGICAL THERAPIES EFFECTIVENESS COMPARISON FOR PATIENTS WITH SEVERE-MODERATE PSORIASIS
	2SPD-036	CENTRALISED PROPOFOL RECONDITIONING PROCEDURE DURING COVID-19
	2SPD-037	ANALYSIS OF DRUG DISPENSES OUTSIDE THE HOSPITAL GUIDE IN A PSYCHIATRIC HOSPITAL
	2SPD-038	BEVACIZUMAB VERSUS RANIBIZUMAB IN OPHTHALMOLOGY OUTPATIENT SURGERY
	2SPD-039	MAKE OR BUY: PHARMACOECONOMIC EVALUATION OF GARGLE SOLUTIONS USED FOR SARS-CoV-2 SAMPLE COLLECTION
	2SPD-040	IMPACT OF AUTOMATED DISPENSING CABINETS ON DISPENSING ERRORS, INTERRUPTIONS AND PILLBOX PREPARATION TIME
	2SPD-041	QUANTITATIVE EVALUATION AND ECONOMIC IMPACT OF MEDICINE SHORTAGES IN A TEACHING HOSPITAL
	2SPD-042	MEDICAL DEVICE’S ACTIVE VIGILANCE OF THE PHARMACIST IN THE DIGITALISATION OF INTRAOCULAR LENSES (IOLs) LOGISTIC PATH
	2SPD-043	PROCEDURE FOR DELIVERY OF RETROCESSION DRUGS BY THE HOSPITAL PHARMACIST TO THE COMMUNITY PHARMACY DURING THE COVID-19 CRISIS: SATISFACTION SURVEY OF PHARMACIES
	2SPD-044	DruGhost: web based platform of drugs’ unavailability
	2SPD-045	OPTIMISATION OF THE BUYING PROCESS: BUILDING A TIME EARNING COMPARATOR TO EASE THE CHOICE BETWEEN EQUIVALENT SPECIALTIES
	2SPD-046	ORGANISATIONAL CHALLENGES OF THE PHARMACY SERVICE AS A CONSEQUENCE OF THE COVID-19 PANDEMIC
	2SPD-047	NEW REQUIREMENTS OF OUTPATIENTS IN THE COVID-19 ERA: ADAPTING PHARMACEUTICAL CARE
	2SPD-048	POLITICAL REPORT–OPTIONS TO BREAK THROUGH MEDICINE SHORTAGES

Section 3: Production and Compounding
PDF document	Poster number	Poster Title
	3PC-001	COMPATIBILITY AND STABILITY ASSESSMENT OF A SODIUM GLYCEROPHOSPHATE FORMULATION MIXED IN BAGS FOR NEONATAL TOTAL PARENTERAL NUTRITION (submitted in 2019)
	3PC-002	MICROBIOLOGICAL STABILITY TEST OF 15% TOPICAL RESORCINOL FOR QUALITY CONTROL (submitted in 2019)
	3PC-003	TERLIPRESSIN PH STABILITY FOR CONTINUOUS INFUSION (submitted in 2019)
	3PC-004	PHYSICOCHEMICAL STABILITY OF CEFEPIME IN POLYPROPYLENE SYRINGES AND IN ELASTOMERIC DEVICES. (submitted in 2019)
	3PC-005	PHYSICOCHEMICAL STABILITY OF CEFAZOLIN IN POLYPROPYLENE SYRINGES AND IN ELASTOMERIC DEVICES. (submitted in 2019)
	3PC-006	PHYSICOCHEMICAL STABILITY OF AZTREONAM IN POLYPROPYLENE SYRINGES AT HIGH CONCENTRATION FOR INTENSIVE CARE UNITS. (submitted in 2019)
	3PC-007	LEVOFLOXACIN 0.05 % EYEDROPS ELABORATION: A CASE OF STUDY (submitted in 2019)
	3PC-008	INTRAVENOUS PERFUSION OF CEFTOLOZANE-TAZOBACTAM USING ELASTOMERIC INFUSION PUMPS (submitted in 2019)
	3PC-009	TREATMENT OF RECURRENT OTOMYCOSIS WITH LOCAL APPLICATION OF A COMPOUNDED FORMULATION OF VORICONAZOLE EAR DROPS: CASE SERIES (submitted in 2019)
	3PC-010	EVALUATION OF THE PRODUCTION ACCURACY AND ERROR RATE IN THE AUTOMATED COMPOUNDING OF CYTOTOXIC PREPARATIONS BY A ROBOT (submitted in 2019)
	3PC-011	CLOSED SYSTEM TRANSFER DEVICE BASED ON AIR FILTRATION: THE DRUG VAPOUR CHALLENGE (submitted in 2019)
	3PC-012	MANAGEMENT OF NON-ADMINISTERED CHEMOTHERAPY PREPARATION: AN OPPORTUNITY TO MINIMISE DRUG WASTE IN ONCOLOGY PHARMACY (submitted in 2019)
	3PC-013	COMPARATIVE BIOPHYSICAL STABILITY STUDY OF ZIV-AFLIBERCEPT (ZALTRAP, OPENED VIALS) STORED AT 4ºC AND ROOM TEMPERATURE FOR 2 WEEKS (submitted in 2019)